

1. 고창권, Matsuda M, 예상규, 민본홍, 이광호, Jong Gu Park. 배양 Monocytes에서 세포농도에 따른 Fc γ Receptors의 선택적 표현. 대한면역학회지. 1998;20(3):277-83.
배제사유 : 동물실험 또는 전임상시험연구
2. 김광수, 박경순. XRP44X Enhances the Cytotoxic Activity of Natural Killer Cells by Activating the c-JUN N-Terminal Kinase Signaling Pathway. 발생과생식. 2020;24(1):53-61.
배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구
3. 김광중, 박성희, 이유신. 원저 : 인체 흑색종 세포주 A - 137 에 대한 감마 인터페론의 세포 살해능, 증식 억제능, HLA항원 표현에 관한 연구. 대한피부과학회지. 1990;28(2):147-58.
배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구
4. 김광중, 박성희, 이유신. 인체 흑색종 세포주 A - 137 에 대한 감마 인터페론의 세포 살해능, 증식 억제능, HLA항원 표현에 관한 연구. 大韓皮膚科學會誌. 1990;28(2):147-58.
배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구
5. 김대원, 이의섭, 최윤표, 강승우, 정재준, 서보승. 게르마늄 수경재배 미나리 추출물 처리에 의한 In Vitro, In Vivo에서의 사이토카인 감소 및 면역 활성화에 대한 효과. 한국식품영양과학회지. 2020;49(1):101-10.
배제사유 : 동물실험 또는 전임상시험연구
6. 김영진, 노홍규, 박은신, 김호, 유순희, 박수정, et al. 갑상선 세포에서 전사보조활성인자인 CBP와 CIITA는 인터페론-감마 활성 부위에 대하여 서로 다른 조절 작용을 나타낸다. Endocrinology and Metabolism(구 대한내분비학회지). 1999;14(3):493-504.
배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구
7. 김용석, 김홍식. 진행 내장암환자에서 5-Fluorouracil 및 재조합 감마 인터페론(인터맥스(r)) 병용요법의 제2상 임상시험. 계명의대논문집. 1994;13(2):131-45.
배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구
8. 김재화, 유익동. 젓버섯아재비 자실체로부터 분리한 Azulene계 화합물이 Interferon-gamma 생성에 미치는 영향. 大韓化粧品學會誌 = Journal of the society of cosmetic scientists of Korea. 2010;36(2):151-6.
배제사유 : 동물실험 또는 전임상시험연구
9. 김재화, 유익동. 젓버섯아재비 자실체로부터 분리한 Azulene계 화합물이 Interferon- γ 생성에 미치는 영향. 대한화장품학회지(J. Soc. Cosmet. Scientists Korea). 2010;36(2):151-6.
배제사유 : 동물실험 또는 전임상시험연구
10. 김창욱, 신주엽, 윤승규, 허원희, 남순우, 장우임, et al. 구연 : 라미부딘을 사용하고 있는 만성 B형 간

염에서 숙주의 HBV 특이 T세포 면역반응을 반영하는 ELISPOT Assay의 유용성. *Clinical and Molecular Hepatology*(대한간학회지). 2003;9(3s):50.

배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구

11. 김홍식, 송홍석. 진행 대장암환자에서 5-Fluorouracil 및 재조합 감마 인터페론(인터맥스) 병용요법의 제2상 임상시험. *啓明醫大論文集*. 1994;13(2):131-45.

배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구

12. 맹선희, 이지수, 박창환, 조영주. 알레르기성 기관지천식환자의 말초 혈액 T세포, NK세포 TNK세포의 Der p 2 항원의 자극에 의한 interferon gamma의 생산. *천식및알레르기*. 2003;23(2):341-8.

배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구

13. 박설희, 문영철, 성주명, 허희진, 허정원. Variable Natural Killer Cell Activity in Hematological Malignancies at Diagnosis. *Laboratory Medicine Online*. 2018;8(2):41-51.

배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구

14. 박재경, 심우영, 허충립, 이춘봉. Retinoids가각질형성세포에서 감마인터페론에 의한 HLA - DR , ICAM - 1 발현에 미치는 영향. *大韓皮膚科學會誌*. 1995;33(1):33-43.

배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구

15. 변진석, 정원일. Involvement of Hepatic Innate Immunity in Alcoholic Liver Disease. *Immune Network*. 2010;10(6):181-7.

배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구

16. 성혜란, 김지연, 박민경, 김일희, 이동욱, 한상배, et al. 결장암에 대한 활성 자연살해세포의 항암효능. *약학회지*. 2010;54(3):192-9.

배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구

17. 안규대, 김경희, 임현호, 김민찬, 이상엽. 건강인에서 NK세포 자극 후와 T세포 자극 후 분비된 Interferon-gamma 농도의 비교. *Laboratory Medicine Online*. 2018;8(1):15-8.

배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구

18. 유수연, 박원봉. 섬오가피 추출물의 항암관련 사이토카인 분비활성. *약학회지*. 2010;54(4):232-9.

배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구

19. 윤도희, 이은경, 김정원. The effect of histamine on the production of interferongamma and interleukin-12 in peripheral blood mononuclear cells from patients with atopic dermatitis. *천식및알레르기*. 1999;19(3):459-67.

배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구

20. 이춘봉, 심우영, 박재경, 허충립. 원저 : Retinoids가각질형성세포에서 감마인터페론에 의한 HLA - DR , ICAM - 1 발현에 미치는 영향. *대한피부과학회지*. 1995;33(1):33-43.

배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구

21. 이해리, 전준호, 이기은. The Poly- γ -D-Glutamic Acid Capsule of Bacillus licheniformis, a Surrogate of Bacillus anthracis Capsule Induces Interferon-Gamma Production in NK Cells through Interactions with Macrophages. *Journal of Microbiology and Biotechnology*. 2017;27(5):1032-7.

배제사유 : 동물실험 또는 전임상시험연구

22. 임영애, 김순선, 조성원, 정재연. 만성B형간염 환자에서의 NK Vue Gold Kit 시약의 유효성 평가. 임

- 상검사와정도관리. 2016;38(3):151-8.
배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구
23. 전준호, 이해리, 이기은. 탄저균 poly- γ -d-glutamic acid 캡슐에 의한 자연살해세포의 인터페론 감마 생산 기전. 주간 건강과 질병. 2018;11(5):128-32.
배제사유 : 동물실험 또는 전임상시험연구
24. 정다운, 변정수, 구나연, 정문희, 김은희, 김형석, et al. 개 유선종양세포에 대한 자연살해세포 독성. 대한수의학회지. 2020;60(1):25-32.
배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구
25. 정원일. 실험적 항섬유화 치료법의 임상적용. Clinical and Molecular Hepatology(대한간학회지). 2011;17(1s):48-54.
배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구
26. 정인배, 한혜경, 김나옥, 하정식, 박현숙, 박주영. 임상연구 : 태반 영양모세포주의 class I 인체백혈구 항원 발현에 미치는 감마 인터페론의 역할. Obstetrics & Gynecology Science. 2003;46(2):378-86.
배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구
27. 정인배, 한혜경, 김나옥, 하정식, 박현숙, 박주영. 태반 영양모세포주의 class I 인체백혈구 항원 발현에 미치는 감마 인터페론의 역할. Obstetrics & Gynecology Science. 2003;46(2):17.
배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구
28. 정인배, 한혜경, 김나옥, 하정식, 박현숙, 박주영. 태반 영양모세포주의 class I 인체백혈구 항원 발현에 미치는 감마 인터페론의 역할. Obstetrics & Gynecology Science. 2003;46(2):378-86.
배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구
29. 정인배, 한혜경, 김나옥, 하정식, 박현숙, 박주영. 태반 영양모세포주의 class I 인체백혈구 항원 발현에 미치는 감마 인터페론의 역할. 대한산부인과학회지. 2003;46(2):378-86.
배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구
30. 정인배. 태반 영양모세포주의 class I 인체백혈구 항원 발현에 미치는 감마 인터페론의 역할. Obstetrics & Gynecology Science. 2003;46(2):17-.
배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구
31. 천은미, 김미선, 장윤희, 박성숙, 조영주. 중증 기관지천식 환자의 말초단핵구에서 자연살해세포의 비율과 자연살해세포에서 interferon gamma의 생산. 천식및알레르기. 2000;20(3):535-44.
배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구
32. 최영희, 이진희, 윤종현. S-689 콜라겐 유도 관절염 마우스 모델에서 편백나무추출오일의 치료 효과. 대한내과학회 추계학술대회. 2016;2016(1):394.
배제사유 : 동물실험 또는 전임상시험연구
33. 최영희, 이진희, 윤종현. S-689 콜라겐 유도 관절염 마우스 모델에서 편백나무추출오일의 치료 효과. 대한내과학회 추계학술발표논문집. 2016;2016(1):394.
배제사유 : 동물실험 또는 전임상시험연구
34. Ablin R J, Bartkus J, M, Gonder M, J. In vitro effects of diethylstilboestrol and the LHRH analogue leuprolide on natural killer cell activity. Immunopharmacology. 1988;15(2):95-101.
배제사유 : 동물실험 또는 전임상시험연구

35. Ablin R J, Gonder M, J, Bartkus J, M. Effect of the luteinizing-hormone-releasing - leuprolide (Lupron) - on the lytic activity of natural killer cells: A preliminary report. *Medical Science Research*. 1988;16(10):533-4.
배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구
36. Ablin R J, Gonder M, J, Bartkus J, M. Leuprolide vs. diethylstilboestrol: effect on natural killer cells. *Anticancer Research*. 1988;8(1):73-6.
배제사유 : NK 세포 활성도를 다루지 않는 연구
37. Ablin R J, Gonder M, J, Bartkus J, M. Suppression of natural killer cells by diethylstilboestrol. *Medical Science Research*. 1987;15(18):1115-6.
배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구
38. Abraham T S, Snook A, E. The swinging pendulum of cancer immunotherapy personalization. *Personalized Medicine*. 2017;14(3):259-70.
배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
39. Ackermann R WM, Hasler L, Okabe T. Characterization of effector cells responsible for cell-mediated cytotoxicity in patients with carcinoma of the prostate. *Urologia Internationalis*. 1981;36(1):46-52.
배제사유 : 동물실험 또는 전임상시험연구
40. Acres B LJ, M. MUC1 as a target antigen for cancer immunotherapy. *Expert Review of Vaccines*. 2005;4(4):493-502.
배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
41. Adcock D M, Fink L, M, Marlar R, A, Cavallo F, Zangari M. The hemostatic system and malignancy. *Clinical Lymphoma and Myeloma*. 2008;8(4):230-6.
배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
42. Adkins I SL, Hradilova N, Tomala J, Tomalova B, Kovar M, Mikyskova R, et al. Use of RLI-15 a clinical grade fusion protein with IL-15 superagonistic activity for the activation of anti-tumor immune response. *Cancer Research. Conference*. 2018;78(13 Supplement 1).
배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
43. Agarwal S BP, J. Innate and adaptive immunosenescence. *Annals of Allergy, Asthma and Immunology*. 2010;104(3):183-90.
배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
44. Agostinelli C SE, Gjorret J, O, Righi S, Rossi M, Mancini M, Piccaluga P, P, et al. Characterization of a new monoclonal antibody against PAX5/BASP in 1525 paraffin-embedded human and animal tissue samples. *Applied Immunohistochemistry and Molecular Morphology*. 2010;18(6):561-72.
배제사유 : 동물실험 또는 전임상시험연구
45. Ahern E HH, Barkauskas D, Allen S, Takeda K, Yagita H, Wyld D, et al. Co-administration of RANKL and CTLA4 antibodies enhances lymphocyte-mediated antitumor immunity in mice. *Clinical Cancer Research*. 2017;23(19):5789-801.
배제사유 : 동물실험 또는 전임상시험연구

46. Ahern E HH, O'Donnell J, S, Allen S, Dougall W, C, Teng M, W, L, Smyth M, J. RANKL blockade improves efficacy of PD1-PD-L1 blockade or dual PD1-PD-L1 and CTLA4 blockade in mouse models of cancer. *OncoImmunology*. 2018;7 (6) (e1431088).
배제사유 : 동물실험 또는 전임상시험연구
47. Ahmad K. 'Desensitising' gene therapy blocks TGFbeta. *Lancet Oncology*. 2003;4(2):65.
배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구
48. Albacker L A, Wu J, Smith P, Warmuth M, Stephens P, J, Zhu P, et al. Loss of function JAK1 mutations occur at high frequency in cancers with microsatellite instability and are suggestive of immune evasion. *PLoS ONE*. 2017;12 (11) (e0176181).
배제사유 : 동물실험 또는 전임상시험연구
49. Al-Delfi F WQ, Herrera G. Prevalence and characteristics of inflammation in prostate cancer. *American Journal of Clinical Pathology*. 2015;2):A377.
배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
50. Alderton G K, Bordon Y. Tumour immunotherapy-leukocytes take up the fight. *Nature Reviews Cancer*. 2012;12(4):235.
배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
51. Aldrich J F, Lowe D, B, Shearer M, H, Winn R, E, Jumper C, A, Kennedy R, C. Vaccines and immunotherapeutics for the treatment of malignant disease. *Clinical and Developmental Immunology*. 2010;2010 (697158).
배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
52. Algarra I GJ, J, Cabrera T, Collado A, Garrido F. The biological consequences of altered MHC class I expression in tumours. *Journal of Biological Regulators and Homeostatic Agents*. 1999;13(2):90-6.
배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
53. Aloysius M M, Robins R, A, Eremin J, M, Eremin O. Vaccination therapy in malignant disease. *Surgeon*. 2006;4(5):309-20.
배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
54. Alshaker H A, Matalka K, Z. IFN-gamma, IL-17 and TGF-beta involvement in shaping the tumor microenvironment: The significance of modulating such cytokines in treating malignant solid tumors. *Cancer Cell International*. 2011;11 (33).
배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
55. Altankova I MM, Tchakarov S, Zoubak S, Botev C, Krusteva E, Kurteva G, et al. Immune cell phenotypes and T-1/T-2 cytokine profile of peripheral blood mononuclear cells as parameters of immune dysfunction in advanced cancer patients. *Clinical Application of Immunology*. 2002;1(1):34-41.
배제사유 : 원문확보불가
56. Amin M LA, C. The potential role of immunotherapy to treat colorectal cancer. *Expert Opinion on Investigational Drugs*. 2015;24(3):329-44.
배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

57. An GD, Kim KH, Lim HH, Kim MC, Lee SY. Comparison of Interferon-gamma Secretion by Stimulated NK Cells and T cells from Healthy Subjects. *Laboratory Medicine Online*. 2018;8(1):15.
 배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구
58. An Y LF, Chen Y, Yang Q. Crosstalk between cancer-associated fibroblasts and immune cells in cancer. *Journal of Cellular and Molecular Medicine*. 2020;24(1):13-24.
 배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
59. Anderson K S. Tumor vaccines for breast cancer. *Cancer Investigation*. 2009;27(4):361-8.
 배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
60. Andrews D M, Maraskovsky E, Smyth M, J. Cancer vaccines for established cancer: How to make them better? *Immunological Reviews*. 2008;222(1):242-55.
 배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
61. Andtbacka R H, Shafren D, R, Grose M, Post L, Weisberg J. CAVATAK-mediated oncolytic immunotherapy in advanced melanoma patients. *Cancer Research. Conference: 105th Annual Meeting of the American Association for Cancer Research, AACR*. 2014;74(19 SUPPL. 1).
 배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
62. Angel Nivya M RK, Kumaravel M, Sasidharan S, Seethapathy G, S. Role of nutraceuticals in cancer. *International Journal of Pharmacy and Pharmaceutical Sciences*. 2012;4(SUPPL. 4):415-20.
 배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
63. Anker J F, Naseem A, F, Mok H, Schaeffer A, J, Abdulkadir S, A, Thumbikat P. Multi-faceted immunomodulatory and tissue-tropic clinical bacterial isolate potentiates prostate cancer immunotherapy. *Nature communications*. 2018;9(1):1591.
 배제사유 : 동물실험 또는 전임상시험연구
64. Anonymous. Analysis of predictors of serious toxicity induced by 3D conformal radiotherapy in prostate cancer patients. *Urology*. 2009;74 (4 SUPPL S):S124.
 배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
65. Anonymous. Corrigendum to: Adipocytes affect castration-resistant prostate cancer cells to develop the resistance to cytotoxic action of NK cells with alterations of PD-L1/NKG2D ligand levels in tumor cells (*The Prostate*, (2018), 78, 5, (353-364), 10.1002/pros.23479). *Prostate*. 2019;79(15):1790.
 배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
66. Anonymous. Utility of platelet vector containing inactivated Sendai viral particles for multi-modal cancer therapy. *Human Gene Therapy*. 2015;26 (10):A34.
 배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
67. Antoni M H. Psychoneuroendocrinology and psychoneuroimmunology of cancer: Plausible mechanisms worth pursuing? *Brain, Behavior, and Immunity*. 2003;17(1 SUPPL.):S84-S91.
 배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

68. Aptsiauri N CT, Pawelec G, Gouttefangeas C, Derhovanessian E, Garrido F, Garcia-Lora A. International conference: Progress in vaccination against cancer-2006 (PIVAC 6), Granada, Spain. *Cancer Immunology, Immunotherapy*. 2007;56(8):1311-22.
 배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
69. Aranda F VE, Eggermont A, Galon J, Fridman W, H, Zitvogel L, Kroemer G, et al. Trial Watch: Immunostimulatory monoclonal antibodies in cancer therapy. *OncoImmunology*. 2014;3 (2) (e27297).
 배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
70. Arber D A, Weiss L, M. CD57 - A review. *Applied Immunohistochemistry*. 1995;3(3):137-52.
 배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
71. Arnon T I, Markel G, Bar-Ilan A, Hanna J, Fima E, Benchetrit F, et al. Harnessing soluble NK cell killer receptors for the generation of novel cancer immune therapy. *PLoS ONE [Electronic Resource]*. 2008;3(5):e2150.
 배제사유 : 동물실험 또는 전임상시험연구
72. Ash S A, Buggy D, J. Does regional anaesthesia and analgesia or opioid analgesia influence recurrence after primary cancer surgery? An update of available evidence. *Best Practice and Research: Clinical Anaesthesiology*. 2013;27(4):441-56.
 배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구
73. Au Q NK, Padmanabhan R, Kuller A, Moler E, Hoe N. MultiOmyx multiplexed tumor infiltrating lymphocyte panel provides comprehensive immunophenotyping from a single FFPE slide. *Cancer Research. Conference: 107th Annual Meeting of the American Association for Cancer Research, AACR*. 2016;76(14 Supplement).
 배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
74. Augusto D G. The impact of KIR polymorphism on the risk of developing cancer: Not as strong as imagined? *Frontiers in Genetics*. 2016;7 (JUN) (121).
 배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
75. Aulitzky W E, Aulitzky W, Gastl G, Lanske B, Reitter J, Frick J, et al. Acute effects of single doses of recombinant interferon-gamma on blood cell counts and lymphocyte subsets in patients with advanced renal cell cancer. *Journal of interferon research*. 1989;9(4):425?33.
 배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구
76. Aw D SA, B, Palmer D, B. Immunosenescence: Emerging challenges for an ageing population. *Immunology*. 2007;120(4):435-46.
 배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
77. Ayala G ST, Li R, Shalev M, Gdor Y, Aguilar-Cordova E, Frolov A, et al. Biological response determinants in HSV-tk + ganciclovir gene therapy for prostate cancer. *Molecular Therapy*. 2006;13(4):716-28.
 배제사유 : NK 세포 활성도를 다루지 않는 연구

78. Azambuja J H, Ludwig N, Braganhol E, Whiteside T, L. Inhibition of the adenosinergic pathway in cancer rejuvenates innate and adaptive immunity. *International Journal of Molecular Sciences*. 2019;20 (22) (5698).
 배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
79. Baci D GM, Mortara L, Noonan D, M, Bruno A. Pro-inflammatory and pro-angiogenic properties of tumor associated natural killer cells in prostate cancer. *Cancer Research. Conference: American Association for Cancer Research Annual Meeting*. 2019;79(13 Supplement).
 배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
80. Bae S OK, Kim H, Kim Y, Kim H, R, Hwang Y, I, Lee D, S, et al. The effect of alloferon on the enhancement of NK cell cytotoxicity against cancer via the up-regulation of perforin/granzyme B secretion. *Immunobiology*. 2013;218(8):1026-33.
 배제사유 : NK 세포 활성도를 다루지 않는 연구
81. Baginska J VE, Paggetti J, Medves S, Berchem G, Moussay E, Janji B. The critical role of the tumor microenvironment in shaping natural killer cell-mediated anti-tumor immunity. *Frontiers in Immunology*. 2013;4 (DEC) (Article 490).
 배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
82. Bailey C KB, Romero M, Han R, Larson J, Becher O, Monje M, et al. Targeting the histone demethylase LSD1 for selective apoptosis and immune-sensitization in pediatric DIPG. *Neuro-Oncology*. 2019;21 (Supplement 2):AA120.
 배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
83. Ballas Z K, Buchta C, M, Rosean T, R, Heusel J, W, Shey M, R. Role of NK cell subsets in organ-specific murine melanoma metastasis. *PLoS ONE [Electronic Resource]*. 2013;8(6):e65599.
 배제사유 : 동물실험 또는 전임상시험연구
84. Baniyash M. TCR zeta-chain downregulation: Curtailing an excessive inflammatory immune response. *Nature Reviews Immunology*. 2004;4(9):675-87.
 배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
85. Barr A M, Silva A, Prato S, Belz G, T, Maraskovsky E, Baz Morelli A. Therapeutic ISCOMATRIX TM adjuvant vaccine elicits effective anti-tumor immunity in the TRAMP-C1 mouse model of prostate cancer. *Cancer Immunology, Immunotherapy*. 2020;09:09.
 배제사유 : 동물실험 또는 전임상시험연구
86. Barsegian V MS, Mockel D, Horn P, Bockisch A, Lindemann M. Lymphocyte function following Radium-223 therapy in patients with metastasized, castration resistant prostate cancer. *European Journal of Nuclear Medicine and Molecular Imaging*. 2016;43 (1 Supplement 1):S422-S3.
 배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
87. Barsoum I B, Hamilton T, K, Li X, Cotechini T, Miles E, A, Siemens D, R, et al. Hypoxia induces escape from innate immunity in cancer cells via increased expression of ADAM10: Role of nitric oxide. *Cancer Research*. 2011;71(24):7433-41.

배제사유 : 동물실험 또는 전임상시험연구

88. Barthel D SB. "Tumor immunology meets oncology (TIMO) VIII" from May 4 to 5, 2012, in Halle/Saale, Germany. *Cancer Immunology, Immunotherapy*. 2013;62(1):197-202.

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

89. Baxevanis C N, Perez S, A, Papamichail M. Cancer immunotherapy. *Critical Reviews in Clinical Laboratory Sciences*. 2009;46(4):167-89.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

90. Beauchemin N AA. Carcinoembryonic antigen-related cell adhesion molecules (CEACAMs) in cancer progression and metastasis. *Cancer and Metastasis Reviews*. 2013;32(3-4):643-71.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

91. Becht E GN, A, Germain C, de Reynies A, Laurent-Puig P, Zucman-Rossi J, Dieu-Nosjean M, C, et al. Immune Contexture, Immunoscore, and Malignant Cell Molecular Subgroups for Prognostic and Theranostic Classifications of Cancers. *Tumor Immunology, 2016. Advances in Immunology*. 2016;130:95-190.

배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구

92. Beck B BC. Unravelling cancer stem cell potential. *Nature Reviews Cancer*. 2013;13(10):727-38.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

93. Bell L K, Ainsworth N, L, Lee S, H, Griffiths J, R. MRI & MRS assessment of the role of the tumour microenvironment in response to therapy. *NMR in Biomedicine*. 2011;24(6):612-35.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

94. Bellinger D L, Millar B, A, Perez S, Carter J, Wood C, ThyagaRajan S, et al. Sympathetic modulation of immunity: Relevance to disease. *Cellular Immunology*. 2008;252(1-2):27-56.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

95. Bellone M. Antigenicity and immunogenicity of prostate cancer stem-like cells. *Cell Journal*. 2015;1):9.

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

96. Belovezhets T N, Matvienko D, A, Volkova O, Y, Koval O, A, Tkachenko A, V, Kuligina E, V, et al. Analysis of in vitro cytotoxicity of human nk cell line co-expressing a psma-specific car and an antitumor agent lactaptin. [Russian]. *Genes and Cells*. 2018;13(3):89-93.

배제사유 : 한국어 또는 영어로 출판되지 않은 연구

97. Benatar T CM, Y, Lee Y, Li H, Feng N, Gu X, Lee V, et al. Virulizin induces production of IL-17E to enhance antitumor activity by recruitment of eosinophils into tumors. *Cancer Immunology, Immunotherapy*. 2008;57(12):1757-69.

배제사유 : 동물실험 또는 전임상시험연구

98. Benites B D, Alvarez M, C, Saad S, T, O. Small particles, big effects: The interplay

between exosomes and dendritic cells in antitumor immunity and immunotherapy. *Cells*. 2019;8 (12) (1648).

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

99. Berger C L, Edelson R. Cancer immunotherapy: From promise to practice. *Drugs of the Future*. 2008;33(5):411-23.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

100. Berger T G, Schultz E, S. Dendritic cell-based immunotherapy. *Current Topics in Microbiology and Immunology*. 2003;276:163-97.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

101. Berman D KA, Peck R, Feltquate D, Lonberg N, Canetta R. The development of immunomodulatory monoclonal antibodies as a new therapeutic modality for cancer: The Bristol-Myers Squibb experience. *Pharmacology and Therapeutics*. 2015;148:132-53.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

102. Berrien-Elliott M M, Romee R, Fehniger T, A. Improving natural killer cell cancer immunotherapy. *Current Opinion in Organ Transplantation*. 2015;20(6):671-80.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

103. Bharati S CT, Bergese S, Ghosh S. Anesthetics impact on cancer recurrence: What do we know? *Journal of Cancer Research and Therapeutics*. 2016;12(2):464-8.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

104. Bhat J DS, Dananberg A, Quabius E, S, Fritsch J, Marie Dowds C, Saxena A, et al. Histone deacetylase inhibitor modulates NKG2D receptor expression and memory phenotype of human gamma/delta T cells upon interaction with tumor cells. *Frontiers in Immunology*. 2019;10 (MAR) (569).

배제사유 : 동물실험 또는 전임상시험연구

105. Bhat J KD. gammadelta T cells and epigenetic drugs: A useful merger in cancer immunotherapy? *OncoImmunology*. 2015;4(6).

배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구

106. Bhutani D VU, N. Monoclonal antibodies in oncology therapeutics: Present and future indications. *Expert Opinion on Biological Therapy*. 2013;13(2):269-82.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

107. Bierie B MH, L. Transforming growth factor beta (TGF-beta) and inflammation in cancer. *Cytokine and Growth Factor Reviews*. 2010;21(1):49-59.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

108. Bird L. Tumour immunology: Innate surveillance. *Nature Reviews Immunology*. 2016;16(3):132-3.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

109. Block K I. In This Issue. *Integrative Cancer Therapies*. 2015;14(5):407-8.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

110. Blomgren H BE, Edsmyr F, Strender L, E, Petrini B, Wasserman J. Natural killer activity

in peripheral lymphocyte population following local radiation therapy. *Acta Radiologica - Oncology*. 1980;19(2):139-43.

배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구

111. Blomgren H BE, Edsmyr F, Strender L, E, Petrini B, Wasserman J. Natural killer activity in peripheral lymphocyte population following local radiation therapy. *Acta Radiologica*. 1980;Oncology Radiation Therapy Physics and Biology. 19(2):139-43.

배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구

112. Blumenthal R D. Technology evaluation: Onyvax-105, Onyvax. *Current Opinion in Molecular Therapeutics*. 2003;5(6):668-72.

배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구

113. Bodey B BJB, Siegel S, E, Kaiser H, E. Fas (Apo-1, CD95) receptor expression in childhood astrocytomas. Is it a marker of the major apoptotic pathway or a signaling receptor for immune escape of neoplastic cells? *In Vivo*. 1999;13(4):357-73.

배제사유 : 동물실험 또는 전임상시험연구

114. Boettcher A N, Usman A, Morgans A, VanderWeele D, J, Sosman J, Wu J, D. Past, Current, and Future of Immunotherapies for Prostate Cancer. *Frontiers in Oncology*. 2019;9 (884).

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

115. Boh B BM. *Grifola frondosa* (Dicks.: Fr.) S.F. Gray (maitake mushroom): Medicinal properties, active compounds, and biotechnological cultivation. *International Journal of Medicinal Mushrooms*. 2007;9(2):89-108.

배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구

116. Bohan P M, K, Cindass J, L, Chick R, C, Vreeland T, J, Hale D, F, Hickerson A, et al. Results of a phase Ib trial of encapsulated rapamycin in prostate cancer patients under active surveillance to prevent progression. *Journal of Clinical Oncology*. Conference. 2020;38(5).

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

117. Bol K F, Schreibelt G, Rabold K, Wculek S, K, Schwarze J, K, Dzionek A, et al. The clinical application of cancer immunotherapy based on naturally circulating dendritic cells. *Journal for ImmunoTherapy of Cancer*. 2019;7 (1) (109).

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

118. Bolhassani A KA, Bathaie S, Z. Saffron and natural carotenoids: Biochemical activities and anti-tumor effects. *Biochimica et Biophysica Acta*. 2014;1845(1):20-30.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

119. Boligan K F, Mesa C, Fernandez L, E, Von Gunten S. Cancer intelligence acquired (CIA): Tumor glycosylation and sialylation codes dismantling antitumor defense. *Cellular and Molecular Life Sciences*. 2015;72(7):1231-48.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

120. Bossenmaier B FT, Gerdes C, Kolm I, Dimoudis N, Lifke V, Reiff U, et al. GE-huMab-HER3, a novel humanized, glycoengineered HER3 antibody with enhanced

ADCC and superior preclinical in vitro and in vivo efficacy. Cancer Research. Conference: 103rd Annual Meeting of the American Association for Cancer Research, AACR. 2012;72(8 SUPPL. 1).

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

121. Bossenmaier B FT, Weisser M, Lechner S, Abraham E, Hoch M, Mirschberger C. RG7116, a novel humanized anti-HER3 antibody with superior preclinical in vitro and in vivo efficacy in combination with, everolimus and other anti-cancer agents. Cancer Research. Conference: 105th Annual Meeting of the American Association for Cancer Research, AACR. 2014;74(19 SUPPL. 1).

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

122. Bouchlaka M N, Redelman D, Murphy W, J. Immunotherapy following hematopoietic stem cell transplantation: Potential for synergistic effects. Immunotherapy. 2010;2(3):399-418.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

123. Bou-Dargham M J, Liu Y, Sang Q, X, A, Zhang J. The different immune evasion mechanisms in human prostate cancer. Cancer Research. Conference. 2018;78(13 Supplement 1).

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

124. Boudreau J E, Bonehill A, Thielemans K, Wan Y. Engineering dendritic cells to enhance cancer immunotherapy. Molecular Therapy. 2011;19(5):841-53.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

125. Bourzac K. Medical imaging: Removing the blindfold. Nature. 2013;504(7480):S10-S2.

배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구

126. Brand L J, Zaslavsky A, B, Palapattu G, S, Knudsen K, E. A PSMA-directed natural killer cell approach for prostate cancer immunotherapy. Cancer Research. Conference: American Association for Cancer Research Annual Meeting. 2017;77(13 Supplement 1).

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

127. Braza M S, Klein B. Anti-tumour immunotherapy with Vgamma9Vdelta2 T lymphocytes: From the bench to the bedside. British Journal of Haematology. 2013;160(2):123-32.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

128. Bregni M UN, T, Childs R. The second international meeting on allogeneic transplantation in solid tumors. Bone Marrow Transplantation. 2006;38(8):527-37.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

129. Brody J D, Engleman E, G. DC-based cancer vaccines: Lessons from clinical trials. Cytotherapy. 2004;6(2):122-7.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

130. Brower V. Researchers attempting to define role of cytokines in cancer risk. Journal of the National Cancer Institute. 2005;97(16):1175-7.

배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구

131. Browne R OS. Acquired hypogammaglobulinaemia causing cutaneous granulomata. *British Journal of Dermatology*. 2019;181 (Supplement 1):134-5.
 배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
132. Brush T P, Trinh S, Brawner C, M, Ali K, H, Hauke R, J, Elkahwaji J, E. RBAC, a modified form of Arabinoxylan from rice bran, impairs prostate cancer cell line proliferation, adhesion, and invasion in vitro. *Cancer Research. Conference: 101st Annual Meeting of the American Association for Cancer Research, AACR*. 2010;70(8 SUPPL. 1).
 배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
133. Bryant G WL, Mulholland D, J. Overcoming oncogenic mediated tumor immunity in prostate cancer. *International Journal of Molecular Sciences*. 2017;18 (7) (1542).
 배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
134. Bryceson Y T, March M, E, Ljunggren H, G, Long E, O. Activation, coactivation, and costimulation of resting human natural killer cells. *Immunological Reviews*. 2006;214(1):73-91.
 배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
135. Budczies J BM, Klauschen F, Stenzinger A, Denkert C. Deciphering the impact of tumor genetics on immune cell infiltration in major solid cancer types. *Cancer Research. Conference: American Association for Cancer Research Annual Meeting*. 2017;77(13 Supplement 1).
 배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
136. Buggy D J, Hemmings H, C. Special issue on anaesthesia and cancer. *British Journal of Anaesthesia*. 2014;113(SUPPL. 1):i1-i3.
 배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
137. Buijs J T, Juarez P, Guise T, A. Therapeutic strategies to target TGF-beta in the treatment of bone metastases. *Current Pharmaceutical Biotechnology*. 2011;12(12):2121-37.
 배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
138. Buller C W, Mathew P, A, Mathew S, O. Roles of NK Cell Receptors 2B4 (CD244), CS1 (CD319), and LLT1 (CLEC2D) in Cancer. *Cancers*. 2020;12(7):01.
 배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
139. Buonaguro L PA, Tornesello M, L, Buonaguro F, M. Translating tumor antigens into cancer vaccines. *Clinical and Vaccine Immunology*. 2011;18(1):23-34.
 배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
140. Burke S LT, Colucci F, Carbone E. New views on natural killer cell-based immunotherapy for melanoma treatment. *Trends in Immunology*. 2010;31(9):339-45.
 배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
141. Burugu S DA, R, Nielsen T, O. Emerging targets in cancer immunotherapy. *Seminars in Cancer Biology*. 2018;Part 2. 52:39-52.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

142. Bussing A TW, Stumpf C, Schietzel M. Local reactions to treatments with viscum album L. extracts and their association with T-lymphocyte subsets and quality of life. *Anticancer Research*. 2008;28(3 B):1893-7.

배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구

143. Byun JS, Jeong WI. Involvement of hepatic innate immunity in alcoholic liver disease. *Immune Netw*. 2010;10(6):181-7.

배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구

144. Caccamo N MS, Scarpa F, La Mendola C, Santini D, Bonanno C, T, Misiano G, et al. Aminobisphosphonate-activated gammadelta T cells in immunotherapy of cancer: Doubts no more. *Expert Opinion on Biological Therapy*. 2008;8(7):875-83.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

145. Cai T SR, Tamanini I, Galli I, C, Perletti G, Bjerklund Johansen T, E, Nesi G. Current knowledge of the potential links between inflammation and prostate cancer. *International Journal of Molecular Sciences*. 2019;20 (15) (3833).

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

146. Camussi G DM, C, Tetta C. Tumor-derived microvesicles and the cancer microenvironment. *Current Molecular Medicine*. 2013;13(1):58-67.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

147. Capitini C M, MacKall C, L, Wayne A, S. Immune-based therapeutics for pediatric cancer. *Expert Opinion on Biological Therapy*. 2010;10(2):163-78.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

148. Carballido J ML, M, Olivier C, Manzano L, Alvarez-Mon M. Analysis of the effect of intravesical treatment with interferon-alpha 2b on the clinical evolution and on the in vivo function of T lymphocytes and natural killer cells in patients with superficial bladder tumors. *Anti-cancer drugs*. 1992;3 Suppl 1:9?12.

배제사유 : 동물실험 또는 전임상시험연구

149. Carlson L E, Specca M, Patel K, D, Goodey E. Mindfulness-based stress reduction in relation to quality of life, mood, symptoms of stress, and immune parameters in breast and prostate cancer outpatients. *Psychosomatic Medicine*. 2003;65(4):571-81.

배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구

150. Cassimatis D C, Crim M, T, Wenger N, K. Low Testosterone in Men with Cardiovascular Disease or Risk Factors: to Treat or Not To Treat? Current treatment options in cardiovascular medicine. 2016;18(12) .

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

151. Catalan V G-AJ, Rodriguez A, Fruhbeck G. Adipose tissue immunity and cancer. *Frontiers in Physiology*. 2013;4 OCT (Article 275).

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

152. Catalona W J. Immunobiology of carcinoma of the prostate. *Investigative Urology*.

1980;17(5):373-7.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

153. Cavassani K A, You S, Meza R, Santiskulvong C, Goodridge H, Posadas E, M. Defining the monocyte subset transcriptional signature associated with progression during androgen-target therapy in prostate cancer patients. *Journal of Clinical Oncology. Conference.* 2020;38(6 Supplement).

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

154. Cecil A GI, Adelfinger M, Nolte I, Dandekar T, Szalay A, A. Antigen profiling analysis of vaccinia virus injected canine tumors: Oncolytic virus efficiency predicted by boolean models. *Bioengineered.* 2014;5(5):319-25.

배제사유 : 동물실험 또는 전임상시험연구

155. Ceeraz S NE, C, Noelle R, J. B7 family checkpoint regulators in immune regulation and disease. *Trends in Immunology.* 2013;34(11):556-63.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

156. Cemazar M JT, Sersa G. Cancer electrogene therapy with interleukin-12. *Current Gene Therapy.* 2010;10(4):300-11.

배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구

157. Chang S LX, Higashikubo R, Toth K, Gelman A, E, Kreisel D, Krupnick A, S. Unique pulmonary antigen presentation may call for an alternative approach for lung cancer immunotherapy. *OncoImmunology.* 2013;2 (3) (e23563).

배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구

158. Chang Y H, Campana D. Increasing the antineoplastic potential of natural killer cells with a chimeric receptor activated by NKG2D ligands. *OncoImmunology.* 2013;2 (7) (e24899).

배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구

159. Chavez-Blanco A DLC-HE, Dominguez G, I, Rodriguez-Cortez O, Alatorre B, Perez-Cardenas E, Chacon-Salinas R, et al. Upregulation of NKG2D ligands and enhanced natural killer cell cytotoxicity by hydralazine and valproate. *International Journal of Oncology.* 2011;39(6):1491-9.

배제사유 : 동물실험 또는 전임상시험연구

160. Check J H, Dix E, Wilson C, Check D. Progesterone receptor antagonist therapy has therapeutic potential even in cancer restricted to males as evidenced from murine testicular and prostate cancer studies. *Anticancer Research.* 2010;30(12):4921-3.

배제사유 : 동물실험 또는 전임상시험연구

161. Check J H, Sansoucie L, Chern J, Amadi N, Srivastava M, Larece K. Evidence that progesterone receptor antagonists may help in the treatment of a variety of cancers by locally suppressing natural killer cell activity. *Clinical and Experimental Obstetrics and Gynecology.* 2007;34(4):207-11.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

162. Chen C H, Li S, X, Xiang L, X, Mu H, Q, Wang S, B, Yu K, Y. HIF-1alpha induces

immune escape of prostate cancer by regulating NCR1/NKp46 signaling through miR-224. *Biochemical & Biophysical Research Communications*. 2018;503(1):228-34.

배제사유 : 동물실험 또는 전임상시험연구

163. Chen D CM, S, Cui Q, C, Yang H, Dou Q, P. Structure-proteasome-inhibitory activity relationships of dietary flavonoids in human cancer cells. *Frontiers in Bioscience*. 2007;12:1935-45.

배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구

164. Chen F QX, Qian M, Dai Y, Sun Y. Tackling the tumor microenvironment: What challenge does it pose to anticancer therapies? *Protein and Cell*. 2014;5(11):816-26.

배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구

165. Chen J Y, Yuan M, Lu S, B. A new strategy to prevent cancer recurrence and metastasis after operation: Research and application of heat shock protein/peptides complex vaccine. *Chinese Journal of Clinical Rehabilitation*. 2002;6(6):913-4.

배제사유 : 동물실험 또는 전임상시험연구

166. Chen L YF, Li T, Xiao P, Han Z, J, Shu L, F, Yuan Z, Z, et al. Extracellular Histone Promotes Prostate Cancer Migration and Epithelial-Mesenchymal Transition through NF-kappaB-Mediated Inflammatory Responses. *Chemotherapy*. 2020;64(4):177-86.

배제사유 : NK 세포 활성도를 다루지 않는 연구

167. Chen S WD, A, Wu J, D, Wan Y, Matei D, E, Zhang Y, Zhang B. CD73: An emerging checkpoint for cancer immunotherapy. *Immunotherapy*. 2019;11(11):983-97.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

168. Chen X DY, Lin X, Qian Y, Zhou T, Huang Z. CD4 + CD25 + regulatory T cells in tumor immunity. *International Immunopharmacology*. 2016;34:244-9.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

169. Chen X H, Lu L, L, Ke H, P, Liu Z, C, Wang H, F, Wei W, et al. The TGF-beta-induced up-regulation of NKG2DLs requires AKT/GSK-3beta-mediated stabilization of SP1. *Journal of Cellular and Molecular Medicine*. 2017;21(5):860-70.

배제사유 : 동물실험 또는 전임상시험연구

170. Cheng S SD. Ganoderma lucidum for cancer treatment: We are close but still not there. *Integrative Cancer Therapies*. 2015;14(3):249-57.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

171. Chesson C B, Zloza A. Nanoparticles: Augmenting tumor antigen presentation for vaccine and immunotherapy treatments of cancer. *Nanomedicine*. 2017;12(23):2693-706.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

172. Chin A I, Miyahira A, K, Covarrubias A, Teague J, Guo B, Dempsey P, W, et al. Toll-like receptor 3-mediated suppression of TRAMP prostate cancer shows the critical role of type I interferons in tumor immune surveillance. *Cancer Research*. 2010;70(7):2595-603.

배제사유 : NK 세포 활성도를 다루었으나 인터페론 감마를 보고하지 않은 연구

173. Chin A MA, Covarrubias A, Teague J, Dempsey P, Cheng G. Tumor surveillance by Toll-like receptor 3 in prostate cancer. *Journal of Urology*. 2010;1):e215-e6.
 배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
174. Chiplunkar S DS, Wesch D, Kabelitz D. gammadelta T cells in cancer immunotherapy: Current status and future prospects. *Immunotherapy*. 2009;1(4):663-78.
 배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
175. Chitadze G LM, Bhat J, Wesch D, Steinle A, Furst D, Mytilineos J, et al. Shedding of endogenous MHC class I-related chain molecules A and B from different human tumor entities: heterogeneous involvement of the "a disintegrin and metalloproteases" 10 and 17. *International Journal of Cancer*. 2013;133(7):1557-66.
 배제사유 : 동물실험 또는 전임상시험연구
176. Choe B K, Frost P, Morrison M, K, Rose N, R. Natural killer cell activity of prostatic cancer patients. *Cancer Investigation*. 1987;5(4):285-91.
 배제사유 : NK 세포 활성도를 다루었으나 인터페론 감마를 보고하지 않은 연구
177. Chow M T, Sceneay J, Paget C, Wong C, S, Duret H, Tschopp J, et al. NLRP3 suppresses NK cell-mediated responses to carcinogen-induced tumors and metastases. *Cancer Research*. 2012;72(22):5721-32.
 배제사유 : 동물실험 또는 전임상시험연구
178. Chuang S S, Chang S, T, Lee Y, H, Chang K, C. Prostatic involvement by nasal NK/T cell lymphoma forming lymphoepithelial lesions. *Journal of Clinical Pathology*. 2008;61(3):399-400.
 배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
179. Chung IB HH, Kim NO, Ha JS, Park HS, Park JY. The role of Interferon-gamma on the Expression of Class I Human Leukocyte Antigens in a Human First Trimester Trophoblast Cell Line. *Korean J Obstet Gynecol*. 2003;Feb 46(2):378-386.
 배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구
180. Cianferoni A. Invariant natural killer T cells. *Antibodies*. 2014;3(1):16-36.
 배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
181. Ciechanowicz S J, Ma D. Anaesthesia for oncological surgery - Can it really influence cancer recurrence? *Anaesthesia*. 2016;71(2):127-31.
 배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
182. Clayton A MJ, P, Court J, Mason M, D, Tabi Z. Human tumor-derived exosomes selectively impair lymphocyte responses to interleukin-2. *Cancer Research*. 2007;67(15):7458-66.
 배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구
183. Clive K S, Tyler J, A, Clifton G, T, Holmes J, P, Mittendorf E, A, Ponniah S, et al. Use of GM-CSF as an adjuvant with cancer vaccines: Beneficial or detrimental? *Expert Review of Vaccines*. 2010;9(5):519-25.
 배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

184. Cohen L PP, A, Vence L, Savary C, Kentor D, Pettaway C, Babaian R, et al. Presurgical stress management improves postoperative immune function in men with prostate cancer undergoing radical prostatectomy. *Psychosomatic Medicine*. 2011;73(3):218-25.
배제사유 : NK 세포 활성도를 다루지 않는 연구
185. Compagno D TC, Garcia J, D, Rondon Y, Corapi E, Velazquez C, Laderach D, J. Galectins as checkpoints of the immune system in cancers, their clinical relevance, and implication in clinical trials. *Biomolecules*. 2020;10 (5) (750).
배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
186. Compagno D TC, Gentilini L, Corapi E, Jaworski F, M, Chauchereau A, Laderach D, J. Low doses of Docetaxel in combination with anti-prostate cancer immunotherapy lead to complete tumor-free outcome through Galectin-3 silencing. *Cancer Research*. Conference: American Association for Cancer Research Annual Meeting. 2019;79(13 Supplement).
배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
187. Cortesi F DG, Grilli A, Calcinotto A, Gorini F, Pucci F, Luciano R, et al. Bimodal CD40/Fas-Dependent Crosstalk between iNKT Cells and Tumor-Associated Macrophages Impairs Prostate Cancer Progression. *Cell Reports*. 2018;22(11):3006-20.
배제사유 : 동물실험 또는 전임상시험연구
188. Coyne G O, Jochems C, Heery C, Singh H, Surolia I, Riley R, et al. A combination trial of vaccine plus ipilimumab in metastatic castration-resistant prostate cancer patients: Immune correlates. *Cancer Research*. Conference: 105th Annual Meeting of the American Association for Cancer Research, AACR. 2014;74(19 SUPPL. 1).
배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
189. Crawford A VK, Van Valkenburgh J, Haber L, Principio J, Gurer C, Olson K, et al. Fully human bispecific antibodies induce potent anti-tumor effects against prostate tumors in mice. *Molecular Cancer Therapeutics*. Conference: AACR NCI EORTC International Conference: Molecular Targets and Cancer Therapeutics. 2015;14(12 SUPPL. 2).
배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
190. Cremel M GN, Barthe Q, Bourgeaux V, Berlier W, Horand F, Godfrin Y. Erythrocytes used as tumor antigen delivery system to target antigen-presenting cells embody an innovative approach for in situ cancer immunotherapy. *Cancer Research*. Conference: 107th Annual Meeting of the American Association for Cancer Research, AACR. 2016;76(14 Supplement).
배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
191. Curran M A, Allison J, P. Tumor vaccines expressing flt3 ligand synergize with ctla-4 blockade to reject preimplanted tumors. *Cancer Research*. 2009;69(19):7747-55.
배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구
192. Dai X J, Jiang W, J, Wang W, M, Zhao S, J. Drug or vaccine?: Selecting the appropriate treatment for malignant glioma patients. *Drugs*. 2010;70(12):1477-86.
배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

193. Dalgleish A G. Practical aspects in the use of biomarkers for the development of cancer vaccines. *Current Cancer Therapy Reviews*. 2008;4(2):161-5.
 배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
194. Daniel K G, Gupta P, Harbach R, H, Guida W, C, Dou Q, P. Organic copper complexes as a new class of proteasome inhibitors and apoptosis inducers in human cancer cells. *Biochemical Pharmacology*. 2004;67(6):1139-51.
 배제사유 : 동물실험 또는 전임상시험연구
195. Danilova A B, Danilov A, O, Fakhruddinova O, L, Badueva I, A, Moiseenko V, M. [Immunochemical assay of MIC A production by tumor cells in vitro and in vivo as a component of antitumor vaccine development]. *Voprosy Onkologii*. 2010;56(5):576-82.
 배제사유 : 한국어 또는 영어로 출판되지 않은 연구
196. Danzaki K KM, Alcazar O, Shinohara M, L. Osteopontin has a protective role in prostate tumor development in mice. *European Journal of Immunology*. 2016;46(11):2669-78.
 배제사유 : 동물실험 또는 전임상시험연구
197. Dao T MS. Role and function of T-cell immunoglobulin- and mucin domain- containing (TIM)-3 receptor on natural killer cells in solid tumors. *Journal for ImmunoTherapy of Cancer*. Conference: 34th Annual Meeting and Pre Conference Programs of the Society for Immunotherapy of Cancer Part. 2019;7(Supplement 1).
 배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
198. Dar T B, Henson R, M, Shiao S, L. Targeting innate immunity to enhance the efficacy of radiation therapy. *Frontiers in Immunology*. 2019;10 (JAN) (3077).
 배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
199. Dasanu C A, Sethi N, Ahmed N. Immune alterations and emerging immunotherapeutic approaches in lung cancer. *Expert Opinion on Biological Therapy*. 2012;12(7):923-37.
 배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
200. Datta R RC, L, Dodi I, A, Rees R, C. NK cell, monocyte and non T cell biomarkers as prognostic indicators in cancer immunotherapy. *Current Cancer Therapy Reviews*. 2008;4(2):120-4.
 배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
201. Davies D M, Maher J. Adoptive T-cell immunotherapy of cancer using chimeric antigen receptor-grafted T Cells. *Archivum Immunologiae et Therapiae Experimentalis*. 2010;58(3):165-78.
 배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
202. De Negri P. Potential influence of the postoperative analgesia regimens on cancer-related outcome. *Regional Anesthesia and Pain Medicine*. 2011;2):E37-E8.
 배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
203. De Velasco M A, Kura Y, Ando N, Sato N, Nozawa M, Yoshimura K, et al. Apalutamide reworks the immune composition of prostate tumors. *Cancer Research*. Conference: American Association for Cancer Research Annual Meeting. 2019;79(13 Supplement).

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

204. De Velasco M A, Kura Y, Sato N, Ando N, Sakai K, Yoshimura K, et al. Immunomodulation of the multi-tyrosine kinase inhibitor TAS-115 in a mouse model of prostate cancer. *Cancer Research. Conference: American Association for Cancer Research Annual Meeting*. 2019;79(13 Supplement).

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

205. Dedeepiya V RG, Munirathnam D, Sumana P, Terunuma H, Senthilkumar R, Srinivasan T, et al. Hurdles overcome in technology transfer for AIET and positive outcome in Indian patients. *Journal of Stem Cells and Regenerative Medicine*. 2012;8(3):207-9.

배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구

206. Delconte R B, Kolesnik T, B, Dagley L, F, Rautela J, Shi W, Putz E, M, et al. CIS is a potent checkpoint in NK cell-mediated tumor immunity. *Nature Immunology*. 2016;17(7):816-24.

배제사유 : 동물실험 또는 전임상시험연구

207. Delconte R B, Kolesnik T, B, Dagley L, F, Shi W, Putz E, M, Zhang J, G, et al. CIS is a potent checkpoint in NK cell-mediated tumor immunity. *Cytokine*. 2016;87:153-4.

배제사유 : 동물실험 또는 전임상시험연구

208. Delconte R B, Kolesnik T, B, Rautela J, Smyth M, J, Nicholson S, E, Huntington N, D. Targeting regulators of natural killer cell homeostasis in cancer immunotherapy. *European Journal of Immunology*. 2016;46 (Supplement 1):65.

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

209. D'Elios M M, Del Prete G, Amedei A. New frontiers in cell-based immunotherapy of cancer. *Expert Opinion on Therapeutic Patents*. 2009;19(5):623-41.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

210. Dell'Agnola C BA. Clinical utilization of chemokines to combat cancer: The double-edged sword. *Expert Review of Vaccines*. 2007;6(2):267-83.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

211. Delwar Z SN, Lee E, Roberts M, Bu L, Liu G, Murad Y, et al. IL12/IL15 and PD-L1 blocker co-expressing oncolytic herpes virus VG161 significantly alters tumor microenvironment and eliminates prostate tumors in animal models. *Journal for ImmunoTherapy of Cancer. Conference: 33rd Annual Meeting and Pre Conference Programs of the Society for Immunotherapy of Cancer, SITC*. 2018;6(Supplement 1).

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

212. D'Errico G MH, L, Sainz B. A current perspective on cancer immune therapy: Step-by-step approach to constructing the magic bullet. *Clinical and Translational Medicine*. 2017;6 (1) (3).

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

213. DeVita Jr V T, Hellman S, Rosenberg S, A. From the editors. *Cancer Journal*. 2003;9(4):231.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

214. Dhar P WJ, D. NKG2D and its ligands in cancer. *Current Opinion in Immunology*. 2018;51:55-61.
 배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
215. Dhar S CS, V. Lysis of aminobisphosphonate-sensitized MCF-7 breast tumor cells by Vgamma9Vdelta2 T cells. *Cancer Immunity*. 2010;10.
 배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구
216. Di Carlo E DTD, Piazza T, Fabbi M, Ferrini S. Role of IL-21 in immune-regulation and tumor immunotherapy. *Cancer Immunology, Immunotherapy*. 2007;56(9):1323-34.
 배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
217. Di Mitri D TA, Alimonti A. Molecular pathways: Targeting Tumor-infiltrating myeloid-derived suppressor cells for cancer therapy. *Clinical Cancer Research*. 2015;21(14):3108-12.
 배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구
218. Diakos C I, Charles K, A, McMillan D, C, Clarke S, J. Cancer-related inflammation and treatment effectiveness. *The Lancet Oncology*. 2014;15(11):e493-e503.
 배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
219. Dillman R O. Cancer immunotherapy. *Cancer Biotherapy and Radiopharmaceuticals*. 2011;26(1):1-64.
 배제사유 : NK 세포 활성도를 다루지 않는 연구
220. Dimberu P M, Leonhardt R, M. Cancer immunotherapy takes a multi-faceted approach to kick the immune system into gear. *Yale Journal of Biology and Medicine*. 2011;84(4):371-80.
 배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
221. Dolman C S, Mueller B, M, Lode H, N, Xiang R, Gillies S, D, Reisfeld R, A. Suppression of human prostate carcinoma metastases in severe combined immunodeficient mice by interleukin 2 immunocytokine therapy. *Clinical Cancer Research*. 1998;4(10):2551-7.
 배제사유 : 동물실험 또는 전임상시험연구
222. Dominguez F GA, L, Tsolas O. Role in disease diagnosis/prognosis/therapy. *International Journal of Thymology*. 1999;7(12-13):642-4.
 배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
223. Dominguez G A, Roop J, Polo A, Campisi A, Gabrilovich D, I, Kumar A. Using machine learning to predict the risk of either having an aggressive form of prostate cancer (PCa) or lower-grade PCa/benign prostatic hyperplasia (BPH) based upon the flow cytometry immunophenotyping of myeloid-derived suppressor cells (MDSCs) and lymphocyte cell populations. *Cancer Research. Conference: American Association for Cancer Research Annual Meeting*. 2019;79(13 Supplement).
 배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
224. Donahue R N, Madan R, A, Richards J, Grenga I, Lepone L, M, Heery C, R, et al. Short-course enzalutamide reveals immune activating properties in patients with

- biochemically recurrent prostate cancer. *Cancer Research. Conference: 107th Annual Meeting of the American Association for Cancer Research, AACR. 2016;76(14 Supplement).*
 배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
225. Dong Z GG, Pettaway C, Dinney C, P, Eue I, Lu W, Bucana C, D, et al. Suppression of angiogenesis, tumorigenicity, and metastasis by human prostate cancer cells engineered to produce interferon-beta. *Cancer Research. 1999;59(4):872-9.*
 배제사유 : 동물실험 또는 전임상시험연구
226. Donini M ML, Fontana E, Dusi S. Prostate carcinoma cells LNCaP and glucan cooperate in induction of cytokine synthesis by dendritic cells: effect on natural killer cells and CD4+ lymphocytes activation. *Prostate. 2012;72(5):566-76.*
 배제사유 : 동물실험 또는 전임상시험연구
227. Donskov F BK, M, Hokland M, Marcussen N, Fisker R, Madsen H, H, Fode K, et al. Leukocyte orchestration in blood and tumour tissue following interleukin-2 based immunotherapy in metastatic renal cell carcinoma. *Cancer immunology, immunotherapy. 2004;53(8):729?39.*
 배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구
228. Donskov F MM, Fode K, Meldgaard P, Mansoor W, Lawrance J, Thatcher N, et al. Two randomised phase II trials of subcutaneous interleukin-2 and histamine dihydrochloride in patients with metastatic renal cell carcinoma. *British journal of cancer. 2005;93(7):757?62.*
 배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구
229. Drake C G. Basic overview of current immunotherapy approaches in urologic malignancy. *Urologic Oncology. 2006;24(5):413-8.*
 배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
230. Drks. Influence of a single bout of endurance exercise on epigenetic modifications, effector function and tumorinfiltration of natural killer cells. <http://www.who.int/trialsearch/Trial2.aspx?TrialID=DRKS00010442>. 2016.
 배제사유 : 동물실험 또는 전임상시험연구
231. Du E WL, Li C, Y, Zhang C, W, Qu Y, C, Liu R, L, Xu Y, et al. Analysis of immune status after iodine-125 permanent brachytherapy in prostate cancer. *OncoTargets and therapy. 2017;10:2561-7.*
 배제사유 : NK 세포 활성도를 다루지 않는 연구
232. Dufresne S GJ, Chiavassa S, Noblet C, Assi M, Rannou-Bekono F, Orfila L, et al. Could exercise training alter radiotherapy efficiency in a murine model of prostate cancer? *Acta Physiologica. Conference: 3rd Congress of Physiology and Integrative Biology, CPBI and 86th Congress of French Physiological Society, SFP. France. 2019;227(Supplement 720).*
 배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
233. Dufresne S GJ, Chiavassa S, Noblet C, Assi M, Rioux-Leclercq N, Rannou-Bekono F, et al. Exercise training improves radiotherapy efficiency in a murine model of prostate

cancer. FASEB journal : official publication of the Federation of American Societies for Experimental Biology. 2020;11.

배제사유 : 동물실험 또는 전임상시험연구

234. Dufresne S GJ, Chiavassa S, Noblet C, Assi M, Rioux-Leclercq N, Rannou-Bekono F, et al. Exercise training improves radiotherapy efficiency in a murine model of prostate cancer. FASEB Journal. 2020;34(4):4984-96.

배제사유 : 동물실험 또는 전임상시험연구

235. Eckert F SP, Zips D, Schmid-Horch B, Rammensee H, G, Gani C, Gouttefangeas C. Impact of curative radiotherapy on the immune status of patients with localized prostate cancer. Oncoimmunology. 2018;7(11):e1496881.

배제사유 : NK 세포 활성도를 다루지 않는 연구

236. Egilmez N K, Kilinc M, O, Gu T, Conway T, F. Controlled-release particulate cytokine adjuvants for cancer therapy. Endocrine, Metabolic and Immune Disorders - Drug Targets. 2007;7(4):266-70.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

237. Einhorn S JC. Decrease in the phagocytic activity of peripheral monocytes in patients treated with human interferon-alpha. Cancer Immunology, Immunotherapy. 1982;13(3):149-52.

배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구

238. Eissler N RC. The role of immune semaphorins in cancer progression. Experimental Cell Research. 2013;319(11):1635-43.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

239. Elaskalani O BM, C, Falasca M, Metharom P. Targeting platelets for the treatment of cancer. Cancers. 2017;9 (7) (94).

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

240. Elhage O GC, Smith R, A, G, Dasgupta P. IL-15 potentiates CD8 and NK effector cell expansion and tumour cell killing in the prostate cancer microenvironment. European Urology, Supplements. 2012;11 (1):e243.

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

241. Elhage O GC, Ukimura O, Gill I, Smith R, A, G, Dasgupta P. IL-15 potentiates CD8, NK and NKT effector cell expansion and tumour cell killing in prostate cancer -PBMC cocultures. Journal of Endourology. 2012;1):A19.

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

242. Elhage O GC, Ukimura O, Gill I, Smith R, Dasgupta P. Selection of optimal cytokine combinations for immunotherapy of prostate cancer. Journal of Urology. 2011;1):e719.

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

243. Elhage O SC, A, Smith R, A, G, Galustian C, Dasgupta P. CD8 T cells inhibit the IL-15 induced expansion of effector cells and the cytotoxic activity of NK cells toward tumour cells in the prostate cancer microenvironment. BJU International. 2015;115 (Supplement 7):70-1.

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

244. Elhage O SC, A, Ukimura O, Gill I, Smith R, A, G, Galustian C, Dasgupta P. IL-15 inhibits expression of killer inhibitory NK receptors and upregulates expression of NKG2D on NK and NKT cells in prostate cancer-PBMC cocultures. *European Urology, Supplements*. 2013;12 (1):e835.

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

245. Elhage O SC, Smith R, A, Galustian C, Dasgupta P. CD8 T cells inhibit the interleukin-15 (IL-15) induced cytotoxic activity of NK and NKT cells toward tumour cells in the prostate cancer microenvironment. *Journal of Urology*. 2015;1):e550.

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

246. Elhage O SC, Ukimura O, Gill I, Smith R, A, Galustian C, Dasgupta P. IL-15 inhibits expression of killer inhibitory NK receptors and upregulates expression of NKG2D on NK and NKT cells in prostate cancer-pbmc cocultures. *Journal of Urology*. 2013;1):e545.

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

247. Elhage O SC, Ukimura O, Gill I, Smith R, A, Galustian C, Dasgupta P. Mechanism of activation of natural killer and CD8 T cells by interleukin 15 in the prostate cancer microenvironment. *The Lancet*. 2014;1):S47.

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

248. Elhage O SC, Ukimura O, Gill I, Smith R, Galustian C, Dasgupta P, et al. IL-15 inhibits expression of killer inhibitory NK receptors and upregulates expression of NKG2D on NK and NKT cells in prostate cancer-pbmc cocultures. *Urology*. 2013;1):S49.

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

249. Elkord E WP, E, Kynaston H, Rowbottom A, W. Differential CTLs specific for prostate-specific antigen in healthy donors and patients with prostate cancer. *International Immunology*. 2005;17(10):1315-25.

배제사유 : NK 세포 활성도를 다루지 않는 연구

250. Elzey B D, Siemens D, R, Ratliff T, L, Lubaroff D, M. Immunization with type 5 adenovirus recombinant for a tumor antigen in combination with recombinant canarypox virus (ALVAC) cytokine gene delivery induces destruction of established prostate tumors. *International Journal of Cancer*. 2001;94(6):842-9.

배제사유 : 동물실험 또는 전임상시험연구

251. Emens L A. It's TIME for a biomarker-driven approach to cancer immunotherapy. *Journal for ImmunoTherapy of Cancer*. 2016;4 (1) (43).

배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구

252. Enting D IM, L, Cahill F, Santaolalla A, Chowdhury S, Van Hemelrijck M, Hayday A, C. Lymphoid stress-surveillance in prostate cancer. *Journal of Clinical Oncology, Conference*. 2015;33(15 SUPPL. 1).

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

253. Enting D IM, L, Chowdhury S, Van Hemelrijck M, Hayday A, C. Lymphoid stress-surveillance in prostate cancer. *Immunology*. 2014;2):154-5.

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

254. Ernstoff M S, Gooding W, Nair S, Bahnson R, R, Miketic L, M, Banner B, et al. Immunological effects of treatment with sequential administration of recombinant interferon gamma and alpha in patients with metastatic renal cell carcinoma during a phase I trial. *Cancer research*. 1992;52(4):851-6.

배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구

255. Escudier B. Emerging immunotherapies for renal cell carcinoma. *Annals of Oncology*. 2012;23(SUPPL.8):viii35-viii40.

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

256. Esplugues E V-RJ, Cartoixa D, Vazquez B, N, Salaet I, Engel P, Lauzurica P. Induction of tumor NK-cell immunity by anti-CD69 antibody therapy. *Blood*. 2005;105(11):4399-406.

배제사유 : 동물실험 또는 전임상시험연구

257. Esteve N FA, Mora C, Gomez G, Ribera H, Garrido P. Does the anesthesia have any influence on surgical outcome?. [Spanish]. *Revista de la Sociedad Espanola del Dolor*. 2014;21(3):162-74.

배제사유 : 한국어 또는 영어로 출판되지 않은 연구

258. Esteves A M, Papaevangelou E, Dasgupta P, Smith R, A, G, Galustian C. Combination of Interleukin-15 with a STING (Stimulator of Interferon Gene) agonist: A potential immunotherapy for prostate cancer. *Cancer Research*. Conference: American Association for Cancer Research Annual Meeting. 2019;79(13 Supplement).

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

259. Eucr F R. Comparison of efficacy and safety of DCVAC/PCa (therapeutic prostate cancer vaccine) against placebo in men with metastatic prostate cancer eligible for chemotherapy. <http://www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2012-002814-38-FR>. 2015.

배제사유 : NK 세포 활성도를 다루지 않는 연구

260. Evans K N, Bulmer J, N, Kilby M, D, Hewison M. Vitamin D and placental-decidual function. *Journal of the Society for Gynecologic Investigation*. 2004;11(5):263-71.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

261. Exley M NM, Yue S, Scheuplein F, Arredouani M, S, Sanda M, Sasada T, et al. Exploiting the good guys: Th1 antiviral & antitumor human & mouse NKT cells. *Clinical Immunology*. 2010;119(1):S34.

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

262. Fairweather-Tait S J, Bao Y, Broadley M, R, Collings R, Ford D, Hesketh J, E, et al. Selenium in human health and disease. *Antioxidants and Redox Signaling*. 2011;14(7):1337-83.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

263. Fan G WZ, Hao M, Li J. Bispecific antibodies and their applications. *Journal of Hematology and Oncology*. 2015;8 (1) (130).

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

264. Fang Y HE, J, Nicholl M, B. A possible role for perforin and granzyme B in resveratrol-enhanced radiosensitivity of prostate cancer. *Journal of Andrology*. 2012;33(4):752-60.
배제사유 : 동물실험 또는 전임상시험연구
265. Fang Y HE, J, Nicholl M, B. A possible role for perforin and granzyme B in resveratrol-enhanced radiosensitivity of prostate cancer. *Journal of Andrology*. 2012;33(4):752-60.
배제사유 : 동물실험 또는 전임상시험연구
266. Fant F TE, Andersson S, O, Magnuson A, Hultgren-Hornquist E, Gupta A. Early perioperative immunological effects of anaesthesia and analgesia in patients undergoing prostate cancer surgery. *European Journal of Anaesthesiology*. 2017;34(4):241-3.
배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
267. Fantini M GS, R, Knudson K, M, Clavijo P, E, Allen C, T, Donahue R, Lepone L, et al. Modulation of antibody-dependent cell-mediated cytotoxicity (ADCC) mediated by the anti-PD-L1 antibody avelumab on human lung and prostate carcinoma cell lines using the HDAC inhibitors vorinostat and entinostat. *Journal for ImmunoTherapy of Cancer*. Conference: 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer, SITC. 2016;4(Supplement 1).
배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
268. Farace F PM, Angevin E, Hercend T, Escudier B, Triebel F. Metastatic renal-cell carcinoma patients treated with interleukin 2 or interleukin 2 plus interferon gamma: immunological monitoring. *International journal of cancer*. 1994;57(6):814-21.
배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구
269. Farooqi A A, Fayyaz S, Qureshi M, Z, Rashid S. Prostate cancer and immunoproteome: awakening and reprogramming the guardian angels. *Archivum Immunologiae et Therapiae Experimentalis*. 2012;60(3):191-8.
배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
270. Farooqi A A, Khalid S, Ahmad A. Regulation of cell signaling pathways and miRNAs by resveratrol in different cancers. *International Journal of Molecular Sciences*. 2018;19 (3) (652).
배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
271. Farsaci B DR, N, Grenga I, Lepone L, M, Kim P, S, Dempsey B, Siebert J, C, et al. Analyses of Pretherapy Peripheral Immunoscore and Response to Vaccine Therapy. *Cancer Immunology Research*. 2016;4(9):755-65.
배제사유 : NK 세포 활성도를 다루지 않는 연구
272. Farsaci B JC, Grenga I, Donahue R, N, Gulley J, L, Heery C, R, Madan R, A, et al. Digital immunohistochemistry analysis of intratumoral immune infiltrates in prostate cancer patients treated with intraprostatic/ systemic PSA-TRICOM vaccine. *Journal for ImmunoTherapy of Cancer*. Conference: 28th Annual Scientific Meeting of the Society for Immunotherapy of Cancer, SITC. 2013;1(SUPPL. 1).
배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

273. Farsaci B JC, Grea I, Donahue R, N, Tucker J, A, Pinto P, A, Merino M, J, et al. Identification by digital immunohistochemistry of intratumoral changes of immune infiltrates after vaccine in the absence of modifications of PBMC immune cell subsets. *International Journal of Cancer*. 2014;135(4):862-70.
 배제사유 : NK 세포 활성도를 다루지 않는 연구
274. Felzmann T. Fourth medical biotech forum of the Chinese medical biotech association. *IDrugs*. 2009;12(10):629-32.
 배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
275. Fenerty K E, Padget M, Wolfson B, Gameiro S, R, Su Z, Lee J, H, et al. Immunotherapy utilizing the combination of natural killer- and antibody dependent cellular cytotoxicity (ADCC)-mediating agents with poly (ADP-ribose) polymerase (PARP) inhibition. *Journal for Immunotherapy of Cancer*. 2018;6(1):133.
 배제사유 : 동물실험 또는 전임상시험연구
276. Fenerty K PM, R, Schlom J, Hodge J, W. Immunotherapy utilizing the combined use of NK and ADCC mediating agents with PARP inhibition. *Journal of Clinical Oncology. Conference*. 2018;36(15 Supplement 1).
 배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
277. Ferraro B WJ, N, Reuschel E, L, Balakrishnan A, Morrow M, P, Khan A, S, Sardesai N, Y, et al. Control of tumor growth in vivo by a synthetic multi-antigen DNA immune therapy for prostate cancer. *Cancer Research. Conference: 107th Annual Meeting of the American Association for Cancer Research, AACR*. 2016;76(14 Supplement).
 배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
278. Ferreira L M, R. Gammadelta T Cells: Innately adaptive immune cells. *International Reviews of Immunology*. 2013;32(3):223-48.
 배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
279. Filaci G. Anti-cancer telomerase vaccines are entering the age of maturity. *European Journal of Clinical Investigation*. 2017;47 (Supplement 1):37.
 배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
280. Finn O J. A Believer's Overview of Cancer Immunosurveillance and Immunotherapy. *Journal of Immunology*. 2018;200(2):385-91.
 배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
281. Finocchiaro G PS. Molecular characterization of factors regulating the immune response in malignant gliomas and immunotherapy. *Clinical Neuropathology*. 2013;32 (3):213.
 배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
282. Fleischmann Jr W R, Wu T, G, Perdigo J, R, Umhoefer T, K, Cao J, Ansari D, A, et al. Heterogeneous interleukin-15 inducibilities in murine B16 melanoma and RM-1 prostate carcinoma by interferon-alpha treatment. *Journal of Interferon and Cytokine Research*. 2009;29(11):719-27.
 배제사유 : 동물실험 또는 전임상시험연구

283. Forget P DKM. Important data about anaesthetics and cancer recurrence. *Acta Anaesthesiologica Scandinavica*. 2014;58(3):371-2.
 배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
284. Formenti S C, Demaria S. Combining radiotherapy and cancer immunotherapy: A paradigm shift. *Journal of the National Cancer Institute*. 2013;105(4):256-65.
 배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
285. Foster B P, Balassa T, Benen T, D, Dominovic M, Elmadjian G, K, Florova V, et al. Extracellular vesicles in blood, milk and body fluids of the female and male urogenital tract and with special regard to reproduction. *Critical Reviews in Clinical Laboratory Sciences*. 2016;53(6):379-95.
 배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
286. Fotin-Mleczek M ZK, Heidenreich R, Lorenz C, Thess A, Duchardt K, M, Kallen K, J. Highly potent mRNA based cancer vaccines represent an attractive platform for combination therapies supporting an improved therapeutic effect. *Journal of Gene Medicine*. 2012;14(6):428-39.
 배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구
287. Foulds G A, Dunning-Foreman N, Stangl S, Gehrmann M, Vadakekolathu J, Boocock D, et al. Membrane Hsp70 as a biomarker for aggressive prostate cancer and therapeutic target. *European Journal of Cancer*. 2016;61 (1):S145-S6.
 배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
288. Fournie J J, Sicard H, Poupot M, Bezombes C, Blanc A, Romagne F, et al. What lessons can be learned from gammadelta T cell-based cancer immunotherapy trials? *Cellular and Molecular Immunology*. 2013;10(1):35-41.
 배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
289. Franco A. Glycoconjugates as vaccines for cancer immunotherapy: Clinical trials and future directions. *Anti-Cancer Agents in Medicinal Chemistry*. 2008;8(1):86-91.
 배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
290. Frankel T L, Burns W, Riley J, Morgan R, A, Davis J, L, Hanada K, et al. Identification and characterization of a tumor infiltrating CD56(+)/CD16 (-) NK cell subset with specificity for pancreatic and prostate cancer cell lines. *Cancer Immunology, Immunotherapy*. 2010;59(12):1757-69.
 배제사유 : 동물실험 또는 전임상시험연구
291. Franks H A, Wang Q, Patel P, M. New anticancer immunotherapies. *Anticancer Research*. 2012;32(7):2439-54.
 배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
292. Frazao A RL, Messaoudene M, Avril M, F, Toubert A, Dulphy N, Caignard A. NKG2D/NKG2-Ligand pathway offers new opportunities in cancer treatment. *Frontiers in Immunology*. 2019;10 (00661).
 배제사유 : 동물실험 또는 전임상시험연구

293. Fremd C SF, Sohn C, Beckhove P, Domschke C. B cell-regulated immune responses in tumor models and cancer patients. *OncoImmunology*. 2013;2 (7) (e25443).
 배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
294. Freytag S O, Barton K, N, Zhang Y. Efficacy of oncolytic adenovirus expressing suicide genes and interleukin-12 in preclinical model of prostate cancer. *Gene Therapy*. 2013;20(12):1131-9.
 배제사유 : 동물실험 또는 전임상시험연구
295. Friedmann-Morvinski D EZ. Adoptive immunotherapy of cancer using effector lymphocytes redirected with antibody specificity. *Update on Cancer Therapeutics*. 2006;1(1):25-32.
 배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
296. Fromm P D, Gottlieb D, Bradstock K, F, Hart D, N. Cellular therapy to treat haematological and other malignancies: progress and pitfalls. *Pathology*. 2011;43(6):605-15.
 배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
297. Frost P CR, Beldegrun A, Bonavida B. Immunosenitization of resistant human tumor cells to cytotoxicity by tumor infiltrating lymphocytes. *International Journal of Oncology*. 2003;22(2):431-7.
 배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구
298. Frost P J, Beldegrun A, Bonavida B. Sensitization of immunoresistant prostate carcinoma cell lines to Fas/Fas ligand-mediated killing by cytotoxic lymphocytes: independence of de novo protein synthesis. *Prostate*. 1999;41(1):20-30.
 배제사유 : 동물실험 또는 전임상시험연구
299. Frost P NC, P, Beldegrun A, Bonavida B. Immunosenitization of prostate carcinoma cell lines for lymphocytes (CTL, TIL, LAK)-mediated apoptosis via the Fas-Fas-ligand pathway of cytotoxicity. *Cellular Immunology*. 1997;180(1):70-83.
 배제사유 : 동물실험 또는 전임상시험연구
300. Frueh K VM, Hansen S, Mansouri M, Nair S, Malouli D, Tewari A, K, et al. Targeting HLA-E for prostate cancer immunotherapy. *Journal of Immunology*. Conference: 105th Annual Meeting of the American Association of Immunologists, IMMUNOLOGY. 2018;200(1 Supplement 1).
 배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
301. Fuenmayor J MR, F. Novel antibody-based proteins for cancer immunotherapy. *Cancers*. 2011;3(3):3370-93.
 배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
302. Fujita K KT, Hatano K, Kawashima A, Ujike T, Uemura M, Imamura R, et al. Intratumoral and s.c. injection of inactivated hemagglutinating virus of Japan envelope (GEN0101) in metastatic castration-resistant prostate cancer. *Cancer Science*. 2020;111(5):1692-8.
 배제사유 : NK 세포 활성도를 다루지 않는 연구

303. Fujita K NY, Hatano K, Kawamura N, Kawashima A, Ujike T, Nagahara A, et al. Phase I/II clinical trial to assess safety and efficacy of intratumoral and subcutaneous injection of HVJ-E to castration resistant prostate cancer patients. *Journal of Urology*. 2016;1):e762.
 배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
304. Fujita K NY, Kato D, Kawashima A, Ujike T, Nagahara A, Uemura M, et al. Open-label, phase I, dose escalation study to assess safety and efficacy of intratumoral and subcutaneous injection of HVJ-E (GEN0101) in castration-resistant prostate cancer patients. *European Urology, Supplements*. 2019;18 (1):e1220.
 배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
305. Fujita K NY, Kato T, Kawashima A, Ujike T, Nagahara A, Uemura M, et al. Intratumoral and subcutaneous injection of HVJ-E (GEN0101) for metastatic castration-resistant prostate cancer: Open-label, phase I, dose escalation study. *Journal of Clinical Oncology, Conference*. 2019;37(Supplement 15).
 배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
306. Fujita K NY, Kawashima A, Ujike T, Nagahara A, Nakajima T, Inoue T, et al. Phase I/II clinical trial to assess safety and efficacy of intratumoral and subcutaneous injection of HVJ-E in castration-resistant prostate cancer patients. *Cancer Gene Therapy*. 2017;24(7):277-81.
 배제사유 : 동물실험 또는 전임상시험연구
307. Fujita T ST, Timme T, L, Hirayama T, Zhu J, X, Kusaka N, Naruishi K, et al. Combined therapeutic effects of adenoviral vector-mediated GLIPR1 gene therapy and radiotherapy in prostate and bladder cancer models. *Urologic Oncology*. 2014;32(2):92-100.
 배제사유 : 동물실험 또는 전임상시험연구
308. Fujita T TB, S, Timme T, L, Mai W, Y, Satoh T, Kusaka N, Naruishi K, et al. Sustained long-term immune responses after in situ gene therapy combined with radiotherapy and hormonal therapy in prostate cancer patients. *International Journal of Radiation Oncology, Biology, Physics*. 2006;65(1):84-90.
 배제사유 : NK 세포 활성도를 다루지 않는 연구
309. Fujita T TT, L, Tabata K, Naruishi K, Kusaka N, Watanabe M, Abdelfattah E, et al. Cooperative effects of adenoviral vector-mediated interleukin 12 gene therapy with radiotherapy in a preclinical model of metastatic prostate cancer. *Gene Therapy*. 2007;14(3):227-36.
 배제사유 : 동물실험 또는 전임상시험연구
310. Fukagai T TK, Higaki Y, Imamura K. [Changes in immunoparameters following cryosurgery in prostate cancer]. *Hinyokika Kiyō - Acta Urologica Japonica*. 1990;36(3):307-17.
 배제사유 : 한국어 또는 영어로 출판되지 않은 연구
311. Fukasawa K. The studies of natural killer cell activity in uro-genital cancer patients. Investigation of natural killer cell activity from the standpoint of stage and antitumor therapy of genito-urinary tract carcinomas. [Japanese]. *Japanese Journal of Urology*.

1988;79(2):239-45.

배제사유 : 한국어 또는 영어로 출판되지 않은 연구

312. Furbert-Harris P P-GD, Laniyan I, Hunter K, A, Okomo-Awich J, Vaughn T, R, Forrest K, C, et al. Inhibition of prostate cancer cell growth by activated eosinophils. *Prostate*. 2003;57(2):165-75.

배제사유 : 동물실험 또는 전임상시험연구

313. Galluzzi L SL, Zitvogel L, Kroemer G. The secret ally: Immunostimulation by anticancer drugs. *Nature Reviews Drug Discovery*. 2012;11(3):215-33.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

314. Galustian C DA. Lenalidomide: A novel anticancer drug with multiple modalities. *Expert Opinion on Pharmacotherapy*. 2009;10(1):125-33.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

315. Galustian C SC, Elhage O, Ukimura O, Gill I, Smith R, Dasgupta P. Interleukin-15 downregulates inhibitory natural killer(NK) cell ligands expressed on prostate cancer cells resulting in increased NK cell activity in prostate cancer-immune effector cell cocultures. *Journal of Urology*. 2014;1):e265.

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

316. Galustian C SD, Sakellariou C, Elhage O, Smith R, A, G, Dasgupta P. A tale of tails-novel approach to immunotherapy of prostate cancer. *BJU International*. 2015;116 (Supplement 1):42-3.

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

317. Galustian C SD, Sakellariou C, Elhage O, Smith R, Dasgupta P. A tale of tails: A novel approach to immunotherapy of prostate cancer. *European Urology, Supplements*. 2017;16 (3):e1301.

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

318. Galustian C SD, Sakellariou C, Elhage O, Smith R, Dasgupta P. A tale of tails-a novel approach to immunotherapy of prostate cancer. *Journal of Urology*. 2016;1):e1092.

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

319. Galvao D. Exercise as a synergistic medicine for cancer. *Clinical Endocrinology*. 2018;89 (Supplement 1):28.

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

320. Galvao D. Exercise as a synergistic medicine for prostate cancer. *Asia-Pacific Journal of Clinical Oncology*. 2016;12 (Supplement 3):30-1.

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

321. Gammaitoni L LV, Mesiano G, Giraud L, Todorovic M, Carnevale-Schianca F, Aglietta M, et al. Immunotherapy of cancer stem cells in solid tumors: Initial findings and future prospective. *Expert Opinion on Biological Therapy*. 2014;14(9):1259-70.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

322. Ganapathy-Kanniappan S. Editorial: Cancer metabolism: Molecular targeting and

implications for therapy. *Frontiers in Oncology*. 2017;7 (SEP) (232).

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

323. Gannon P O, Poisson A, O, Delvoye N, Lapointe R, Mes-Masson A, M, Saad F. Characterization of the intra-prostatic immune cell infiltration in androgen-deprived prostate cancer patients. *Journal of Immunological Methods*. 2009;348(1-2):9-17.

배제사유 : 동물실험 또는 전임상시험연구

324. Gao J BC, Sharma P, Radvanyi L, G, Hwu P. Advances in the development of cancer immunotherapies. *Trends in Immunology*. 2013;34(2):90-8.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

325. Gao P ZA, Sun Z, Shan Y. Autologous natural killer cells have a therapeutic effect in advanced prostate cancer patients and can mediate cytotoxicity in vitro. *International Journal of Clinical and Experimental Medicine*. 2016;9(2):2399-406.

배제사유 : 동물실험 또는 전임상시험연구

326. Gao Y ZS, Jiang W, Huang M, Dai X. Effects of Ganopoly (a *Ganoderma lucidum* polysaccharide extract) on the immune functions in advanced-stage cancer patients. *Immunological Investigations*. 2003;32(3):201-15.

배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구

327. Garren H. Biological therapeutics research and development-GTCbio's fifth annual conference. *IDrugs*. 2010;13(12):840-2.

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

328. Garrido F. MHC/HLA class I loss in cancer cells. *Advances in Experimental Medicine and Biology*. 2019;1151:15-78.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

329. Gasparri A M, Sacchi A, Basso V, Cortesi F, Freschi M, Rrapaj E, et al. Boosting Interleukin-12 Antitumor Activity and Synergism with Immunotherapy by Targeted Delivery with isoDGR-Tagged Nanogold. *SMALL*. 2019;15(45):e1903462.

배제사유 : 동물실험 또는 전임상시험연구

330. Gavriiliuc O ZR, Bojin F, Paunescu V. CAR-based immunotherapy of EGFR-positive solid tumours using cytokine-activated peripheral blood killer cells. *Human Gene Therapy*. 2019;30 (12):A7.

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

331. GC J. Natural killer T cell and pathophysiology of asthma. *Korean J Pediatr*. 2010;2010 Feb 53(2):136-145.

배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구

332. Ge C LR, Song X, Qin S. Advances in evidence-based cancer adoptive cell therapy. *Chinese Clinical Oncology*. 2017;6(2):1-18.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

333. George D J, Moul J, W. Combined GM-CSF/docetaxel beneficial against HR prostate cancer. *Oncology Report*. 2005(SPRING):51-2.

배제사유 : 동물실험 또는 전임상시험연구

334. Ghiringhelli F MC, Martin F, Zitvogel L. The role of regulatory T cells in the control of natural killer cells: Relevance during tumor progression. *Immunological Reviews*. 2006;214(1):229-38.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

335. Ghiringhelli F RC, Hichami A, Delmas D. Immunomodulation and anti-inflammatory roles of polyphenols as anticancer agents. *Anti-Cancer Agents in Medicinal Chemistry*. 2012;12(8):852-73.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

336. Ghoneum M WM, Salem F, McKlain A, Attallah N, Gill G. Immunomodulatory and anticancer effects of active hemicellulose compound (AHCC). *International Journal of Immunotherapy*. 1995;11(1):23-8.

배제사유 : 동물실험 또는 전임상시험연구

337. Ghosh M RK, I, Maity S, Bhattacharjee S, Manjunath Y, Chakrabarty S, P, Dubey A, K, et al. Novel monoclonal antibody therapeutics for metastatic castration resistant prostate cancer. *Journal of Clinical Oncology. Conference*. 2019;37(Supplement 15).

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

338. Gil-Bernabe A M, Lucotti S, Muschel R, J. Coagulation And Metastasis: What Does The Experimental Literature Tell Us? *British Journal of Haematology*. 2013;162(4):433-41.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

339. Gillessen S G-VU, S, Gallerani E, Beck J, Sessa C, Omlin A, Mattiacci M, R, et al. A phase i dose-escalation study of the immunocytokine EMD 521873 (Selectikine) in patients with advanced solid tumours. *European Journal of Cancer*. 2013;49(1):35-44.

배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구

340. Gillgrass A E, Ashkar A, A. Innate immunosurveillance: The next frontier in the cancer immunotherapy toolbox. *Translational Cancer Research*. 2016;5(Supplement1):S66-S70.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

341. Gilliam A C. Update on graft versus host disease. *Journal of Investigative Dermatology*. 2004;123(2):251-7.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

342. Giuliani N AI. Novel insights into the role of interleukin-27 and interleukin-23 in human malignant and normal plasma cells. *Clinical Cancer Research*. 2011;17(22):6963-70.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

343. Glumac P M, LeBeau A, M. The role of CD133 in cancer: a concise review. *Clinical and Translational Medicine*. 2018;7 (1) (18).

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

344. Goddard E T, Bozic I, Riddell S, R, Ghajar C, M. Dormant tumour cells, their niches and the influence of immunity. *Nature Cell Biology*. 2018;20(11):1240-9.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

345. Goedegebuure R S, A, De Klerk L, K, Bass A, J, Derks S, Thijssen V, L, J, L. Combining radiotherapy with anti-angiogenic therapy and immunotherapy: A therapeutic triad for cancer? *Frontiers in Immunology*. 2019;10 (JAN) (3107).

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

346. Gogoi D CS, V. Targeting gamma delta T cells for cancer immunotherapy: Bench to bedside. *Indian Journal of Medical Research, Supplement*. 2013;138(NOV):755-61.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

347. Goldstein M R, Mascitelli L. Effect of statin use on biochemical outcome following radical prostatectomy. *BJU International*. 2011;108(2):E6-E8.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

348. Goldstein M R, Mascitelli L. Surgery and cancer promotion: Are we trading beauty for cancer? *Qjm*. 2011;104(9):811-5.

배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구

349. Gomes A Q, Martins D, S, Silva-Santos B. Targeting gammadelta T lymphocytes for cancer immunotherapy: From novel mechanistic insight to clinical application. *Cancer Research*. 2010;70(24):10024-7.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

350. Goutagny N EY, Hasan U, Lebecque S, Caux C. Targeting pattern recognition receptors in cancer immunotherapy. *Targeted Oncology*. 2012;7(1):29-54.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

351. Graham C H, Hamilton T, Barsoum I, Hu N, Li X, Elliott J, et al. Nitric oxide-mediated inhibition of hypoxia-induced immune escape in cancer. *Nitric Oxide - Biology and Chemistry*. 2010;1):S18.

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

352. Graham C H, Siemens D, R. Nitric oxide-mediated regulation of cancer immune escape. *Forum on Immunopathological Diseases and Therapeutics*. 2010;1(4):231-49.

배제사유 : NK 세포 활성도를 다루지 않는 연구

353. Grant J F, Iwasawa T, Sinn H, W, Siemens D, R, Griffith T, S, Takacs E, B, et al. Induction of protective immunity to RM-1 prostate cancer cells with ALVAC-IL-2/IL-12/TNF-alpha combination therapy. *International Journal of Cancer*. 2006;119(11):2632-41.

배제사유 : 동물실험 또는 전임상시험연구

354. Gridley D S, Makinde A, Y, Luo X, Rizvi A, Crapo J, D, Dewhirst M, W, et al. Radiation and a metalloporphyrin radioprotectant in a mouse prostate tumor model. *Anticancer Research*. 2007;27(5A):3101-9.

배제사유 : 동물실험 또는 전임상시험연구

355. Griffith T S, Kawakita M, Tian J, Ritchey J, Tartaglia J, Sehgal I, et al. Inhibition of murine prostate tumor growth and activation of immunoregulatory cells with

recombinant canarypox viruses. Journal of the National Cancer Institute. 2001;93(13):998-1007.

배제사유 : 동물실험 또는 전임상시험연구

356. Groner B vMV. Jak Stat signaling and cancer: Opportunities, benefits and side effects of targeted inhibition. Molecular and Cellular Endocrinology. 2017;451:1-14.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

357. Guang Hua X, Jae Wha K, Gao L, Ick Dong Y. Modulatory Effect of Four Azulene Derivatives from the Fruiting Bodies of Lactarius hatsudake on Interferon- γ Production. 대한화장품학회지. 2010;36(2):151-6.

배제사유 : 동물실험 또는 전임상시험연구

358. Guang Hua X, 김재화, Gao L, 유익동. 젓버섯아재비 자실체로부터 분리한 Azulene계 화합물이 Interferon- γ 생성에 미치는 영향. 대한화장품학회지. 2010;36(2):151-6.

배제사유 : 동물실험 또는 전임상시험연구

359. Guenechea-Sola M GK, E. Clinical phenotypes of patients with NK cell functional abnormalities. Journal of Allergy and Clinical Immunology. 2015;1):AB181.

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

360. Guerra N TY, X, Joncker N, T, Choy A, Gallardo F, Xiong N, Knoblaugh S, et al. NKG2D-deficient mice are defective in tumor surveillance in models of spontaneous malignancy. Immunity. 2008;28(4):571-80.

배제사유 : 동물실험 또는 전임상시험연구

361. Gujar S A, Pan D, A, Marcato P, Garant K, A, Lee P, W. Oncolytic virus-initiated protective immunity against prostate cancer. Molecular Therapy: the Journal of the American Society of Gene Therapy. 2011;19(4):797-804.

배제사유 : 동물실험 또는 전임상시험연구

362. Gulley J L, Madan R, A, Tsang K, Y, Jochems C, Marte J, L, Farsaci B, et al. Immune impact induced by PROSTVAC (PSA-TRICOM), a therapeutic vaccine for prostate cancer. Cancer Immunology Research. 2014;2(2):133-41.

배제사유 : NK 세포 활성도를 다루지 않는 연구

363. Guo T L, McCay J, A, Zhang L, X, Brown R, D, You L, Karrow N, A, et al. Genistein modulates immune responses and increases host resistance to B16F10 tumor in adult female B6C3F1 mice. Journal of Nutrition. 2001;131(12):3251-8.

배제사유 : 동물실험 또는 전임상시험연구

364. Guo X CS, Y. Deducator of Cytokinesis 2 in Cell Signaling Regulation and Disease Development. Journal of Cellular Physiology. 2017;232(8):1931-40.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

365. Gutkin D W, Shurin M, R. Clinical evaluation of systemic and local immune responses in cancer: Time for integration. Cancer Immunology, Immunotherapy. 2014;63(1):45-57.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

366. Guyre C A, Fanger M, W. Macrophage-targeted killing and vaccines. Research in

Immunology. 1998;149(7-8):655-60.

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

367. H YDAS. Current Status and Future Perspectives of Dendritic Cell-Based Cancer Immunotherapy. *Scandinavian Journal of Immunology*. 2013;78(2):167-71.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

368. Haas G P, Solomon D, Rosenberg S, A. Tumor-infiltrating lymphocytes from nonrenal urological malignancies. *Cancer Immunology Immunotherapy*. 1990;30(6):342-50.

배제사유 : 동물실험 또는 전임상시험연구

369. Haas G P, Solomon D, Rosenberg S, A. Tumor-infiltrating lymphocytes from nonrenal urological malignancies. *Cancer Immunology, Immunotherapy*. 1990;30(6):342-50.

배제사유 : 동물실험 또는 전임상시험연구

370. Hackett R QX, Swanson P, Luk K, C, Das Gupta J, Onlamoon N, Gaughan C, et al. XM RV: Analysis of viral kinetics, tissue tropism and identification of serological markers of infection. *Vox Sanguinis*. 2010;1):71.

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

371. Hagooly A GC, Dotan S, Dissoki S, Billauer H, Abourbeh G, Elmachliy S, et al. Can NK cells ligands be targeted for cancer diagnosis and treatment? *Molecular Imaging and Biology*. 2010;2):S961.

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

372. Hahm E R, Singh S, V. D, L-Sulforaphane inhibits constitutive and interleukin 6-induced activation of signal transducer and activator of transcription 3 in human prostate cancer cells. *Cancer Research. Conference: 101st Annual Meeting of the American Association for Cancer Research, AACR*. 2010;70(8 SUPPL. 1).

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

373. Hakansson L. Cancer immunosuppression induced by albumin derived neo-structures. *Journal of Translational Medicine. Conference: Immunotherapy Bridge and Melanoma Bridge*. 2018;17(Supplement 1).

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

374. Hall S J, Canfield S, E, Yan Y, Hassen W, Selleck W, A, Chen S, H. A novel bystander effect involving tumor cell-derived Fas and FasL interactions following Ad.HSV-tk and Ad.mIL-12 gene therapies in experimental prostate cancer. *Gene Therapy*. 2002;9(8):511-7.

배제사유 : 동물실험 또는 전임상시험연구

375. Hall S J, Sanford M, A, Atkinson G, Chen S, H. Induction of potent antitumor natural killer cell activity by herpes simplex virus-thymidine kinase and ganciclovir therapy in an orthotopic mouse model of prostate cancer. *Cancer Research*. 1998;58(15):3221-5.

배제사유 : 동물실험 또는 전임상시험연구

376. Hamilton T K, Barsoum I, Li X, Miles E, A, Elliott J, Siemens D, R, et al. A mechanism of hypoxia-induced immune escape in cancer cells. *Cancer Research. Conference: 102nd Annual Meeting of the American Association for Cancer Research, AACR*. 2011;71(8

SUPPL. 1).

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

377. Hamilton T K, Hu N, Kolomitro K, Bell E, N, Maurice D, H, Graham C, H, et al. Potential therapeutic applications of phosphodiesterase inhibition in prostate cancer. *World Journal of Urology*. 2013;31(2):325-30.

배제사유 : 동물실험 또는 전임상시험연구

378. Han Y GZ, Si T, Wang H. Effect of cryosurgery on regulatory CD4+CD25+ T lymphocytes in the peripheral blood of patients with advanced prostate carcinoma. [Chinese]. *Chinese Journal of Clinical Oncology*. 2009;36(8):227-9.

배제사유 : 한국어 또는 영어로 출판되지 않은 연구

379. Han Y LJ, Zhang M, Kim J, Wu X, Sun D, Gu J. Genome-wide DNA methylation profiling of peripheral blood leukocytes identifies predictors of aggressive prostate cancer. *Cancer Research. Conference*. 2018;78(13 Supplement 1).

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

380. Hansen T F, Nelderby L, Zedan A, H, Mejlholm I, Henriksen J, R, Steffensen K, D, et al. Correlation Between Natural Killer Cell Activity and Treatment Effect in Patients with Disseminated Cancer. *Translational Oncology*. 2019;12(7):968-72.

배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구

381. Hansen T NL, Zedan A, H, Mejlholm I, Henriksen J, Steffensen K, D, Thomsen C, B, et al. Correlation between natural killer cell activity and treatment effect in patients with disseminated cancer. *Journal of Clinical Oncology. Conference*. 2018;36(15 Supplement 1).

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

382. Hao Y B, Yi S, Y, Ruan J, Zhao L, Nan K, J. New insights into metronomic chemotherapy-induced immunoregulation. *Cancer Letters*. 2014;354(2):220-6.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

383. Hara T TK. Pleiotropic functions of the CXC-type chemokine CXCL14 in mammals. *Journal of Biochemistry*. 2012;151(5):469-76.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

384. Hardy B RA, Rubin M, Sprecher E, Sella A, Flex D, Lelcuk S, et al. Cancer disease predictive diagnosis: BAT/CD3-positive lymphocytes in cancer patients. *International Journal of Oncology*. 2005;26(4):971-5.

배제사유 : NK 세포 활성도를 다루지 않는 연구

385. Hare N C, Arnott I, D, R, Satsangi J. Therapeutic options in acute severe ulcerative colitis. *Expert Review of Gastroenterology and Hepatology*. 2008;2(3):357-70.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

386. Haris M YS, K, Rizwan A, Singh A, Wang E, Hariharan H, Reddy R, et al. Molecular magnetic resonance imaging in cancer. *Journal of Translational Medicine*. 2015;13 (1) (313).

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

387. Hassan W SM, A, Woo S, L, Chen S, H, Hall S, J. Prospects for herpes-simplex-virus thymidine-kinase and cytokine gene transduction as immunomodulatory gene therapy for prostate cancer. *World Journal of Urology*. 2000;18(2):130-5.
 배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
388. Hatano K KY, Miyamoto Y, Nonomura N, Kaneda Y. Efficient eradication of castration-resistant human prostate cancers by inactivated sendai virus particle. *Molecular Therapy*. 2011;1):S89.
 배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
389. Hatano K KY, Miyamoto Y, Nonomura N, Kaneda Y. Efficient eradication of castration-resistant human prostate cancers by nonreplicating oncolytic virus, inactivated sendai virus particle. *Journal of Gene Medicine*. 2014;16 (7-8):258.
 배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
390. Hatano K NY, Miyamoto Y, Kaneda Y, Nonomura N. Mechanism of efficient eradication of castration-resistant human prostate cancer cells by inactivated Sendai virus particle. *Cancer Research. Conference: 102nd Annual Meeting of the American Association for Cancer Research, AACR*. 2011;71(8 SUPPL. 1).
 배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
391. Hattori T SM, Nishimura T, Kawamura N, Akimoto M. Different susceptibilities of lymphokine-activated killer cells (LAK cells) among primary and metastatic renal cell carcinoma derived from the same patient. *British Journal of Urology*. 1995;75(4):448-51.
 배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
392. Haukaas S A. Immunological effects of diethylstilbestrol and estramustine phosphate. *Scandinavian Journal of Urology & Nephrology Supplementum*. 1984;83:1-32.
 배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
393. Havranek E G, Whelan M, A, Greenhalgh R, Dalglish A, G, Pandha H. Advances in prostate cancer immunotherapy. *Surgical Oncology*. 2002;11(1-2):35-45.
 배제사유 : NK 세포 활성도를 다루지 않는 연구
394. Hayakawa M MK, Nagakura K, Hata M, Fujioka T, Nakamura H, Murai M. [Studies on human natural killer (NK) cell activity against cell lines derived from malignant urinary tract tumors. Part 3: Effects of OK432 on human NK cell activity and proliferation of tumor cells]. *Nippon Hinyokika Gakkai Zasshi - Japanese Journal of Urology*. 1984;75(7):1124-33.
 배제사유 : 한국어 또는 영어로 출판되지 않은 연구
395. Hayashi Y K-YT, Mizokami A, Hazekawa M, Yakura T, Naito M, Takeuchi H, et al. Uncarboxylated osteocalcin induces antitumor immunity against mouse melanoma cell growth. *Journal of Cancer*. 2017;8(13):2478-86.
 배제사유 : 동물실험 또는 전임상시험연구
396. Hayes B D, Brady L, Pollak M, Finn S, P. Exercise and Prostate Cancer: Evidence and Proposed Mechanisms for Disease Modification. *Cancer Epidemiology, Biomarkers & Prevention*. 2016;25(9):1281-8.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

397. Haynes N M, Smyth M, J. Immunotherapeutic strategies as adjuncts to local radiotherapy. *Immunotherapy*. 2012;4(2):129-31.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

398. Healy C G, Simons J, W, Carducci M, A, DeWeese T, L, Bartkowski M, Tong K, P, et al. Impaired expression and function of signal-transducing zeta chains in peripheral T cells and natural killer cells in patients with prostate cancer. *Cytometry*. 1998;32(2):109-19.

배제사유 : NK 세포 활성도를 다루지 않는 연구

399. Hefferon K L. Repurposing plant virus nanoparticles. *Vaccines*. 2018;6 (1) (11).

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

400. Helmy K Y, Patel S, A, Nahas G, R, Rameshwar P. Cancer immunotherapy: Accomplishments to date and future promise. *Therapeutic Delivery*. 2013;4(10):1307-20.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

401. Hermanson D L, Kaufman D, S. Utilizing chimeric antigen receptors to direct natural killer cell activity. *Frontiers in Immunology*. 2015;6 (APR) (195).

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

402. Hershkovitz O JS, Bloushtain N, Zilka A, Landau G, Bar-Ilan A, Lichtenstein R, G, et al. Characterization of the recognition of tumor cells by the natural cytotoxicity receptor, NKp44. *Biochemistry*. 2007;46(25):7426-36.

배제사유 : 동물실험 또는 전임상시험연구

403. Herskind C FK, Lohr J, Li C, Y, Wenz F, Lohr F. Antitumoral action of interferons and interleukins in combination with radiotherapy. Part II: Radiobiological and immunologic strategies. [German]. *Strahlentherapie und Onkologie*. 2004;180(6):331-9.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

404. Herting F HS, Friess T, Lehmann C, Bacac M, Dangl M, Klein C. Combination of the glycoengineered type II CD20 antibody obinutuzumab (GA101) and the MDM2 selective antagonist RG7388 results in superior anti-tumor activity. *Blood*. Conference: 56th Annual Meeting of the American Society of Hematology, ASH. 2014;124(21).

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

405. Hickman O GC, Elhage O, Smith R, A, Ukimura O, Gill I, Vyakarnam A, et al. Ps20 inhibits expansion of CD8-t cells and nk cells in the prostate cancer microenvironment and inhibits killing of prostate cancer cells. *Journal of Endourology*. 2012;1):A425.

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

406. Hickman O GC, Elhage O, Smith R, A, Ukimura O, Gill I, Vyakarnam A, et al. Ps20 inhibits expansion of CD8-T cells and NK cells in the prostate cancer microenvironment and inhibits killing of prostate cancer cells. *Journal of Urology*. 2012;1):e133.

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

407. Hicks K C, Fantini M, Donahue R, N, Schwab A, Knudson K, M, Tritsch S, R, et al. Epigenetic priming of both tumor and NK cells augments antibody-dependent cellular

cytotoxicity elicited by the anti-PD-L1 antibody avelumab against multiple carcinoma cell types. *OncoImmunology*. 2018;7 (11) (e1466018).

배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구

408. Higano C S, Vogelzang N, J, Sosman J, A, Feng A, Caron D, Small E, J. Safety and biological activity of repeated doses of recombinant human Flt3 ligand in patients with bone scan-negative hormone-refractory prostate cancer. *Clinical Cancer Research*. 2004;10(4):1219-25.

배제사유 : 동물실험 또는 전임상시험연구

409. Hiller J BG, Gottschalk A. Understanding clinical strategies that may impact tumour growth and metastatic spread at the time of cancer surgery. *Best Practice and Research: Clinical Anaesthesiology*. 2013;27(4):427-39.

배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구

410. Hirayasu K AH. Functional and genetic diversity of leukocyte immunoglobulin-like receptor and implication for disease associations. *Journal of Human Genetics*. 2015;60(11):703-8.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

411. Hisamatsu T, Mikami Y, Matsuoka K, Kanai T, Hibi T. Immunological Abnormalities in the Pathogenesis of Inflammatory Bowel Disease. *Intestinal Research*. 2012;10(4):317.

배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구

412. Holdenrieder S SP, Peterfi A, Nagel D, Steinle A, Salih H, R. Soluble MICA in malignant diseases. *International Journal of Cancer*. 2006;118(3):684-7.

배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구

413. Hong H S, Hipp M, M, Doener F, Billingsley J, M, Backert L, Kohlbacher O, et al. Up-regulation of a T and NK cell gene signature in peripheral blood is associated with mRNA-based immunotherapy in lung and prostate cancer. *Journal for ImmunoTherapy of Cancer*. Conference: 32nd Annual Meeting and Pre Conference Programs of the Society for Immunotherapy of Cancer, SITC. 2017;5(Supplement 2).

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

414. Hong J T, Son D, J, Lee C, K, Yoon D, Y, Lee D, H, Park M, H. Interleukin 32, inflammation and cancer. *Pharmacology & Therapeutics*. 2017;174:127-37.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

415. Hood S P, Foulds G, A, Imrie H, Reeder S, McArdle S, E, B, Khan M, et al. Phenotype and Function of Activated Natural Killer Cells From Patients With Prostate Cancer: Patient-Dependent Responses to Priming and IL-2 Activation. *Frontiers in Immunology*. 2018;9:3169.

배제사유 : 동물실험 또는 전임상시험연구

416. Hood S P, Foulds G, A, Imrie H, Reeder S, McArdle S, W, B, Khan M, et al. Phenotype and function of activated natural killer cells from patients with prostate cancer: Patient-dependent responses to priming and IL-2 activation. *Frontiers in Immunology*. 2019;10 (JAN) (03169).

배제사유 : 동물실험 또는 전임상시험연구

417. Horinaka M YT, Kishi A, Akatani K, Yasuda T, Kouhara J, Wakada M, et al. Lactobacillus plantarum induces TRAIL production and facilitates natural killer activity against cancer cells. Cancer Research. Conference: 102nd Annual Meeting of the American Association for Cancer Research, AACR. 2011;71(8 SUPPL. 1).
배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
418. Horinaka M YT, Kishi A, Akatani K, Yasuda T, Kouhara J, Wakada M, et al. Lactobacillus strains induce TRAIL production and facilitate natural killer activity against cancer cells. FEBS Letters. 2010;584(3):577-82.
배제사유 : 동물실험 또는 전임상시험연구
419. Horowitz M NE, Sharon E, Ben-Eliyahu S. Exploiting the critical perioperative period to improve long-term cancer outcomes. Nature Reviews Clinical Oncology. 2015;12(4):213-26.
배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
420. Hu Q P, Kuang J, Y, Yang Q, K, Bian X, W, Yu S, C. Beyond a tumor suppressor: Soluble E-cadherin promotes the progression of cancer. International Journal of Cancer. 2016;138(12):2804-12.
배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
421. Hu S WX. The role of helper innate lymphoid cells in cancer. Immunotherapy. 2019;11(12):1067-81.
배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구
422. Hu W GZ, Y, Wang W. [Bortezomib enhances the sensitivity of prostate cancer cells to natural killer cell-mediated cytotoxicity]. Zhong Hua Nan Ke Xue. 2014;20(3):218-24.
배제사유 : 한국어 또는 영어로 출판되지 않은 연구
423. Hu W LJ, Sun D, S, Liu H, R, Liu X, L, Li Y. Anti-CD3 monoclonal antibody activated autologous killer cells in treatment of advanced malignant tumor: An observation of short-term effectiveness. [Chinese]. Chinese Journal of Cancer Biotherapy. 2008;15(2):155-8.
배제사유 : 한국어 또는 영어로 출판되지 않은 연구
424. Hu W ZR, R, Cui H, X, Yue D, Wang Y, Jiang Y, H. Effects of bortezomib in sensitizing human prostate cancer cell lines to NK-mediated cytotoxicity. Asian Journal of Andrology. 2012;14(5):695-702.
배제사유 : 동물실험 또는 전임상시험연구
425. Hu Y C, Yao K, Wu T, Y. Baculovirus as an expression and/or delivery vehicle for vaccine antigens. Expert Review of Vaccines. 2008;7(3):363-71.
배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
426. Hu Y L, Fu Y, H, Tabata Y, Gao J, Q. Mesenchymal stem cells: A promising targeted-delivery vehicle in cancer gene therapy. Journal of Controlled Release. 2010;147(2):154-62.
배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

427. Huber M L, Haynes L, Parker C, Iversen P. Response. *Journal of the National Cancer Institute*. 2012;104(14):1109-12.
배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
428. Huntington N. CIS is a potent checkpoint in NK cell-mediated tumour immunity. *European Journal of Immunology*. 2016;46 (Supplement 1):792.
배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
429. Huon Y PB, Leclerc-Desaulniers K, Delvoye N, Mes-Masson A, M, Saad F. Towards understanding the interplay between androgen receptors, androgens, and IKK in the tumour growth control of prostate cancer cells. *Canadian Urological Association Journal*. 2016;10 (5-6 Supplement 1):S45.
배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
430. Hurwitz M D, Kaur P, Nagaraja G, M, Bausero M, A, Manola J, Asea A. Radiation therapy induces circulating serum Hsp72 in patients with prostate cancer. *Radiotherapy & Oncology*. 2010;95(3):350-8.
배제사유 : 동물실험 또는 전임상시험연구
431. Iannello A TT, W, Ardolino M, Marcus A, Raulet D, H. Immunosurveillance and immunotherapy of tumors by innate immune cells. *Current Opinion in Immunology*. 2016;38:52-8.
배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
432. Ichikawa T LJ, C, Christensson P, I, Hartley-Asp B, Isaacs J, T. The antitumor effects of the quinoline-3-carboxamide linomide on Dunning R-3327 rat prostatic cancers. *Cancer Research*. 1992;52(11):3022-8.
배제사유 : 동물실험 또는 전임상시험연구
433. Iida S IT, Shinagawa A, Suzuki K, Takezako N, Aoki M. Safety and efficacy of daratumumab in combination with bortezomib and dexamethasone in Japanese patients with relapsed or refractory multiple myeloma. *International Journal of Hematology*. 2018;107(4):460-7.
배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구
434. Ilett E KT, Donnelly O, Thompson J, Willmon C, Diaz R, Zaidi S, et al. Cytokine conditioning enhances systemic delivery and therapy of an oncolytic virus. *Molecular Therapy*. 2014;22(10):1851-63.
배제사유 : 동물실험 또는 전임상시험연구
435. Ilic D. Latest developments in the field of stem cell research and regenerative medicine compiled from publicly available information and press releases from nonacademic institutions 1-30 June, 2017. *Regenerative Medicine*. 2017;12(7):887-92.
배제사유 : 동물실험 또는 전임상시험연구
436. Inamoto T AH. Immunotherapy of genitourinary malignancies. *Journal of Oncology*. 2012;(397267).
배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

437. Inman B VT, Yu E, Y, Campogan D, Haynes H, Sheikh N, A, George D. Real-time imaging demonstrating T-cell mediated destruction of prostatic acid phosphatase (PAP)-expressing cells in patients (pts) treated with sipuleucel-T (SIP-T). *Journal of Urology*. 2018;199 (4 Supplement 1):e307.
 배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
438. Inui T KD, Kubo K, Mette M, Uto Y, Hori H, Sakamoto N. Clinical experience of integrative cancer immunotherapy with GcMAF. *Anticancer Research*. 2013;33(7):2917-9.
 배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
439. Iscaro A HN, F, Muthana M. Nanoparticles: Properties and applications in cancer immunotherapy. *Current Pharmaceutical Design*. 2019;25(17):1962-79.
 배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
440. Isenalumhe L L, Van Den Bergh M, Wang E, Schaible B, Ma Z, Zhang L, et al. Frequency of secondary malignancies (SM) in patients with large granular lymphocytic leukemia (LGLL): A single institutional experience. *Journal of Clinical Oncology. Conference*. 2017;35(15 Supplement 1).
 배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
441. Isenalumhe L VDBM, Wang E, Schaible B, Ma Z, Zhang L, Sokol L. High frequency of secondary malignancies in patients with large granular lymphocytic leukemia: A single institutional experience. *Haematologica*. 2017;102 (Supplement 2):748.
 배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
442. Ishii T WE, Yanagawa T. Novel roles of peroxiredoxins in inflammation, cancer and innate immunity. *Journal of Clinical Biochemistry and Nutrition*. 2012;50(2):91-105.
 배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
443. Ito A KY, Kakoi N, Shimada S, Saito S, Arai Y. [Disialosyl globopentaosylceramide (DSGb5) as a biomarker of prostate cancer]. *Nippon Rinsho - Japanese Journal of Clinical Medicine*. 2016;74 Suppl 3:196-200.
 배제사유 : 한국어 또는 영어로 출판되지 않은 연구
444. Jachetti E MS, Grioni M, Ricupito A, Brambillasca C, Calcinotto A, Freschi M, et al. Targeting cancer stem/initiating cells results in successful immunotherapy of autochthonous prostate tumors. *Immunology*. 2012;1:54.
 배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
445. Jachetti E MS, Grioni M, Ricupito A, Brambillasca C, Generoso L, Calcinotto A, et al. Prostate cancer stem cells are targets of both innate and adaptive immunity and elicit tumor-specific immune responses. *Oncoimmunology*. 2013;2(5):e24520.
 배제사유 : 동물실험 또는 전임상시험연구
446. Jachetti E MS, Grioni M, Ricupito A, Brambillasca C, Generoso L, Calcinotto A, et al. Prostate cancer stem/initiating cells are targets of both innate and adaptive immunity and elicit potent immune responses against autochthonous prostate tumors. *Cancer Research. Conference: 104th Annual Meeting of the American Association for Cancer Research, AACR*. 2013;73(8 SUPPL. 1).

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

447. Jachimowicz R D, Fracasso G, Yazaki P, J, Power B, E, Borchmann P, Engert A, et al. Induction of in vitro and in vivo NK cell cytotoxicity using high-avidity immunoligands targeting prostate-specific membrane antigen in prostate carcinoma. *Molecular Cancer Therapeutics*. 2011;10(6):1036-45.

배제사유 : 동물실험 또는 전임상시험연구

448. Jackson H J, Rafiq S, Brentjens R, J. Driving CAR T-cells forward. *Nature Reviews Clinical Oncology*. 2016;13(6):370-83.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

449. Jacobs J F, M, Coulie P, G, Figdor C, G, Adema G, J, De Vries I, J, M, Hoogerbrugge P, M. Targets for active immunotherapy against pediatric solid tumors. *Cancer Immunology, Immunotherapy*. 2009;58(6):831-41.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

450. Jain A. Curcumin suppresses PhIP induced inflammatory protein expression in breast epithelial cells. *Cancer Research*. Conference: American Association for Cancer Research Annual Meeting. 2019;79(13 Supplement).

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

451. Jain P IS, Dunavin N, Klotz J, K, Lu K, Koklanaris E, Draper D, et al. Clofarabine followed by lenalidomide for treatment of high risk myelodysplastic syndromes and acute myeloid leukemia-preliminary clinical outcomes and potential immune-modulating effects. *Blood*. Conference: 58th annual meeting of the american society of hematology, ASH 2016. United states. Conference start: 20161203. Conference end: 20161206. 2016;128(22) .

배제사유 : 동물실험 또는 전임상시험연구

452. Janakiram M SU, A, Liu W, Zhao A, Schoenberg M, P, Zang X. The third group of the B7-CD28 immune checkpoint family: HHLA2, TMIGD2, B7x, and B7-H3. *Immunological Reviews*. 2017;276(1):26-39.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

453. Jang Y J, Kim J, H, Byun S. Modulation of autophagy for controlling immunity. *Cells*. 2019;8 (2) (138).

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

454. Jeon J M, Kwon O, K, Na A, Y, Sung E, J, Cho I, J, Kim M, et al. Secretome profiling of PC3/nKR cells, a novel highly migrating prostate cancer subline derived from PC3 cells. *PLoS ONE [Electronic Resource]*. 2019;14(8):e0220807.

배제사유 : 동물실험 또는 전임상시험연구

455. Jha G G, Miller J, S. A randomized, double-blind phase 2 study of sipuleucel-T followed by indoximod or placebo in the treatment of patients with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer. *Journal of Clinical Oncology*. Conference. 2014;32(15 SUPPL. 1).

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

456. Jia Y J, Li X, J, Li C, Zhao C. Clinical efficacy analysis of treating advanced prostate cancer by yiqi jiedu quyu recipe combined endocrine therapy. Zhongguo zhong xi yi jie he za zhi zhongguo zhongxiyi jiehe zazhi = chinese journal of integrated traditional and western medicine. 2013;33(4):448-51.
배제사유 : NK 세포 활성도를 다루지 않는 연구
457. Jo DS HJ, Kim SY, Kim MS, Yi HK, Lee DY, Hwang PH. Changes in the expression of cytokines and apoptosis-related genes in children with infectious mononucleosis. Korean J Pediatr. 2009;Dec 52(12):1348-1357.
배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구
458. Jochems C BB, Madan R, A, Poole D, J, Ning Y, M, Figg W, D, Liewehr D, J, et al. Analysis of immune cell subsets in a multidrug therapeutic regimen for patients with metastatic castration-resistant prostate cancer. Cancer Research. Conference: 105th Annual Meeting of the American Association for Cancer Research, AACR. 2014;74(19 SUPPL. 1).
배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
459. Jochems C MR, A, Fernando R, I, Gulley J, L, Tsang K, Y, Schlom J. Analysis of immune responses as a consequence of androgen deprivation therapy in patients with biochemical progression of prostate cancer. Cancer Research. Conference: 107th Annual Meeting of the American Association for Cancer Research, AACR. 2016;76(14 Supplement).
배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
460. Jochems C TJ, A, Madan R, A, Dahut W, L, Gulley J, L, Schlom J, Tsang K, Y. A combination trial of vaccine plus ipilimumab in patients with metastatic castration-resistant prostate cancer: Immune correlates. Cancer Research. Conference: 104th Annual Meeting of the American Association for Cancer Research, AACR. 2013;73(8 SUPPL. 1).
배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
461. Jochems C TJ, A, Poole D, J, Beatson M, Mulquin M, Madan R, A, Figg W, D, et al. Combination treatment with Bevacizumab, Lenalidomide, Docetaxel and Prednisone (ART-P) does not impact the immune response in patients with metastatic castration-resistant prostate cancer. Cancer Research. Conference: 103rd Annual Meeting of the American Association for Cancer Research, AACR. 2012;72(8 SUPPL. 1).
배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
462. Jochems C TJ, A, Tsang K, Y, Madan R, A, Dahut W, L, Liewehr D, J, Steinberg S, M, et al. A combination trial of vaccine plus ipilimumab in metastatic castration-resistant prostate cancer patients: immune correlates. Cancer Immunology, Immunotherapy. 2014;63(4):407-18.
배제사유 : NK 세포 활성도를 다루지 않는 연구
463. Johansson S LM, Henriksson R. Alterations of tumour cells, stroma and apoptosis in rat prostatic adenocarcinoma following treatment with histamine, interleukin-2 and irradiation. Anticancer Research. 1999;19(3A):1961-9.

배제사유 : 동물실험 또는 전임상시험연구

464. John E LT, C, Buchser W, J, Pitt B, R, Basse P, H, Butterfield L, H, Kalinski P, et al. Zinc in innate and adaptive tumor immunity. *Journal of Translational Medicine*. 2010;8 (118).

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

465. Johnke R M, Edwards J, M, Kovacs C, J, Evans M, J, Daly B, M, Karlsson U, L, et al. Response of T lymphocyte populations in prostate cancer patients undergoing radiotherapy: Influence of neoadjuvant total androgen suppression. *Anticancer Research*. 2005;25(4):3159-66.

배제사유 : NK 세포 활성도를 다루지 않는 연구

466. Johnson L D, S, Nesslinger N, J, Blood P, A, Chima N, Richier L, R, Ludgate C, et al. Tumor-associated autoantibodies correlate with poor outcome in prostate cancer patients treated with androgen deprivation and external beam radiation therapy. *OncoImmunology*. 2014;3 (6) (e29243).

배제사유 : NK 세포 활성도를 다루지 않는 연구

467. Johnson L E, Olson B, M, McNeel D, G. Antigen-specific immunity and regulation as predictive biomarkers for anti-tumor vaccination. *Cancer Research*. Conference: 107th Annual Meeting of the American Association for Cancer Research, AACR. 2016;76(14 Supplement).

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

468. Johnson L E, Olson B, M, McNeel D, G. Pretreatment antigen-specific immunity and regulation - association with subsequent immune response to anti-tumor DNA vaccination. *Journal for Immunotherapy of Cancer*. 2017;5(1):56.

배제사유 : 동물실험 또는 전임상시험연구

469. Johrer K PL, Olivier A, Maizner E, Zelle-Rieser C, Greil R. Tumour-immune cell interactions modulated by chemokines. *Expert Opinion on Biological Therapy*. 2008;8(3):269-90.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

470. Joshi H N, Langerod A, Troyanskaya O, G, Borresen-Dale A, L, Kristensen V, N. Differential enrichment of pathways in association with TP53 mutation status of breast cancers. *European Journal of Cancer, Supplement*. 2010;8 (5):204.

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

471. Kabiljo J HF, Carotta S, Bergmann M. Radiotherapy as a backbone for novel concepts in cancer immunotherapy. *Cancers*. 2020;12 (1) (79).

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

472. Kalinski P EH, Zeh H, J, Okada H, Butterfield L, H, Kirkwood J, M, Bartlett D, L. Dendritic cells in cancer immunotherapy: Vaccines or autologous transplants? *Immunologic Research*. 2011;50(2-3):235-47.

배제사유 : 평가대상 암 환자를 대상으로 하지 않는 연구

473. Kalinski P MR, Urban J. Dendritic cells in cancer immunotherapy: Vaccines and

combination immunotherapies. *Expert Review of Vaccines*. 2013;12(3):285-95.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

474. Kalinski P NY, Watchmaker P, Giermasz A, Muthuswamy R, Mailliard R, B. Helper roles of NK and CD8+ T cells in the induction of tumor immunity: Polarized dendritic cells as cancer vaccines. *Immunologic Research*. 2006;36(1-3):137-46.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

475. Kalinski P OH. Polarized dendritic cells as cancer vaccines: Directing effector-type T cells to tumors. *Seminars in Immunology*. 2010;22(3):173-82.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

476. Kalinski P UJ, Narang R, Berk E, Wieckowski E, Muthuswamy R. Dendritic cell-based therapeutic cancer vaccines: What we have and what we need. *Future Oncology*. 2009;5(3):379-90.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

477. Kalland T HS. Effect of treatment with diethylstilbestrol-polyestradiol phosphate or estramustine phosphate (estracyt) on natural killer cell activity in patients with prostatic cancer. *Investigative Urology*. 1981;18(8):437-9.

배제사유 : NK 세포 활성도를 다루지 않는 연구

478. Kamigaki T IH, Okada S, Matsuda E, Tanaka M, Oguma E, Kinoshita Y, et al. Improvement of impaired immunological status of patients with various types of advanced cancers by autologous immune cell therapy. *Anticancer Research*. 2015;35(8):4535-44.

배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구

479. Kaneda Y. Development of anti-cancer strategies using HVJ envelope. *Journal of Gene Medicine*. 2012;14 (11):652.

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

480. Kang J DS, Cardenes H, R, R, Pilonis K, A, Jozsef G, Ng J, Ballman K, V, et al. Effect of Radiotherapy Variables on Circulating Effectors of Immune Response and Local Microbiome. *International Journal of Radiation Oncology Biology Physics*. 2019;105 (1 Supplement):E646.

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

481. Karzai F VD, Madan R, A, Owens H, Cordes L, M, Hankin A, Couvillon A, et al. Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations 11 *Medical and Health Sciences* 1112 *Oncology and Carcinogenesis*. *Journal for ImmunoTherapy of Cancer*. 2018;6 (1) (141).

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

482. Kastelan M KI, Tarle M. NK cell activity in treated prostate cancer patients as a probe for circulating tumor cells: hormone regulatory effects in vivo. *Prostate*. 1992;21(2):111-20.

배제사유 : 동물실험 또는 전임상시험연구

483. Kastelan M KK, Tarle R, Kraljic I, Tarle M. Analysis of NK cell activity, lymphocyte

- reactivity to mitogens and serotest PSA and TPS values in patients with primary and disseminated prostate cancer, PIN and BPH. *Anticancer Research*. 1997;17(3 B):1671-5.
 배제사유 : NK 세포 활성도를 다루었으나 인터페론 감마를 보고하지 않은 연구
484. Kastelan M KK, Tarle R, Kraljic I, Tarle M. Analysis of NK cell activity, lymphocyte reactivity to mitogens and serotest PSA and TPS values in patients with primary and disseminated prostate cancer, PIN and BPH. *Anticancer Research*. 1997;17(3B):1671-5.
 배제사유 : NK 세포 활성도를 다루었으나 인터페론 감마를 보고하지 않은 연구
485. Katoh M KM. Identification and characterization of human FMNL1, FMNL2 and FMNL3 genes in silico. *International Journal of Oncology*. 2003;22(5):1161-8.
 배제사유 : 동물실험 또는 전임상시험연구
486. Kawaguchi Y MY, Inoue T, Kaneda Y. Efficient eradication of hormone-resistant human prostate cancers by inactivated Sendai virus particle. *International Journal of Cancer*. 2009;124(10):2478-87.
 배제사유 : 동물실험 또는 전임상시험연구
487. Kawakami K KM, Puri R, K. IL-13 receptor-targeted cytotoxin cancer therapy leads to complete eradication of tumors with the aid of phagocytic cells in nude mice model of human cancer. *Journal of Immunology*. 2002;169(12):7119-26.
 배제사유 : 동물실험 또는 전임상시험연구
488. Kawalec P SK, Malinowska-Lipien I, Brzostek T, Kozka M. European perspective on the management of rheumatoid arthritis: Clinical utility of tofacitinib. *Therapeutics and Clinical Risk Management*. 2018;14:15-29.
 배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
489. Kawasaki B T, Farrar W, L. Cancer stem cells, CD200 and immunoevasion. *Trends in Immunology*. 2008;29(10):464-8.
 배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
490. Kazi A HR, Long T, E, Kuhn D, J, Turos E, Dou Q, P. Novel N-thiolated beta-lactam antibiotics selectively induce apoptosis in human tumor and transformed, but not normal or nontransformed, cells. *Biochemical Pharmacology*. 2004;67(2):365-74.
 배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구
491. Kazi A UD, A, Kuhn D, J, Acebo A, L, Jackson E, R, Greenfelder G, P, Kumar N, B, et al. A natural musaceas plant extract inhibits proteasome activity and induces apoptosis selectively in human tumor and transformed, but not normal and non-transformed, cells. *International Journal of Molecular Medicine*. 2003;12(6):879-87.
 배제사유 : 동물실험 또는 전임상시험연구
492. Kees T EM. Innate immune cells in breast cancer - From villains to heroes? *Journal of Mammary Gland Biology and Neoplasia*. 2011;16(3):189-203.
 배제사유 : 동물실험 또는 전임상시험연구
493. Kesebir S. Bipolar disorders and cancer. *Psycho-Oncology*. 2011;2):25.
 배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

494. Khagi Y KG, Christos P, Akhtar N, H, Nanus D, M, Bander N, H, Tagawa S, T. Anti-prostate-specific membrane antigen (PSMA) monoclonal antibody J591 plus low-dose interleukin-2 (IL-2) in patients with recurrent prostate cancer (PC). *Cancer Research. Conference: 105th Annual Meeting of the American Association for Cancer Research, AACR. 2014;74(19 SUPPL. 1).*
 배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
495. Khatri A ZB, Doherty E, Chapman J, Ow K, Pwint H, Martiniello-Wilks R, et al. Combination of cytosine deaminase with uracil phosphoribosyl transferase leads to local and distant bystander effects against RM1 prostate cancer in mice. *Journal of Gene Medicine. 2006;8(9):1086-96.*
 배제사유 : 동물실험 또는 전임상시험연구
496. Khosravi N SL, Farajivafa V, Hanson E, D. Exercise training, circulating cytokine levels and immune function in cancer survivors: A meta-analysis. *Brain, Behavior, and Immunity. 2019;81:92-104.*
 배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
497. Kieliszek M BS. Selenium: Significance, and outlook for supplementation. *Nutrition. 2013;29(5):713-8.*
 배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
498. Kim DH KM, Cho JH, Lim NK, Park JI, Jeong SH, Lee HW, et al. Aging Effects on Dendritic Cells after Total Body Irradiation in Mice. *Korean J Hematol. 2007;Sep 42(3):224-232.*
 배제사유 : 동물실험 또는 전임상시험연구
499. Kim H EH, S, Kong S, Y, Park S, R, Kim S, Y, Ro J, Park S, Y. Prognostic significance of immune thrombocytopenic purpura in patients with malignancy. *Blood. Conference: 52nd Annual Meeting of the American Society of Hematology, ASH. 2010;116(21).*
 배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
500. Kim H GT, S, Panyam J. Poly(D,L-lactide-co-glycolide) Nanoparticles as Delivery Platforms for TLR7/8 Agonist-Based Cancer Vaccine. *Journal of Pharmacology and Experimental Therapeutics. 2019;370(3):715-24.*
 배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
501. Kim JY, Huh K, Lee KY, Yang JM, Kim TJ. Nickel induces secretion of IFN-gamma by splenic natural killer cells. *Exp Mol Med. 2009;41(4):288-95.*
 배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구
502. Kim KJ PS, Lee YS. Immunologic Effect of Gamma Interferon on Human Melanoma Cell Lime A - 375 - With Special Emphasis on Cytolytic Activity , Antiproliferative Activity and HLA Antigen Expression. *Korean J Dermatol. 1990;Apr 28(2):147-158.*
 배제사유 : 동물실험 또는 전임상시험연구
503. King T PA, D. Co-expression of an engineered cell-surface sialidase by CART cells improves anti-cancer activity of NK cells in solid tumors. *Cytherapy. 2019;21 (5 Supplement):S27.*

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

504. Kis Z PE, Endresz V, Burian K, Jelinek I, Gonczol E, Valyi-Nagy I. The interactions between human dendritic cells and microbes: possible clinical applications of dendritic cells. *Inflammation Research*. 2004;53(9):413-23.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

505. Klatter T IA, R?hl F, W, Ecke M, Allhoff E, P, B?hm M. Perioperative immunomodulation with interleukin-2 in patients with renal cell carcinoma: results of a controlled phase II trial. *British journal of cancer*. 2006;95(9):1167?73.

배제사유 : NK 세포 활성도를 다루었으나 인터페론 감마를 보고하지 않은 연구

506. Klatter T IA, R?hl F, W, Ecke M, Allhoff E, P, B?hm M. Pretreatment with interferon-alpha2a modulates perioperative immunodysfunction in patients with renal cell carcinoma. *Onkologie*. 2008;31(1?2):28?34.

배제사유 : NK 세포 활성도를 다루었으나 인터페론 감마를 보고하지 않은 연구

507. Klausz K K-TA, Buck M, Krohn S, Otte A, K, Kellner C, Croci G, A, et al. Targeting the glyco-antigen CD75s with the Tetravalent, Fc-Engineered Antibody 'Ebu-141 Tetra' Induces Potent Killing of B cell lymphoma and plasma cell tumors. *Blood*. Conference: 60th Annual Meeting of the American Society of Hematology, ASH. 2018;132(Suppl. 1).

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

508. Kleeff J LM, Hedderich D, M, Friess H. B7-H3 and its role in antitumor immunity. *Clinical and Developmental Immunology*. 2010;2010 (683875).

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

509. Kleinknecht S BK, H, Strohmaier W, L. Postoperative long-term course of peripheral blood immune parameters and immunomodulating effects of keyhole limpet hemocyanin in patients with nonmetastatic renal cell carcinoma. *European urology*. 1992;21(4):315?22.

배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구

510. Kleinnijenhuis J VCR, Netea M, G. Trained immunity: Consequences for the heterologous effects of BCG vaccination. *Transactions of the Royal Society of Tropical Medicine and Hygiene*. 2014;109(1):29-35.

배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구

511. Klyushnenkova E KD, Alexander R, Riabov V. Immunostimulatory early phenotype of tumor-associated macrophages does not predict tumor growth outcome in the HLA-DR mouse model of prostate cancer. *Journal of Immunology*. Conference: 101st Annual Meeting of the American Association of Immunologist, IMMUNOLOGY. 2014;192(1 SUPPL. 1).

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

512. Knapp D W, Dhawan D, Ramos-Vara J, A, Ratliff T, L, Cresswell G, M, Utturkar S, et al. Naturally-Occurring Invasive Urothelial Carcinoma in Dogs, a Unique Model to Drive Advances in Managing Muscle Invasive Bladder Cancer in Humans. *Frontiers in Oncology*. 2020;9 (1493).

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

513. Ko Y J, Bublely G, J, Weber R, Redfern C, Gold D, P, Finke L, et al. Safety, pharmacokinetics, and biological pharmacodynamics of the immunocytokine EMD 273066 (huKS-IL2): results of a phase I trial in patients with prostate cancer. *Journal of Immunotherapy*. 2004;27(3):232-9.
 배제사유 : NK 세포 활성도를 다루지 않는 연구
514. Komaru A UY, Furuya A, Tanaka S, Yoshida K, Kato T, Kinoh H, et al. Sustained and NK/CD4+ T cell-dependent efficient prevention of lung metastasis induced by dendritic cells harboring recombinant Sendai virus. *Journal of Immunology*. 2009;183(7):4211-9.
 배제사유 : 동물실험 또는 전임상시험연구
515. Korbecki J SD, Kojder K, Grochans S, Gutowska I, Chlubek D, Baranowska-Bosiacka I. Fractalkine/CX3CL1 in Neoplastic Processes. *International Journal of Molecular Sciences*. 2020;21(10):25.
 배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
516. Koretz M J, Lawson D, H, York R, M, Graham S, D, Murray D, R, Gillespie T, M, et al. Randomized study of interleukin 2 (IL-2) alone vs IL-2 plus lymphokine-activated killer cells for treatment of melanoma and renal cell cancer. *Archives of surgery (Chicago, Ill. : 1960)*. 1991;126(7):898-903.
 배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구
517. Kosty M P. PC-SPES: Hope or hype? *Journal of Clinical Oncology*. 2004;22(18):3657-9.
 배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
518. Kotturi M OE, Whelan S, Liang S, Logronio K, Hansen K, Alteber Z, et al. COM902, a novel therapeutic antibody targeting TIGIT augments T cell function and the activity of PVRIG pathway blockade in vitro and in vivo. *Journal for Immunotherapy of Cancer*. Conference: 34th Annual Meeting and Pre Conference Programs of the Society for Immunotherapy of Cancer Part. 2019;7(Supplement 1).
 배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
519. Kovacsovics-Bankowski M CL, Vercellini J, Crittenden M, Lary S, Curti B, Weinberg A. Phase I/II clinical trial of anti-OX40, radiation and cyclophosphamide in patients with prostate cancer: Immunological analysis. *Journal for Immunotherapy of Cancer*. Conference: 28th Annual Scientific Meeting of the Society for Immunotherapy of Cancer, SITC. 2013;1(SUPPL. 1).
 배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
520. Koval O VO, Kulemzin S, Gorchakov A, Tkachenko A, Nushtaeva A, Kuligina E, et al. NK-cell based delivery of anticancer therapeutics. *Annals of Oncology*. 2017;28 (Supplement 11):xi20.
 배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
521. Kozlowski J M, Fidler I, J, Campbell D, Xu Z, L, Kaighn M, E, Hart I, R. Metastatic behavior of human tumor cell lines grown in the nude mouse. *Cancer Research*. 1984;44(8):3522-9.
 배제사유 : 동물실험 또는 전임상시험연구

522. Kreymborg K HS, Murali R, Wei J, Waitz R, Gasteiger G, Savage P, A, et al. Ablation of B7-H3 but not B7-H4 results in highly increased tumor burden in a murine model of spontaneous prostate cancer. *Cancer Immunology Research*. 2015;3(8):849-54.
 배제사유 : 동물실험 또는 전임상시험연구
523. Krishnaveni M. A review on transfer factor an immune modulator. *Drug Invention Today*. 2013;5(2):153-6.
 배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
524. Kruger C GT, F, Korangy F. Immune based therapies in cancer. *Histology and Histopathology*. 2007;22(4-6):687-96.
 배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
525. Kubler H MT, Stenzl A, Feyerabend S, Steiner U, Schostak M, Schultze-Seemann W, et al. Final analysis of a phase I/II study with CV9103: An intradermally administered prostate cancer vaccine based on self-adjuvanted mRNA (RNActive). *European Urology, Supplements*. 2012;11 (5):189.
 배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
526. Kubler H MT, Stenzl A, Feyerabend S, Steiner U, Schostak M, Schultze-Seemann W, et al. Final analysis of a phase I/IIa study with CV9103, an intradermally administered prostate cancer immunotherapy based on self-adjuvanted mRNA. *Journal of Clinical Oncology. Conference: ASCO Annual Meeting*. 2011;29(15 SUPPL. 1).
 배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
527. Kubler H SA, Schultze-Seemann W, Vom Dorp F, Pilla L, Hampel C, Jocham D, et al. Final analysis of a phase I/IIa study with CV9103, an intradermally administered prostate cancer immunotherapy based on self adjuvanted mRNA. *European Journal of Cancer*. 2011;1):S498-S9.
 배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
528. Kubo H GT, A, Wada Y, Koeneman K, S, Gotoh A, Yang L, Kao C, et al. Phase I dose escalation clinical trial of adenovirus vector carrying osteocalcin promoter-driven herpes simplex virus thymidine kinase in localized and metastatic hormone-refractory prostate cancer. *Human Gene Therapy*. 2003;14(3):227-41.
 배제사유 : NK 세포 활성도를 다루지 않는 연구
529. Kumar N SU, Singh C, Singh B. Thalidomide: Chemistry, therapeutic potential and oxidative stress induced teratogenicity. *Current Topics in Medicinal Chemistry*. 2012;12(13):1436-55.
 배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
530. Kumar S SJ, Malik S, Singh U, P, Ponnazhagan S, Manne U, Mishra M, K. FoxP3+ T cells program/re-program the prostatic tumor Microenvironment. *Cancer Research. Conference*. 2018;78(13 Supplement 1).
 배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
531. Kumar S SJ, Malik S, Singh U, P, Singh R, Ponnazhagan S, Manne U, et al. Regulatory T cells modulate immune cells and promote tumor growth in prostatic tumor

microenvironment. *Journal of Immunology*. Conference: 105th Annual Meeting of the American Association of Immunologists, IMMUNOLOGY. 2018;200(1 Supplement 1).

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

532. Kumar S SR, Malik S, Manne U, Mishra M. Prostate cancer health disparities: An immuno-biological perspective. *Cancer Letters*. 2018;414:153-65.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

533. Kumar V SA, K, Makkar H, P, S, Becker K. Dietary roles of phytate and phytase in human nutrition: A review. *Food Chemistry*. 2010;120(4):945-59.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

534. Kundu N MX, Goloubeva O, Holt D, Kochel T, Fulton A, M. A natural plant product to inhibit breast cancer metastasis. *Cancer Research*. Conference: 103rd Annual Meeting of the American Association for Cancer Research, AACR. 2012;72(8 SUPPL. 1).

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

535. Kunnumakkara A B, Bordoloi D, Sailo B, L, Roy N, K, Thakur K, K, Banik K, et al. Cancer drug development: the missing links. *Experimental biology and medicine*. 2019;244(8):663-89.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

536. Kuo M C, Huang C, Y, Kung H, N, Lu Y, C. Natural killer cell activity: An innovative biomarker predicting prostate cancer severity. *European Urology, Supplements*. 2019;18(1):e474.

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

537. Kursunel M A, Esendagli G. The untold story of IFN-gamma in cancer biology. *Cytokine and Growth Factor Reviews*. 2016;31:73-81.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

538. Kusmartsev S VJ, Prima V. Development of human NKG2D-CD3ε chimeric antigen receptor (CAR) for T-cell-mediated cancer immunotherapy. *Journal of Clinical Oncology*. 2017;35 (7 Supplement 1):150.

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

539. Kusmartsev S VJ. Enhancing the efficacy of cancer vaccines in urologic oncology: New directions. *Nature Reviews Urology*. 2009;6(10):540-9.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

540. LaFleur M W, Muroyama Y, Drake C, G, Sharpe A, H. Inhibitors of the PD-1 Pathway in Tumor Therapy. *Journal of Immunology*. 2018;200(2):375-83.

배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구

541. Lahat N AB, Levin D, R, Moskovitz B. The relationship between clinical stage, natural killer activity and related immunological parameters in adenocarcinoma of the prostate. *Cancer Immunology, Immunotherapy*. 1989;28(3):208-12.

배제사유 : 동물실험 또는 전임상시험연구

542. Lai H ZD, Liu C, Zhang Q, Wang X, Chen T. Selenium-containing ruthenium complex

synergizes with natural killer cells to enhance immunotherapy against prostate cancer via activating TRAIL/FasL signaling. *Biomaterials*. 2019;219:119377.

배제사유 : 동물실험 또는 전임상시험연구

543. Laine A IP, Pandita T, K. The role of inflammatory pathways in cancer-associated cachexia and radiation resistance. *Molecular Cancer Research*. 2013;11(9):967-72.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

544. Lamm D L, Riggs D, R. Enhanced immunocompetence by garlic: role in bladder cancer and other malignancies. *Journal of Nutrition*. 2001;131(3s):1067S-70S.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

545. Landstrom M FK. Apoptosis in rat prostatic adenocarcinoma is associated with rapid infiltration of cytotoxic T-cells and activated macrophages. *International Journal of Cancer*. 1997;71(3):451-5.

배제사유 : 동물실험 또는 전임상시험연구

546. Lang K RJ. Leptin and Adiponectin: New players in the field of tumor cell and leukocyte migration. *Cell Communication and Signaling*. 2009;7 (27).

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

547. Larish Y KM, Stoffels G, Samadi D. Absolute neutrophil count kinetics in response to surgery segregates by gleason sum. *Journal of Urology*. 2016;1:e496-e7.

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

548. Larsen S K, Svane I, M, Straten P, T, Andersen M, H. Therapeutic cancer vaccines. *Current Cancer Therapy Reviews*. 2010;6(2):163-74.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

549. Lau B H. Phytotherapy boosts innate immunity to maximize cancer survival. *Cancer Research. Conference: 107th Annual Meeting of the American Association for Cancer Research, AACR*. 2016;76(14 Supplement).

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

550. Lazzeri M SA, Casale P, Buffi N, M, Hurle R, Lughezzani G, Fasulo V, et al. Profiling of the immune microenvironment in prostate cancer at single cell level. *European Urology, Supplements*. 2019;18 (1):e338-e9.

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

551. Le Buanec H BA, Bagot M, Gallo R, C, Zagury D. Active and Passive Anticytokine Immune Therapies: Current Status and Development. *Advances in Immunology*. 2012;115:187-227.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

552. Leavy O. Tumour immunology: Tumour surveillance by NKG2D. *Nature Reviews Immunology*. 2008;8(5):324+5.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

553. Lebel-Binay S TN, De Pinieux G, Vieillefond A, Debre B, Bonnefoy J, Y, Fridman W, H, et al. IL-18 is produced by prostate cancer cells and secreted in response to interferons.

International Journal of Cancer. 2003;106(6):827-35.

배제사유 : 동물실험 또는 전임상시험연구

554. Leblanc R PO. Metastasis: new functional implications of platelets and megakaryocytes. Blood. 2016;128(1):24-31.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

555. Lechleider R J, Arlen P, M, Tsang K, Y, Steinberg S, M, Yokokawa J, Cereda V, et al. Safety and immunologic response of a viral vaccine to prostate-specific antigen in combination with radiation therapy when metronomic-dose interleukin 2 is used as an adjuvant. Clinical Cancer Research. 2008;14(16):5284-91.

배제사유 : NK 세포 활성도를 다루지 않는 연구

556. Lee CB SW, Park JK, Haw CR. Effects of REtinoids on Keratinocytes HLA - DR and ICAM - 1 Expression Induced by Interferon - gamma. Korean J Dermatol. 1995;Feb 33(1):33-43.

배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구

557. Lee JS YC, Lyu CJ, Park SM, Cho HS, Kim KY. T Cell Function before, during and after Chemotherapy in Children with Acute Lymphoblastic Leukemia. Korean J Pediatr Hematol Oncol. 1997;Oct 4(2):350-362.

배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구

558. Lee JT PS, Lee JH, Kim BK, Kim NK. Efficacy of in vitro treatment of chronic myelogenous leukemia cell line, K562 cells, using 4-hydroperoxycyclophosphamide, alpha-interferon and gamma-interferon. J Korean Med Sci. 1996;Feb 11(1):26-32.

배제사유 : 동물실험 또는 전임상시험연구

559. Lee K ZJ, Norris M, K, Chow C, Dieli-Conwright C, M. Prehabilitative Exercise for the Enhancement of Physical, Psychosocial, and Biological Outcomes Among Patients Diagnosed with Cancer. Current Oncology Reports. 2020;22 (7) (71).

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

560. Lee P GS. Potentiating prostate cancer immunotherapy with oncolytic viruses. Nature Reviews Urology. 2018;15(4):235-50.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

561. Lee S SB, Park G, Kim H, Kang H, Jeon J, Youn H, et al. Immunogenic effect of hyperthermia on enhancing radiotherapeutic efficacy. International Journal of Molecular Sciences. 2018;19 (9) (2795).

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

562. Leibovitz A BY, Segal R. Increased incidence of pathological and clinical prostate cancer with age: Age related alterations of local immune surveillance. Journal of Urology. 2004;172(2):435-7.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

563. Leone K PC, Zamarchi R. The interplay between circulating tumor cells and the immune system: From immune escape to cancer immunotherapy. Diagnostics. 2018;8 (3) (59).

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

564. Lesinski G B, Mace T, A, Reville P, Ahn-Jarvis J, Bill M, Nicholas C, et al. Reduced pro-inflammatory cytokines and immunosuppressive cells in patients with prostate cancer following consumption of soy isoflavone enriched bread. *Cancer Research*. Conference: 104th Annual Meeting of the American Association for Cancer Research, AACR. 2013;73(8 SUPPL. 1).
 배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
565. Lesinski G B, Reville P, K, Mace T, A, Young G, S, Ahn-Jarvis J, Thomas-Ahner J, et al. Consumption of soy isoflavone enriched bread in men with prostate cancer is associated with reduced proinflammatory cytokines and immunosuppressive cells. *Cancer Prevention Research*. 2015;8(11):1036-44.
 배제사유 : NK 세포 활성도를 다루지 않는 연구
566. Li D W. Editorial. *Current Molecular Medicine*. 2012;12(2):111-2.
 배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
567. Li H CM, Y, Lee Y, Benatar T, Lee V, Feng N, Gu X, et al. Virulizin, a novel immunotherapy agent, stimulates TNFalpha expression in monocytes/macrophages in vitro and in vivo. *International Immunopharmacology*. 2007;7(10):1350-9.
 배제사유 : 동물실험 또는 전임상시험연구
568. Li H CM, Y, Lee Y, Benatar T, Lee V, Feng N, Gu X, et al. Virulizin, a novel immunotherapy agent, stimulates TNFalpha expression in monocytes/macrophages in vitro and in vivo. *International Immunopharmacology*. 2007;7(10):1350-9.
 배제사유 : 동물실험 또는 전임상시험연구
569. Li H CM, Y, Lee Y, Lee V, Feng N, Benatar T, Jin H, et al. Virulizin, a novel immunotherapy agent, activates NK cells through induction of IL-12 expression in macrophages. *Cancer Immunology, Immunotherapy*. 2005;54(11):1115-26.
 배제사유 : 동물실험 또는 전임상시험연구
570. Li S. IL-12-Based therapy of malignancies. *Drugs of Today*. 2001;37(9):629-37.
 배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구
571. Li Y R, Gupta P. Immune aspects of the bi-directional neuroimmune facilitator TRPV1. *Molecular Biology Reports*. 2019;46(1):1499-510.
 배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
572. Li Z LD. Cell therapy must be regulated as medicine. *Experimental Hematology and Oncology*. 2016;5 (1) (26).
 배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
573. Liang P GJ, Li S, Guan Q, Vanderheyden T, So A, Wang Y, et al. Prevention of Prostate Tumor Development by Stimulation of Antitumor Immunity Using a Standardized Herbal Extract (Deep Immune) in TRAMP Mice. *Evidence-based Complementary and Alternative Medicine*. 2018;2018 (9707543).
 배제사유 : 동물실험 또는 전임상시험연구
574. Liechtenstein T DI, Lanna A, Breckpot K, Escors D. Modulating co-stimulation during

antigen presentation to enhance cancer immunotherapy. *Immunology, Endocrine and Metabolic Agents in Medicinal Chemistry*. 2012;12(3):224-35.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

575. Lim J LA, Wilson N, Wong A. Natural Killer cells propagated under pressurized culture conditions show enhanced tumor killing activity. *Journal for ImmunoTherapy of Cancer. Conference: 33rd Annual Meeting and Pre Conference Programs of the Society for Immunotherapy of Cancer, SITC*. 2018;6(Supplement 1).

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

576. Lim YA, Kim SS, Cho SW, Cheong JY. Evaluation of the Effectiveness of NK Vue Gold Kit in Patients with Chronic Hepatitis B. *Journal of Laboratory Medicine and Quality Assurance*. 2016;38(3):151-8.

배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구

577. Limacher J M, Quoix E. TG4010: A therapeutic vaccine against MUC1 expressing tumors. *OncoImmunology*. 2012;1(5):791-2.

배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구

578. Lin C ZJ. Reformation in chimeric antigen receptor based cancer immunotherapy: Redirecting natural killer cell. *Biochimica et Biophysica Acta - Reviews on Cancer*. 2018;1869(2):200-15.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

579. Lin D W, Nelson P, S. The role of cyclooxygenase-2 inhibition for the prevention and treatment of prostate carcinoma. *Clinical Prostate Cancer*. 2003;2(2):119-26.

배제사유 : 동물실험 또는 전임상시험연구

580. Lin S J, Chou F, J, Li L, Lin C, Y, Yeh S, Chang C. Natural killer cells suppress enzalutamide resistance and cell invasion in the castration resistant prostate cancer via targeting the androgen receptor splicing variant 7 (ARv7). *Cancer Letters*. 2017;398:62-9.

배제사유 : 동물실험 또는 전임상시험연구

581. Linch S N, Kasiewicz M, J, McNamara M, J, Hilgart-Martiszus I, F, Farhad M, Redmond W, L. Combination OX40 agonism/CTLA-4 blockade with HER2 vaccination reverses T-cell anergy and promotes survival in tumor-bearing mice. *Proceedings of the National Academy of Sciences of the United States of America*. 2016;113(3):E319-E27.

배제사유 : 동물실험 또는 전임상시험연구

582. Liu B QL, Yan S. Cyclooxygenase-2 promotes tumor growth and suppresses tumor immunity. *Cancer Cell International*. 2015;15 (1) (106).

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

583. Liu C F, Guo Z, Si T, G, Xing W, G, Liu F, Xing J, Z. Effect of transcatheter renal arterial embolization combined with cryoablation on regulatory CD4+ CD25+ T lymphocytes in the peripheral blood of patients with advanced renal carcinoma. *Zhonghua yi xue za zhi*. 2010;90(13):902?5.

배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구

584. Liu D TS, Zhang K, Xiong W, Lubaki N, M, Chen Z, Han W. Chimeric antigen receptor

(CAR)-modified natural killer cell-based immunotherapy and immunological synapse formation in cancer and HIV. *Protein and Cell*. 2017;8(12):861-77.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

585. Liu E T, Keck J, Airhart S, Shultz L, Lee C, Bult C. The patient-derived xenograft program at the jackson laboratory. *Clinical Cancer Research*. Conference: Patient Derived Cancer Models: Present and Future Applications from Basic Science to the Clinic. 2016;22(16 Supplement 1).

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

586. Liu G LS, Wang X, Page S, T, Higano C, S, Plymate S, R, Greenberg N, M, et al. Perturbation of NK cell peripheral homeostasis accelerates prostate carcinoma metastasis. *Journal of Clinical Investigation*. 2013;123(10):4410-22.

배제사유 : 동물실험 또는 전임상시험연구

587. Liu L W, Nishikawa T, Kaneda Y. An RNA Molecule Derived From Sendai Virus DI Particles Induces Antitumor Immunity and Cancer Cell-selective Apoptosis. *Molecular Therapy: the Journal of the American Society of Gene Therapy*. 2016;24(1):135-45.

배제사유 : 동물실험 또는 전임상시험연구

588. Liu X CI, Plummer S, J, Suarez B, K, Casey G, Catalona W, J, Witte J, S. Fine-mapping of prostate cancer aggressiveness loci on chromosome 7q22-35. *Prostate*. 2011;71(7):682-9.

배제사유 : 동물실험 또는 전임상시험연구

589. Liu X CQ, Yan J, Wang Y, Zhu C, Chen C, Zhao X, et al. MiRNA-296-3p-ICAM-1 axis promotes metastasis of prostate cancer by possible enhancing survival of natural killer cell-resistant circulating tumour cells. *Cell Death & Disease*. 2013;4:e928.

배제사유 : 동물실험 또는 전임상시험연구

590. Liu X H, Yoshiki T, Kokuho M, Okada Y, Tomoyoshi T, Higuchi K. The prognostic value of the HNK-1 (Leu-7) antigen in prostatic cancer--an immunohistochemical study. *Hinyokika Kyo - Acta Urologica Japonica*. 1993;39(5):439-44.

배제사유 : NK 세포 활성도를 다루지 않는 연구

591. Liu X ZB, Tomoyoshi T, Masanori T. Immunohistochemical study of HNK-1 (Leu-7) antigen in prostate cancer and its clinical significance. *Chinese Medical Journal*. 1995;108(7):516-21.

배제사유 : NK 세포 활성도를 다루지 않는 연구

592. Liu Y GJ, Huang L. Modulation of tumor microenvironment for immunotherapy: Focus on nanomaterial-based strategies. *Theranostics*. 2020;10(7):3099-117.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

593. Liu Y GX, Xing M, Zhao K, Luo L, Du J. Prognostic value of serum levels of soluble MICA (sMICA) in patients with prostate cancer. *British Journal of Biomedical Science*. 2018;75(2):98-100.

배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구

594. Liu Z ZQ, Peng H, Zhang W, Z. Animal lectins: Potential antitumor therapeutic targets

- in apoptosis. *Applied Biochemistry and Biotechnology*. 2012;168(3):629-37.
배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
595. Ljunggren H G. Cancer Immunosurveillance: NKG2D Breaks Cover. *Immunity*. 2008;28(4):492-4.
배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
596. Loeb C R, Harris J, L, Craik C, S. Granzyme B proteolyzes receptors important to proliferation and survival, tipping the balance toward apoptosis. *Journal of Biological Chemistry*. 2006;281(38):28326-35.
배제사유 : 동물실험 또는 전임상시험연구
597. Logan R W, Sarkar D, K. Circadian nature of immune function. *Molecular and Cellular Endocrinology*. 2012;349(1):82-90.
배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
598. Loi M DI, Greto D, Mangoni M, Sottili M, Meattini I, Becherini C, et al. Radiotherapy in the age of cancer immunology: Current concepts and future developments. *Critical Reviews in Oncology/Hematology*. 2017;112:1-10.
배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
599. Lombardi V R, M, Lombardi C, Cacabelos R. Nutrition, immune system activation and anti-cancer strategies in animals and humans. *Current Topics in Pharmacology*. 2008;12(2):1-30.
배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
600. Lorenz G SL, Bachmann Q, Angermann S, Slotta-Huspenina J, Heemann U, Kuchle C, et al. Hemophagocytic lymphohistiocytosis secondary to pembrolizumab treatment with insufficient response to high-dose steroids. *Rheumatology (United Kingdom)*. 2019;58(6):1106-9.
배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
601. Lotha R SA. Flavonoids nutraceuticals in prevention and treatment of cancer: A review. *Asian Journal of Pharmaceutical and Clinical Research*. 2018;11(1):42-7.
배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
602. Lotze M T, Rees R, C. Identifying biomarkers and surrogates of tumors (cancer biometrics): Correlation with immunotherapies and immune cells. *Cancer Immunology, Immunotherapy*. 2004;53(3):256-61.
배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
603. Lotze M T, Wang E, Marincola F, M, Hanna N, Bugelski P, J, Burns C, A, et al. Workshop on cancer biometrics: Identifying biomarkers and surrogates of cancer in patients - A meeting held at the masur auditorium, national institutes of health. *Journal of Immunotherapy*. 2005;28(2):79-119.
배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
604. Loukili N VI, Delfour O, Fraboul F, Chetaille E, Cruzalegui F, Corvaia N, et al. K01401-020 is a novel anti-VISTA antibody for cancer treatment: Pharmacodynamic impact on non-human primates and human immune system. *Cancer Research*.

Conference: American Association for Cancer Research Annual Meeting. 2019;79(13 Supplement).

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

605. Lu C WA, K, Chalasani V, Martinez C, H, Chin J. Immunotherapy for metastatic prostate cancer: Where are we at with sipuleucel-T? Expert Opinion on Biological Therapy. 2011;11(1):99-108.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

606. Lu J ZQ, Liang C, M, Xia S, J, Zhong C, P, Wang D, W. Antitumor immunity by a dendritic cell vaccine encoding secondary lymphoid chemokine and tumor lysate on murine prostate cancer. Asian Journal of Andrology. 2008;10(6):883-9.

배제사유 : 동물실험 또는 전임상시험연구

607. Lu S ZJ, Liu D, Li G, Staveley-O'Carroll K, F, Li Z, Wu J, D. Nonblocking monoclonal antibody targeting soluble MIC revamps endogenous innate and adaptive antitumor responses and eliminates primary and metastatic tumors. Clinical Cancer Research. 2015;21(21):4819-30.

배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구

608. Lu Y C, Jaw F, S, Huang C, Y. Natural killer cell activity: An innovative biomarkers predicting prostate cancer severity. International Journal of Urology. 2019;26 (Supplement 2):14.

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

609. Lum L G, Al-Kadhimi Z. Development and prospects for bispecific antibody-based therapeutics in cancer and other applications. Expert Opinion on Drug Discovery. 2008;3(9):1081-97.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

610. Luna J I, Grossenbacher S, K, Murphy W, J, Canter R, J. Targeting Cancer Stem Cells with Natural Killer Cell Immunotherapy. Expert Opinion on Biological Therapy. 2017;17(3):313-24.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

611. Lundholm M SM, Nagaeva O, Baranov V, Widmark A, Mincheva-Nilsson L, Wikstrom P. Prostate tumor-derived exosomes down-regulate NKG2D expression on natural killer cells and CD8+ T cells: mechanism of immune evasion. PLoS ONE [Electronic Resource]. 2014;9(9):e108925.

배제사유 : 동물실험 또는 전임상시험연구

612. Luo G HY, Zhao Q, Yu X. Immune Cells Act as Promising Targets for the Treatment of Bone Metastasis. Recent Patents on Anti-Cancer Drug Discovery. 2017;12(3):221-33.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

613. Lv W WQ, Chen H, Jiang Y, Zheng J, Shi M, Xu Y, et al. Prioritization of rheumatoid arthritis risk subpathways based on global immune subpathway interaction network and random walk strategy. Molecular Biosystems. 2015;11(11):2986-97.

배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구

614. Ma C P, Yu D, S, Yeh M, Y, Chang S, Y, Han S, H. Natural killer cell activity in patients with urologic cancer. *European Urology*. 1987;13(6):397-400.
 배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구
615. Mace T A, King S, Farren M, McMichael E, Scoville S, Carson W, E, et al. Soy isoflavones and their metabolites modulate IL-12-induced NK cell IFN-gamma production. *Cancer Research. Conference: 106th Annual Meeting of the American Association for Cancer Research, AACR*. 2015;75(15 SUPPL. 1).
 배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
616. Mace T A, Loftus S, King S, Young G, Geraghy C, Fareen M, R, et al. Soy-enriched diet limits tumor progression and reduces myeloid derived suppressor cells in the murine TRAMP model of prostate cancer. *Journal of Immunology. Conference: 105th Annual Meeting of the American Association of Immunologists, IMMUNOLOGY*. 2018;200(1 Supplement 1).
 배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
617. Mackean M J, Kerr D, Lesko M, Svedberg A, Hansson F, Jodrell D, et al. A feasibility study of roquinimex (Linomide) and alpha interferon in patients with advanced malignant melanoma or renal carcinoma. *British journal of cancer*. 1998;78(12):1620-3.
 배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구
618. Mackiewicz J KU, Kotlarski M, Dondajewska E, Kozłowska A, Kwiatkowska E, Nowicka-Kotlarska A, et al. Cellular Vaccines Modified with Hyper IL6 or Hyper IL11 Combined with Docetaxel in an Orthotopic Prostate Cancer Model. *Anticancer Research*. 2015;35(6):3275-88.
 배제사유 : 동물실험 또는 전임상시험연구
619. Madan R A, Antonarakis E, S, Drake C, G, Fong L, Yu E, Y, McNeel D, G, et al. Putting the Pieces Together: Completing the Mechanism of Action Jigsaw for Sipuleucel-T. *Journal of the National Cancer Institute*. 2020;112(6):562-73.
 배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
620. Madan R A, Donahue R, N, Singh H, Karzai F, Theoret M, R, Heery C, R, et al. Clinical and immunologic impact of short course enzalutamide without androgen deprivation therapy for biochemically recurrent prostate cancer. *Journal of Clinical Oncology. Conference*. 2016;34(2 SUPPL. 1).
 배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
621. Madan R GJ. The current and emerging role of immunotherapy in prostate cancer. *Clinical Genitourinary Cancer*. 2010;8(1):10-6.
 배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
622. Madhuri S PG. Anticancer activity of *Withania somnifera* dunal (Ashwagandha). *Indian Drugs*. 2009;46(8):5-11.
 배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
623. Maeng SH LJ, Park CW, Cho YJ. The effect of Der p 2 antigen on the production of interferon gamma by CD3+T, CD56+NK and CD3+CD56+TNK cells from patients with

mild persistent allergic asthma. *J Asthma Allergy Clin Immunol.* 2003;Jun 23(2):341-348.
배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구

624. Maia M C, Hansen A, R. A comprehensive review of immunotherapies in prostate cancer. *Critical Reviews in Oncology/Hematology.* 2017;113:292-303.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

625. Maimon Y SN, Cohen Z, Berger R, Rosenthal D, S. Botanical Formula LCS101: A Multi-Targeted Approach to Cancer Care. *Integrative Cancer Therapies.* 2018;17(4):1020-6.

배제사유 : 동물실험 또는 전임상시험연구

626. Maio M NH, J, M, Ascierto P, A, Belardelli F, Camerini R, Colombo M, P, Queirolo P, et al. Sixth annual meeting of the Italian network for tumor biotherapy (NIBIT), Siena, 16-18 October 2008. *Cancer Immunology, Immunotherapy.* 2010;59(6):963-9.

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

627. Maio M NH, J, M, Ascierto P, A, Belardelli F, Camerini R, Colombo M, P, Queirolo P, et al. Tenth annual meeting of the Italian Network for Tumor Biotherapy (NIBIT), SIENA, Italy, November 5-7, 2012. *Cancer Immunology, Immunotherapy.* 2013;62(12):1851-8.

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

628. Maitra R GM, H, Goel S. Reovirus: A targeted therapeutic - Progress and potential. *Molecular Cancer Research.* 2012;10(12):1514-25.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

629. Makinde A Y, Luo-Owen X, Rizvi A, Crapo J, D, Pearlstein R, D, Slater J, M, et al. Effect of a metalloporphyrin antioxidant (MnTE-2-PyP) on the response of a mouse prostate cancer model to radiation. *Anticancer Research.* 2009;29(1):107-18.

배제사유 : 동물실험 또는 전임상시험연구

630. Malaguarnera L. Influence of resveratrol on the immune response. *Nutrients.* 2019;11 (5) (946).

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

631. Mallett C L, McFadden C, Chen Y, Foster P, J. Migration of iron-labeled KHYG-1 natural killer cells to subcutaneous tumors in nude mice, as detected by magnetic resonance imaging. *Cytotherapy.* 2012;14(6):743-51.

배제사유 : 동물실험 또는 전임상시험연구

632. Mallett C RC, Foster P. Human natural killer cells labeled with dual iron/fluorescent agent tracked to subcutaneous prostate tumors in nude mice after both intravenous and subcutaneous administration. *Molecular Imaging and Biology.* 2010;2:S585.

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

633. Malyguine A UV, Kotlan B, Aptsiauri N, Shurin M, R. Conference overview: Cancer Immunotherapy and Immunomonitoring (CITIM): Moving forward. *Journal of Immunotoxicology.* 2012;9(3):231-5.

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

634. Mandl S J, Rountree R, B, dela Cruz T, B, Foy S, P, Cote J, J, Gordon E, J, et al. Elucidating immunologic mechanisms of prostrvac cancer immunotherapy. *Journal for ImmunoTherapy of Cancer*. 2014;2 (1) (34).
 배제사유 : 동물실험 또는 전임상시험연구
635. Mantovani A SB, Locati M, Zammataro L, Allavena P, Bonecchi R. The chemokine system in cancer biology and therapy. *Cytokine and Growth Factor Reviews*. 2010;21(1):27-39.
 배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
636. Marchesi F LM, Solinas G, Erreni M, Allavena P, Mantovani A. Role of CX3CR1/CX3CL1 axis in primary and secondary involvement of the nervous system by cancer. *Journal of Neuroimmunology*. 2010;224(1-2):39-44.
 배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
637. Markman J WD, Crother T, R, Arditi M. The impact of androgens on neutrophils and melanoma tumor burden. *Journal of Immunology. Conference: 105th Annual Meeting of the American Association of Immunologists, IMMUNOLOGY*. 2018;200(1 Supplement 1).
 배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
638. Maroni P. Megakaryocytes in bone metastasis: Protection or progression? *Cells*. 2019;8 (2) (134).
 배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
639. Martiniello-Wilks R RJ, E, J. Cell and gene therapy in Australia. *Cytotherapy*. 2007;9(3):209-21.
 배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
640. Martino A PF. gammadelta T cells and dendritic cells: Close partners and biological adjuvants for new therapies. *Current Molecular Medicine*. 2007;7(7):658-73.
 배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
641. Marumo K IK, Baba S, Ueno M, Tazaki H. Natural killer cell activity and recycling capacity of natural killer cells in patients with carcinoma of the prostate. *Keio Journal of Medicine*. 1989;38(1):27-35.
 배제사유 : NK 세포 활성도를 다루지 않는 연구
642. Marumo K UM, Hayakawa M. Mechanism of augmentation of natural cytotoxicity by human beta-interferon. *Keio Journal of Medicine*. 1984;33(4):201-9.
 배제사유 : 동물실험 또는 전임상시험연구
643. Masetti M PF, Carriero R, Partini B, Morina N, Ponzetta A, Colombo P, et al. High-dimensional single cell-based immune profiling of the tumor immune microenvironment in prostate cancer. *Journal of Clinical Oncology. Conference*. 2020;38(6 Supplement).
 배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
644. Mathers J C. Folate intake and bowel cancer risk. *Genes & Nutrition*. 2009;4(3):173-8.
 배제사유 : NK 세포 활성도를 다루지 않는 연구

645. Mathew P HN, Bowen K, Mathew S. Lectin-like transcript-1 (LLT1) and exosomal PCNA inhibit NK cell effector function against prostate cancer cells. *Journal of Immunology*. Conference: 101st Annual Meeting of the American Association of Immunologist, IMMUNOLOGY. 2014;192(1 SUPPL. 1).
 배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
646. Mathew S MP. Overexpression of LLT1 (CLEC2D) on prostate cancer cells inhibits NK cell-mediated killing through LLT1-NKRP1A interaction (TUM10P.1052). *Journal of Immunology*. Conference: 102nd Annual Meeting of the American Association of Immunologist, IMMUNOLOGY. 2015;194(1 SUPPL. 1).
 배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
647. Mathew S O, Chaudhary P, Powers S, B, Vishwanatha J, K, Mathew P, A. Overexpression of LLT1 (OCIL, CLEC2D) on prostate cancer cells inhibits NK cell-mediated killing through LLT1-NKRP1A (CD161) interaction. *Oncotarget*. 2016;7(42):68650-61.
 배제사유 : 동물실험 또는 전임상시험연구
648. Matsueda S GD, Y. Immunotherapy in gastric cancer. *World Journal of Gastroenterology*. 2014;20(7):1657-66.
 배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구
649. Mattarollo S R, Kenna T, Nieda M, Nicol A, J. Chemotherapy pretreatment sensitizes solid tumor-derived cell lines to Valpha24+ NKT cell-mediated cytotoxicity. *International Journal of Cancer*. 2006;119(7):1630-7.
 배제사유 : 동물실험 또는 전임상시험연구
650. Matvienko D A, Kulemzin S, V, Smagina A, S, Belovezhets T, N, Chikaev A, N, Volkova O, Y, et al. Analysis of in vitro activity of PSCA-specific CARs in the context of human NK cell line YT. *Cellular Therapy and Transplantation*. 2018;7(2):70-7.
 배제사유 : 동물실험 또는 전임상시험연구
651. Matyszewski A CA, M, Solarek W, Korzen P, Safir I, J, Kukwa W, Szczylik C. Molecular basis of carcinogenesis in diabetic patients (Review). *International Journal of Oncology*. 2015;46(4):1435-43.
 배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
652. Maughan B L, Bailey E, Gill D, M, Agarwal N. Incidence of immune-related adverse events with program death receptor-1- and program death receptor-1 ligand-directed therapies in genitourinary cancers. *Frontiers in Oncology*. 2017;7 (APR) (56).
 배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
653. Maus M V, Fraietta J, A, Levine B, L, Kalos M, Zhao Y, June C, H. Adoptive immunotherapy for cancer or viruses. *Annual Review of Immunology*. 2014;32:189-225.
 배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
654. McArdle S RR. Tenth International Conference on Progress in Vaccination against cancer (PIVAC 10), Cambridge, UK, 27th-30th September 2010: New hopes and strategies for cancer vaccines. *Cancer Immunology, Immunotherapy*. 2011;60(8):1207-10.
 배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

655. McGuire J U-WT, J, Reed D, R, Lynch C, C. Re-calculating! Navigating through the osteosarcoma treatment roadblock. *Pharmacological Research*. 2017;117:54-64.
 배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
656. McNerney K O, Karageorgos S, A, Hogarty M, D, Bassiri H. Enhancing Neuroblastoma Immunotherapies by Engaging iNKT and NK Cells. *Frontiers in Immunology*. 2020;11(873).
 배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
657. Meeus M MW, Lambrecht L, Nijs J. Immunological similarities between cancer and chronic fatigue syndrome: the common link to fatigue? *Anticancer Research*. 2009;29(11):4717-26.
 배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
658. Meier R GD, Tavri S, Henning T, D, Knopp C, Piontek G, Rudelius M, et al. Depicting adoptive immunotherapy for prostate cancer in an animal model with magnetic resonance imaging. *Magnetic Resonance in Medicine*. 2011;65(3):756-63.
 배제사유 : 동물실험 또는 전임상시험연구
659. Melenhorst J J, Barrett A, J. Tumor vaccines and beyond. *Cytotherapy*. 2011;13(1):8-18.
 배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
660. Melero I H-CD, Morales-Kastresana A, Sanmamed M, F, Wolchok J, D. Agonist antibodies to TNFR molecules that costimulate T and NK cells. *Clinical Cancer Research*. 2013;19(5):1044-53.
 배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구
661. Melero I H-SS, Glennie M, Pardoll D, M, Chen L. Immunostimulatory monoclonal antibodies for cancer therapy. *Nature Reviews Cancer*. 2007;7(2):95-106.
 배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
662. Mellman I CG, Dranoff G. Cancer immunotherapy comes of age. *Nature*. 2011;480(7378):480-9.
 배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
663. Mett V KE, A, Greene K, Beshpalov I, Brackett C, Gillard B, Gleiberman A, S, et al. Mobilan: a recombinant adenovirus carrying Toll-like receptor 5 self-activating cassette for cancer immunotherapy. *Oncogene*. 2018;37(4):439-49.
 배제사유 : 동물실험 또는 전임상시험연구
664. Mickey D D, Bencuya P, S, Foulkes K. Effects of the immunomodulator PSK on growth of human prostate adenocarcinoma in immunodeficient mice. *International Journal of Immunopharmacology*. 1989;11(7):829-38.
 배제사유 : 동물실험 또는 전임상시험연구
665. Miguel J F, S, Schlag R, Khuageva N, K, Dimopoulos M, A, Shpilberg O, Kropff M, et al. Persistent overall survival benefit and no increased risk of second malignancies with bortezomib-melphalan-prednisone versus melphalan-prednisone in patients with previously untreated multiple myeloma. *Journal of clinical oncology*. 2013;31(4):448?55.

배제사유 : NK 세포 활성도를 다루지 않는 연구

666. Mikovits J A, Hagen K, S, Peterson D, L, Dean M, Lombardi V, C. Aberrant type I IFN pathway response to viral infection in chronic fatigue syndrome (CFS). *Cytokine*. 2009;48 (1-2):64-5.

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

667. Mills D R, Yang D, Q, Callanan H, Brilliant K, Wan Y, Sikov M, et al. A model of spontaneous transformation of rat prostate epithelial cells. *FASEB Journal. Conference: Experimental Biology*. 2011;25(Meeting Abstracts).

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

668. Misso G DMM, T, De Rosa G, Farooqi A, A, Lombardi A, Campani V, Zarone M, R, et al. Mir-34: A new weapon against cancer? *Molecular Therapy - Nucleic Acids*. 2014;3:e194.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

669. Mitchell M J, King M, R. Fluid Shear Stress Sensitizes Cancer Cells to Receptor-Mediated Apoptosis via Trimeric Death Receptors. *New Journal of Physics*. 2013;15:015008.

배제사유 : 동물실험 또는 전임상시험연구

670. Mitchell M J, Wayne E, Rana K, Schaffer C, B, King M, R. TRAIL-coated leukocytes that kill cancer cells in the circulation. *Proceedings of the National Academy of Sciences of the United States of America*. 2014;111(3):930-5.

배제사유 : 동물실험 또는 전임상시험연구

671. Mitchell M J, Wayne E, Rana K, Schaffer C, B, King M, R. Trail-coated leukocytes that kill cancer cells in the circulation. *Proceedings of the National Academy of Sciences of the United States of America*. 2014;111(3):930-5.

배제사유 : 동물실험 또는 전임상시험연구

672. Mizoguchi I CY, Furusawa J, I, Xu M, Tsunoda R, Higuchi K, Yoshimoto T. Therapeutic potential of interleukin-27 against cancers in preclinical mouse models. *OncoImmunology*. 2015;4(10).

배제사유 : 동물실험 또는 전임상시험연구

673. Mizukoshi E KS. Immune cell therapy for hepatocellular carcinoma. *Journal of Hematology and Oncology*. 2019;12 (1) (52).

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

674. Mladenov V MD, Mihailova A, Naumova E, Tzvetkov M. Decreased peripheral blood CD8+ T cell subsets may be a marker for immune disturbance in benign prostatic hyperplasia. *European Urology, Supplements*. 2010;9 (6):575.

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

675. Mocchegiani E CL, Giacconi R, Cipriano C, Muti E, Malavolta M. Zinc-binding proteins (metallothionein and alpha-2 macroglobulin) and immunosenescence. *Experimental Gerontology*. 2006;41(11):1094-107.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

676. Mocellin S MS, Bronte V, Lise M, Nitti D. Part I: Vaccines for solid tumours. *Lancet Oncology*. 2004;5(11):681-9.
 배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
677. Mocellin S. Priming anticancer active specific immunotherapy with dendritic cells. *Current Opinion in Investigational Drugs*. 2005;6(6):576-81.
 배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
678. Mohan K V, Devadas K, Sainath Rao S, Hewlett I, Atreya C. Identification of XMRV infection-associated microRNAs in four cell types in culture. *PLoS ONE [Electronic Resource]*. 2012;7(3):e32853.
 배제사유 : 동물실험 또는 전임상시험연구
679. Monteiro H P, Rodrigues E, G, Amorim Reis A, K, C, Longo L, S, Ogata F, T, Moretti A, I, S, et al. Nitric oxide and interactions with reactive oxygen species in the development of melanoma, breast, and colon cancer: A redox signaling perspective. *Nitric Oxide - Biology and Chemistry*. 2019;89:1-13.
 배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
680. Moody D B, Robinson J, C, Ewing C, M, Lazenby A, J, Isaacs W, B. Interleukin-2 transfected prostate cancer cells generate a local antitumor effect in vivo. *Prostate*. 1994;24(5):244-51.
 배제사유 : 동물실험 또는 전임상시험연구
681. Moon H S, Liu X, Diakopoulos K, N, Nagel J, M, Mantzoros C, S. Role of LKB1 in adiponectin-regulated malignant potential of human colon cancer in vivo and in vitro. *Endocrine Reviews*. Conference: 93rd Annual Meeting and Expo of the Endocrine Society, ENDO. 2011;32(3 Meeting Abstracts).
 배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
682. Morris J C, Ramlogan-Steel C, A, Yu P, Black B, A, Mannan P, Allison J, P, et al. Vaccination with tumor cells expressing IL-15 and IL-15Ralpha inhibits murine breast and prostate cancer. *Gene Therapy*. 2014;21(4):393-401.
 배제사유 : 동물실험 또는 전임상시험연구
683. Mortara L GM, Baci D, Bosi A, Albini A, Noonan D, M, Bruno A. Tumor associated Natural Killer cells in prostate cancer are endowed with decidual-like phenotype and proangiogenic function. *European Journal of Immunology*. 2019;49 (Supplement 1):160-1.
 배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
684. Moss J MJ, Neiman D, Zemmour H, Loyfer N, Korach A, Samet Y, et al. Comprehensive human cell-type methylation atlas reveals origins of circulating cell-free DNA in health and disease. *Nature Communications*. 2018;9 (1) (5068).
 배제사유 : 동물실험 또는 전임상시험연구
685. Mossoba M E, Walia J, S, Rasaiah V, I, Buxhoeveden N, Head R, Ying C, et al. Tumor protection following vaccination with low doses of lentivirally transduced DCs expressing the self-antigen erbB2. *Molecular Therapy: the Journal of the American Society of Gene Therapy*. 2008;16(3):607-17.

배제사유 : 동물실험 또는 전임상시험연구

686. Mu H LS, Xiang L, Chen C, Yu K. GAS5 enhances natural killer cell-mediated killing by promoting ubiquitination of SESN2 in prostate cancer cells. *Experimental and molecular pathology*. 2020:104479.

배제사유 : 동물실험 또는 전임상시험연구

687. Mu H LS, Xiang L, Chen C, Yu K. WITHDRAWN: GAS5 enhances natural killer cell-mediated killing by promoting ubiquitination of SESN2 in prostate cancer cells. *Experimental & Molecular Pathology*. 2020:104479.

배제사유 : 동물실험 또는 전임상시험연구

688. Muenst S LH, Soysal S, D, Zippelius A, Tzankov A, Hoeller S. The immune system and cancer evasion strategies: Therapeutic concepts. *Journal of Internal Medicine*. 2016;279(6):541-62.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

689. Muller I US. The PFP/RAG2 double-knockout mouse in metastasis research: small-cell lung cancer and prostate cancer. *Methods in Molecular Biology*. 2014;1070:191-201.

배제사유 : 동물실험 또는 전임상시험연구

690. Muller-Hubenthal B AM, Lorenzen D, Huber M, Freudenberg M, A, Galanos C, Unger C, et al. Tumour biology: Tumour-associated inflammation versus antitumor immunity. *Anticancer Research*. 2009;29(11):4795-805.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

691. Mullin G E. Folate: Is too much of a good thing harmful? *Nutrition in Clinical Practice*. 2011;26(1):84-7.

배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구

692. Munoz D P, Yannone S, M, Daemen A, Sun Y, Vakar-Lopez F, Kawahara M, et al. Targetable mechanisms driving immunoevasion of persistent senescent cells link chemotherapy-resistant cancer to aging. *JCI Insight*. 2019;4 (14) (e124716).

배제사유 : 동물실험 또는 전임상시험연구

693. Murakami Y. Involvement of a cell adhesion molecule, TSLC1/IGSF4, in human oncogenesis. *Cancer Science*. 2005;96(9):543-52.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

694. Murugan S ZC, Boyadjieva N, Jabbar S, Sarkar D. Beta-endorphin neuronal regulation of cancer growth, progression and metastasis in alcohol-exposed and control animals. *Alcoholism: Clinical and Experimental Research*. 2018;42 (Supplement 1):311A.

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

695. Muthumani K ML, Kudchodkar S, B, Perales-Puchalt A, Choi H, Agarwal S, Scott V, L, et al. Novel prostate cancer immunotherapy with a DNA-encoded anti-prostate-specific membrane antigen monoclonal antibody. *Cancer Immunology, Immunotherapy*. 2017;66(12):1577-88.

배제사유 : 동물실험 또는 전임상시험연구

696. Nada M H, Hussein A, J, Wang H, Morita C, T. 12P IL-18 improves the anti-cancer immunity of human gamma delta T cells against prostate cancer. *Annals of Oncology*. 2020;31 (Supplement 1):S6.
 배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
697. Nagamine T KK, Tomori M, Nakajima K, Iha M. Activation of NK cells in male cancer survivors by fucoidan extracted from cladosiphon okamuranus. *Molecular and Clinical Oncology*. 2020;12(1):81-8.
 배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구
698. Nanus D M, Milowsky M, I, Kostakoglu L, Smith-Jones P, M, Vallabahajosula S, Goldsmith S, J, et al. Clinical use of monoclonal antibody HuJ591 therapy: Targeting prostate specific membrane antigen. *Journal of Urology*. 2003;170(6 II):S84-S9.
 배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
699. Naruishi K TT, L, Kusaka N, Fujita T, Yang G, Goltsov A, Satoh T, et al. Adenoviral vector-mediated RTVP-1 gene-modified tumor cell-based vaccine suppresses the development of experimental prostate cancer. *Cancer Gene Therapy*. 2006;13(7):658-63.
 배제사유 : 동물실험 또는 전임상시험연구
700. Nasry W H, S, Rodriguez-Lecompte J, C, Martin C, K. Role of COX-2/PGE2 mediated inflammation in oral squamous cell carcinoma. *Cancers*. 2018;10 (10) (348).
 배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
701. Nasu Y BC, H, Hull G, W, Lee H, M, Hu J, Wang J, McCurdy M, A, et al. Adenovirus-mediated interleukin-12 gene therapy for prostate cancer: suppression of orthotopic tumor growth and pre-established lung metastases in an orthotopic model. *Gene Therapy*. 1999;6(3):338-49.
 배제사유 : 동물실험 또는 전임상시험연구
702. Nasu Y BC, H, Hull G, W, Yang G, Wang J, Shimura S, McCurdy M, A, et al. Combination gene therapy with adenoviral vector-mediated HSV-tk+GCV and IL-12 in an orthotopic mouse model for prostate cancer. *Prostate Cancer & Prostatic Diseases*. 2001;4(1):44-55.
 배제사유 : 동물실험 또는 전임상시험연구
703. Naucner C S, Geisler J, Vetvik K. The emerging role of human cytomegalovirus infection in human carcinogenesis: A review of current evidence and potential therapeutic implications. *Oncotarget*. 2019;10(42):4333-47.
 배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
704. Nayar S K, Sakellariou C, A, Elhage O, Ukimura O, Gill I, Smith R, A, et al. Interleukin-15 boosts expansion of CD8 T, NK and NKT cells by upregulation of telomerase activity. *European Urology, Supplements*. 2014;13 (1):e10.
 배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
705. Nct. A Multicenter Randomized Double-blind Placebo-controlled Pilot Study of Safety, Pharmacodynamics and Efficacy of Different Treatments of Immunotherapeutic Drug Mobilan (M-VM3) in Patients With Diagnosed Prostate Cancer.

<https://clinicaltrials.gov/show/NCT02844699>. 2016.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

706. Nct. Analgesia and Pancreatic Cancer Surgery.

<https://clinicaltrials.gov/show/NCT01929915>. 2013.

배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구

707. Nct. Assessment the Activity Value of 13- Cis-Retinoic Acid (Isotretinoin) in the Treatment of COVID-19 (Randomized). <https://clinicaltrials.gov/show/NCT04353180>. 2020.

배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구

708. Nct. Evaluation of Post-operative Biochemical Recurrence in Patients Submitted to Radical Prostatectomy Under General Opioid-free Anesthesia Compared to Conventional General Anesthesia. <https://clinicaltrials.gov/show/NCT03212456>. 2017.

배제사유 : NK 세포 활성도를 다루지 않는 연구

709. Nct. Impact of Anesthesia Maintenance Methods on Long-term Survival Rate. <https://clinicaltrials.gov/show/NCT02660411>. 2016.

배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구

710. Nct. IRB-HSR# 13957: IV Lidocaine for Patients Undergoing Primary Breast Cancer Surgery: effects on Postoperative Recovery and Cancer Recurrence. <https://clinicaltrials.gov/show/NCT01204242>. 2010.

배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구

711. Nct. Phase I/II Study of Immunotherapy Combination BN-Brachyury Vaccine, M7824, ALT-803 and Epacadostat (QuEST1). <https://clinicaltrials.gov/show/NCT03493945>. 2018.

배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구

712. Nct. PROstaTe Cancer - Exercise-STudy (PRO-TEST). <https://clinicaltrials.gov/show/NCT02954783>. 2016.

배제사유 : NK 세포 활성도를 다루지 않는 연구

713. Neeman E ZO, Ben-Eliyahu S. A new approach to reducing postsurgical cancer recurrence: Perioperative targeting of catecholamines and prostaglandins. *Clinical Cancer Research*. 2012;18(18):4895-902.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

714. Nemunaitis J M, Nemunaitis J. Potential of Advexin: A p53 gene-replacement therapy in Li-Fraumeni syndrome. *Future Oncology*. 2008;4(6):759-68.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

715. Ngiow S F, Teng M, W, L, Smyth M, J. A balance of interleukin-12 and -23 in cancer. *Trends in Immunology*. 2013;34(11):548-55.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

716. Nguyen-Pham T N, Lee Y, K, Lee H, J, Kim M, H, Yang D, H, Kim H, J, et al. Cellular immunotherapy using dendritic cells against multiple myeloma. *Korean Journal of Hematology*. 2012;47(1):17-27.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

717. Nicholson L T, Fong L. Immune Checkpoint Inhibition in Prostate Cancer. *Trends in Cancer*. 2020;6(3):174-7.
 배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
718. Nickols N G, Ganapathy E, Nguyen C, Kane N, Lin L, Diaz-Perez S, et al. The intraprostatic immune balance after prostate SBRT in patients. *Journal of Clinical Oncology. Conference*. 2020;38(6 Supplement).
 배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
719. Nicol A J, Tazbirkova A, Nieda M. Comparison of clinical and immunological effects of intravenous and intradermal administration of alpha-GalactosylCeramide (KRN7000)-pulsed dendritic cells. *Clinical Cancer Research*. 2011;17(15):5140-51.
 배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구
720. Nieda M OM, Tazbirkova A, Lin H, Yamaura A, Ide K, Abraham R, et al. Therapeutic activation of Valpha24+Vbeta11+ NKT cells in human subjects results in highly coordinated secondary activation of acquired and innate immunity. *Blood*. 2004;103(2):383-9.
 배제사유 : NK 세포 활성도를 다루지 않는 연구
721. Nikitina E Y, Desai S, A, Zhao X, Song W, Luo A, Z, Gangula R, D, et al. Versatile prostate cancer treatment with inducible caspase and interleukin-12. *Cancer Research*. 2005;65(10):4309-19.
 배제사유 : 동물실험 또는 전임상시험연구
722. Ning H LH, E, Xu Y, D, Guan R, L, Venstrom J, M, Lin G, Lue T, F, et al. Conversion of adipose-derived stem cells into natural killer-like cells with anti-tumor activities in nude mice. *PLoS ONE [Electronic Resource]*. 2014;9(8):e106246.
 배제사유 : 동물실험 또는 전임상시험연구
723. Nishikawa T KY. Cancer immunotherapy using a cancer-targeting platelet vector incorporating viral particles. *Molecular Therapy*. 2014;1):S244.
 배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
724. Nishikawa T KY. Systemic administration of platelet vector containing inactivated sendai virus particle eradicates melanoma in mice. *Molecular Therapy*. 2012;1):S264.
 배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
725. Nishikawa T LL, W, Kaneda Y. In vitro-synthesized Sendai virus RNA fragments induced antitumor immunity and cancer cell-selective apoptosis. *Molecular Therapy*. 2016;1):S59-S60.
 배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
726. Nishikawa T LS, Kaneda Y. Enhancement of NK Sensitivity against ICAM-1 Over-expressing Cancer Cell by Inactivated Sendai Virus Particles. *Cancer Science*. 2018;109 (Supplement 2):335.
 배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
727. Nishikawa T LS, Kaneda Y. Inactivated sendai virus particles upregulate cancer cell

ICAM-1 expression with enhancing NK cell sensitivity on cancer cell. *Molecular Therapy*. 2018;26 (5 Supplement 1):339.

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

728. Nissola L AK, Bhardwaj N, Galsky M, Wentzel K, Lucey V, Selinsky C, et al. A multicenter, open-label, exploratory platform study to evaluate biomarkers and immunotherapy combinations for the treatment of patients with metastatic castration-resistant prostate cancer (PORTER). *Journal for ImmunoTherapy of Cancer*. Conference: 34th Annual Meeting and Pre Conference Programs of the Society for Immunotherapy of Cancer Part. 2019;7(Supplement 1).

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

729. Noguchi A KT, Naitoh K, Saito M, Iwai K, Maekawa R, Kamigaki T, et al. Impaired and imbalanced cellular immunological status assessed in advanced cancer patients and restoration of the T cell immune status by adoptive T-cell immunotherapy. *International Immunopharmacology*. 2014;18(1):90-7.

배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구

730. Nolan M W, Kent M, S, Boss M, K. Emerging Translational Opportunities in Comparative Oncology With Companion Canine Cancers: Radiation Oncology. *Frontiers in Oncology*. 2019;9 (1291).

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

731. Norstrom M M, Stikvoort A, Egevad L, Bergqvist M, Henningsohn L, Mattsson J, et al. Novel method to characterize immune cells from human prostate tissue. *Prostate*. 2014;74(14):1391-9.

배제사유 : NK 세포 활성도를 다루지 않는 연구

732. Noto F K, Ravi K, Arey A, McClain C, Zhang W, Narla G, et al. Novel immunodeficient rat models capable of supporting the growth of human tumor xenografts. *Cancer Research*. Conference: AACR Special Conference: Advances in Modeling Cancer Technology, Biology, and Beyond. United States. 2018;78(10 Supplement 1).

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

733. Nowak M AM, S, Tun-Kyi A, Schmidt-Wolf I, Sanda M, G, Balk S, P, Exley M, A. Defective NKT cell activation by CD1d+ TRAMP prostate tumor cells is corrected by interleukin-12 with alpha-galactosylceramide. *PLoS ONE* [Electronic Resource]. 2010;5(6):e11311.

배제사유 : 동물실험 또는 전임상시험연구

734. Oberneder R WD, Ebner B, Quadt C, Kirchinger P, Raum T, Locher M, et al. A phase I study with adecatumumab, a human antibody directed against epithelial cell adhesion molecule, in hormone refractory prostate cancer patients. *European Journal of Cancer*. 2006;42(15):2530-8.

배제사유 : NK 세포 활성도를 다루지 않는 연구

735. Ogbomo H MM, Geiler J, van Rikxoort M, Muster T, Egorov A, Doerr H, W, et al. Tumor cells infected with oncolytic influenza A virus prime natural killer cells for lysis of resistant tumor cells. *Medical Microbiology & Immunology*. 2010;199(2):93-101.

배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구

736. Oikawa T KK, Ishiwata I, Ohno T, Akaza H. Induction of potent antitumour natural-killer cells from peripheral blood of patients with advanced prostate cancer. *BJU International*. 2003;92(9):1009-15.

배제사유 : 동물실험 또는 전임상시험연구

737. Okada S VK, Kariya R. Application of highly immunocompromised mice for the establishment of patient-derived xenograft (PDX) models. *Cells*. 2019;8 (8) (889).

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

738. Okamoto T TY, Yamamoto H, Hatakeyama S, Imai A, Yoneyama T, Okamoto A, et al. Glycosylation of MUC1 expressing on prostate cancer cell has crucial impact on susceptibility to natural killer cell immunity in TRAIL dependent manner. *European Urology, Supplements*. 2014;13 (1):e845-ea.

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

739. Okamoto T YM, S, Hatakeyama S, Mori K, Yamamoto H, Koie T, Saitoh H, et al. Core2 O-glycan-expressing prostate cancer cells are resistant to NK cell immunity. *Molecular Medicine Reports*. 2013;7(2):359-64.

배제사유 : 동물실험 또는 전임상시험연구

740. Olencki T FJ, Tubbs R, Tuason L, Greene T, McLain D, Swanson S, J, et al. Immunomodulatory effects of interleukin-2 and interleukin-4 in patients with malignancy. *Journal of immunotherapy with emphasis on tumor immunology*. 1996;19(1):69-80.

배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구

741. Onsrud M SS. Influence of in vivo diethylstilbesterol phosphate on some human blood lymphocyte sub-populations. *Acta Pathologica, Microbiologica, et Immunologica Scandinavica - Section C, Immunology*. 1982;90(5):271-6.

배제사유 : 동물실험 또는 전임상시험연구

742. Oucherif O ND. Function of HLA-G in cancer immunoediting and its clinical benefits. *Journal African du Cancer*. 2015;7(3):132-9.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

743. Owais M ZS, Agrawal A, Chang Y, F. *Cancer Immunology and Immunotherapy*. *BioMed Research International*. 2015;2015 (393454).

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

744. Pachynski R HL, Appleman L, Monk P, Bitting R, Kucuk O, Millard F, et al. T cell response induced by the addition of IL-7 treatment following sipuleucel-T immunotherapy in metastatic castration resistant prostate cancer. *Journal for ImmunoTherapy of Cancer*. Conference: 33rd Annual Meeting and Pre Conference Programs of the Society for Immunotherapy of Cancer, SITC. 2018;6(Supplement 1).

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

745. Pachynski R K, Zabel B, Tejeda N, Butcher E. Is the chemoattractant chemerin a natural tumor-suppressive cytokine? *Journal of Clinical Oncology*. Conference: ASCO Annual

Meeting. 2011;29(15 SUPPL. 1).

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

746. Palucka K BJ. Dendritic-Cell-Based Therapeutic Cancer Vaccines. *Immunity*. 2013;39(1):38-48.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

747. Pandey J P, Namboodiri A, M. Genetic variants of IgG1 antibodies and FcγRIIIa receptors influence the magnitude of antibody-dependent cell-mediated cytotoxicity against prostate cancer cells. *Oncoimmunology*. 2014;3(1):e27317.

배제사유 : 동물실험 또는 전임상시험연구

748. Pantuck A J, van Ophoven A, Gitlitz B, J, Tso C, L, Acres B, Squiban P, et al. Phase I trial of antigen-specific gene therapy using a recombinant vaccinia virus encoding MUC-1 and IL-2 in MUC-1-positive patients with advanced prostate cancer. *Journal of Immunotherapy*. 2004;27(3):240-53.

배제사유 : 동물실험 또는 전임상시험연구

749. Pantuck M PN, Drakaki A. Next generation T-cell therapy for genitourinary malignancies, part B: Overcoming obstacles and future strategies for success. *Cancer Treatment and Research Communications*. 2018;17:1-7.

배제사유 : NK 세포 활성화 측정 시 인터페론 감마를 평가대상 검사기술로 측정하지 않은 연구

750. Papaevangelou E SD, Elhage O, Smith R, A, Dasgupta P, Galustian C. An intratumoural cytotoxic immunotherapy approach to target prostate cancer in a syngeneic murine model. *European Urology, Supplements*. 2019;18 (1):e1334.

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

751. Papamichos S I. NKG2E comprises an immunogenic peptide, derived from an alu-retrotransposon: An attractive novel target for immunotherapeutic approaches. *Annals of Oncology*. 2019;30 (Supplement 11):xi53.

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

752. Paravar T LD, J. Thalidomide: Mechanisms of action. *International Reviews of Immunology*. 2008;27(3):111-35.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

753. Pardoll D. Does the immune system see tumors as foreign or self? *Annual Review of Immunology*. 2003;21:807-39.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

754. Park AJ LM. Peripheral Th1 and Th2 Lymphocytes Values by Intracellular Cytokine Staining for Interferon-γ and Interleukin-4 in the Patients with Repeated Spontaneous Abortion. *Korean J Lab Med*. 2005;Apr 25(2):111-115.

배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구

755. Park H OK, Nojima S, Tahara S, Kurashige M, Hori Y, Okuzaki D, et al. Adenylosuccinate lyase enhances aggressiveness of endometrial cancer by increasing killer cell lectin-like receptor C3 expression by fumarate. *Laboratory Investigation*. 2018;98(4):449-61.

배제사유 : 동물실험 또는 전임상시험연구

756. Park M H, Song M, J, Cho M, C, Moon D, C, Yoon D, Y, Han S, B, et al. Interleukin-32 enhances cytotoxic effect of natural killer cells to cancer cells via activation of death receptor 3. *Immunology*. 2012;135(1):63-72.

배제사유 : 동물실험 또는 전임상시험연구

757. Park S Y, Nam J, S. The force awakens: metastatic dormant cancer cells. *Experimental and Molecular Medicine*. 2020;52(4):569-81.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

758. Park S, Mun YC, Seong C-M, Huh HJ, Huh J. Variable Natural Killer Cell Activity in Hematological Malignancies at Diagnosis. *Laboratory Medicine Online*. 2018;8(2):41.

배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구

759. Parra S PR, Vargas R, Sepulveda C, Miranda D, Puente J. Natural killer cytolytic activity in renal and prostatic cancer. [Spanish]. *Revista medica de Chile*. 1994;122(6):630-7.

배제사유 : 한국어 또는 영어로 출판되지 않은 연구

760. Pasero C GG, Granjeaud S, Guerin M, Thomassin-Piana J, Rocchi P, Salem N, et al. Highly effective NK cells are associated with good prognosis in patients with metastatic prostate cancer. *Oncotarget*. 2015;6(16):14360-73.

배제사유 : NK 세포 활성도를 다루지 않는 연구

761. Pasero C GG, Guerin M, Granjeaud S, Thomassin-Piana J, Rocchi P, Paciencia-Gros M, et al. Inherent and Tumor-Driven Immune Tolerance in the Prostate Microenvironment Impairs Natural Killer Cell Antitumor Activity. *Cancer Research*. 2016;76(8):2153-65.

배제사유 : 동물실험 또는 전임상시험연구

762. Pasero C GG, Guerin M, Rocchi P, Thomassin J, Granjeaud S, Walz J, et al. Highly functional natural killer (NK) cells as predictive biomarkers associated to long response to castration in newly diagnosed metastatic prostate cancer. *Journal of Clinical Oncology*. Conference. 2014;32(15 SUPPL. 1).

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

763. Pasero C GG, Rocchi P, Sylvaine J, L, Livrati P, Thomassin J, Brunelle S, et al. Alterations of natural killer cell receptors as biomarkers associated with the severity of the disease in prostate cancer. *Journal of Clinical Oncology*. Conference. 2012;30(15 SUPPL. 1).

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

764. Pasero C TA, Olive D. Cosignaling molecules around LIGHT-HVEM-BTLA: From immune activation to therapeutic targeting. *Current Molecular Medicine*. 2009;9(7):911-27.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

765. Patero Y. Searching for the ideal cancer vaccine. *Cancer Biology and Therapy*. 2009;8(2):104-5.

배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구

766. Paul S LG. The molecular mechanism of natural killer cells function and its importance

in cancer immunotherapy. *Frontiers in Immunology*. 2017;8 (SEP) (1124).

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

767. Pedroza-Pacheco I MA, Saudemont A. Interaction between natural killer cells and regulatory T cells: Perspectives for immunotherapy. *Cellular and Molecular Immunology*. 2013;10(3):222-9.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

768. Peek E M, Song W, Zhang H, Huang J, Chin A, I. Loss of MyD88 leads to more aggressive TRAMP prostate cancer and influences tumor infiltrating lymphocytes. *Prostate*. 2015;75(5):463-73.

배제사유 : 동물실험 또는 전임상시험연구

769. Pellegrini M MT, W, Ohashi P, S. Fighting cancers from within: Augmenting tumor immunity with cytokine therapy. *Trends in Pharmacological Sciences*. 2010;31(8):356-63.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

770. Penedo F J, Dahn J, R, Kinsinger D, Antoni M, H, Molton I, Gonzalez J, S, et al. Anger suppression mediates the relationship between optimism and natural killer cell cytotoxicity in men treated for localized prostate cancer. *Journal of Psychosomatic Research*. 2006;60(4):423-7.

배제사유 : NK 세포 활성도를 다루지 않는 연구

771. Petrylak D P, Antonarakis E, S, Kandadi H, Fong L, Lance R, S, Vu T, et al. The association of humoral antigen spread (AgS) with cytotoxic T lymphocyte (CTL) activity after sipuleucel-T (sip-T) treatment in two phase II clinical studies: STAMP and STRIDE. *Journal of Clinical Oncology. Conference*. 2020;38(6 Supplement).

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

772. Pett S L. Immunotherapies in HIV-1 infection. *Current Opinion in HIV and AIDS*. 2009;4(3):188-93.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

773. Phan T G, Long G, V, Scolyer R, A. Multiple checkpoints on the long road towards cancer immunotherapy. *Immunology and Cell Biology*. 2015;93(4):323-5.

배제사유 : NK 세포 활성도 측정 시 인터페론 감마를 평가대상 검사기술로 측정하지 않은 연구

774. Pili R. A phase II randomized, open label study of sipuleucel-T versus sipuleucel-T and tasquinimod in patients with metastatic castrate-resistant prostate cancer (CRPC). *Journal of Clinical Oncology. Conference*. 2014;32(15 SUPPL. 1).

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

775. Pinkas J TB, A. TGF-beta in cancer and as a therapeutic target. *Biochemical Pharmacology*. 2006;72(5):523-9.

배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구

776. Pinthus J H, Waks T, Kaufman-Francis K, Schindler D, G, Harmelin A, Kanety H, et al. Immuno-gene therapy of established prostate tumors using chimeric receptor-redirection human lymphocytes. *Cancer Research*. 2003;63(10):2470-6.

배제사유 : 동물실험 또는 전임상시험연구

777. Pinthus J H, Waks T, Malina V, Kaufman-Francis K, Harmelin A, Aizenberg I, et al. Adoptive immunotherapy of prostate cancer bone lesions using redirected effector lymphocytes. *Journal of Clinical Investigation*. 2004;114(12):1774-81.
배제사유 : 동물실험 또는 전임상시험연구
778. Poggi A ZM, R. gammadelta T lymphocytes as a first line of immune defense: Old and new ways of antigen recognition and implications for cancer immunotherapy. *Frontiers in Immunology*. 2014;5 (NOV) (575).
배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구
779. Polimeno M EA, Napolitano M, Aiello T, A, Portella L, Castello G, Scala S. CXCR4 AND CXCR7 are concomitantly expressed in HCC. *Annals of Oncology*. 2010;6:vi94.
배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
780. Porta C LP, Rimoldi M, Grazia Totaro M, Allavena P, Mantovani A, Sica A. Cellular and molecular pathways linking inflammation and cancer. *Immunobiology*. 2009;214(9-10):761-77.
배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
781. Portela P JL, F, Salim P, H, Koff W, J, Wilson T, J, Jobim M, R, Schwartzmann G, et al. Analysis of KIR gene frequencies and HLA class I genotypes in prostate cancer and control group. *International Journal of Immunogenetics*. 2012;39(5):423-8.
배제사유 : NK 세포 활성도를 다루지 않는 연구
782. Prima V KS, Vieweg J. Prostate cancer immunotherapy development using tumor-specific CAR design. *Cancer Immunology Research*. Conference: AACR Special Conference: Tumor Immunology and Immunotherapy: A New Chapter. United States. 2015;3(10 Supplement).
배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
783. Pucci F PM, J. Molecular pathways: Tumor-derived microvesicles and their interactions with immune cells In vivo. *Clinical Cancer Research*. 2013;19(10):2598-604.
배제사유 : 동물실험 또는 전임상시험연구
784. Putz E M, Guillerey C, Kos K, Stannard K, Miles K, Delconte R, B, et al. Targeting cytokine signaling checkpoint CIS activates NK cells to protect from tumor initiation and metastasis. *Oncoimmunology*. 2017;6(2):e1267892.
배제사유 : 동물실험 또는 전임상시험연구
785. Putz E M, Mayfosh A, J, Kos K, Barkauskas D, S, Nakamura K, Town L, et al. NK cell heparanase controls tumor invasion and immune surveillance. *Journal of Clinical Investigation*. 2017;127(7):2777-88.
배제사유 : 동물실험 또는 전임상시험연구
786. Qu S XH, Dong X, Lin D, Wu R, Nabavi N, Collins C, C, et al. Aneustat (OMN54) has aerobic glycolysis-inhibitory activity and also immunomodulatory activity as indicated by a first-generation PDX prostate cancer model. *International Journal of Cancer*. 2018;143(2):419-29.
배제사유 : 동물실험 또는 전임상시험연구

787. Quail D F, Joyce J, A. Microenvironmental regulation of tumor progression and metastasis. *Nature Medicine*. 2013;19(11):1423-37.
 배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
788. Quemener V BY, Chamaillard L, Havouis R, Cipolla B, Moulinoux J, P. Polyamine deprivation: a new tool in cancer treatment. *Anticancer Research*. 1994;14(2A):443-8.
 배제사유 : 동물실험 또는 전임상시험연구
789. Quemener V CL, Brachet P, Havouis R, Moulinoux J, P. [Involvement of polyamines in malignant proliferative processes: antineoplastic effects of a polyamine deficiency]. *Bulletin de l Academie Nationale de Medecine*. 1994;178(8):1591-605; discussion 606-8.
 배제사유 : 한국어 또는 영어로 출판되지 않은 연구
790. Quemener V CL, Brachet P, Havouis R, Moulinoux J, P. Involvement of polyamines in tumor growth: Antitumoral effects of polyamine deprivation. [French]. *Annales de Gastroenterologie et d'Hepatology*. 1995;31(3):181-9.
 배제사유 : 한국어 또는 영어로 출판되지 않은 연구
791. Quemener V CL, Brachet P, Havouis R, Moulinoux J, P. The involvement of polyamines in the malignant proliferative process. The anticancer effect of polyamine deprivation. [French]. *Annales de gastroenterologie et d'hepatologie*. 1995;31(3):181-8; discussion 8-9.
 배제사유 : 한국어 또는 영어로 출판되지 않은 연구
792. Quintanar J L. Neuroimmunomodulation by gonadotropin releasing hormone. *Advances in Neuroimmune Biology*. 2011;1(2):125-32.
 배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구
793. Rabinovich G A, Conejo-Garcia J, R. Shaping the Immune Landscape in Cancer by Galectin-Driven Regulatory Pathways. *Journal of Molecular Biology*. 2016;428(16):3266-81.
 배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
794. Rachel H C-CL. Recent advances toward the development of inhibitors to attenuate tumor metastasis via the interruption of lectin-ligand interactions. *Advances in Carbohydrate Chemistry and Biochemistry*. 2013;69:125-207.
 배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구
795. Radestad E EL, Jorns C, Mattsson J, Sundberg B, Nava S, Ericzon B, G, et al. Characterization of infiltrating lymphocytes in human benign and malignant prostate tissue. *Oncotarget*. 2017;8(36):60257-69.
 배제사유 : NK 세포 활성도를 다루지 않는 연구
796. Radom-Aizik S ZF, Cooper D, M. Combined analysis of gene and MicroRNA expression in natural killer cells in response to exercise. *FASEB Journal. Conference: Experimental Biology*. 2012;26(Meeting Abstracts).
 배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
797. Radom-Aizik S ZF, Haddad F, Cooper D, M. Impact of brief exercise on peripheral blood NK cell gene and microRNA expression in young adults. *Journal of Applied Physiology*. 2013;114(5):628-36.

배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구

798. Rahman S IR, Swaraz A, M, Ansari A, Parvez A, K, Paul D, K. An insight on genistein as potential pharmacological and therapeutic agent. *Asian Pacific Journal of Tropical Biomedicine*. 2012;2(3 SUPPL.):S1924-S37.

배제사유 : 동물실험 또는 전임상시험연구

799. Raja Gabaglia C DdDY, Graham F, L, Gauldie J, Sercarz E, E, Braciak T, A. Attenuation of the glucocorticoid response during Ad5IL-12 adenovirus vector treatment enhances natural killer cell-mediated killing of MHC class I-negative LNCaP prostate tumors. *Cancer Research*. 2007;67(5):2290-7.

배제사유 : NK 세포 활성도를 다루지 않는 연구

800. Rajarubendra N LN, Bolton D, M, Klotz L, Davis I, D. Prostate cancer immunology - An update for urologists. *BJU International*. 2011;107(7):1046-51.

배제사유 : NK 세포 활성도를 다루지 않는 연구

801. Raman D BP, J, Thu Y, M, Richmond A. Role of chemokines in tumor growth. *Cancer Letters*. 2007;256(2):137-65.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

802. Randhawa M A, Alghamdi M, S. Anticancer activity of *Nigella sativa* (Black Seed) - A review. *American Journal of Chinese Medicine*. 2011;39(6):1075-91.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

803. Rani A GR, Murphy J, Galustian C. Regulation of the CCL2-CCR2 axis through the JAK-STAT pathway and role in cancer metastasis. *Cytokine*. 2016;87:59.

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

804. Rao Q ZH, Zhang C, Zhuang Q, Du G, Wang S, Ye Z, et al. Leinal polypeptide promotes NK cells to suppress PCa survival in vitro. *Oncology Letters*. 2018;16(1):425-30.

배제사유 : 동물실험 또는 전임상시험연구

805. Rastelli L GS, Dahiya A, Jagga Z, Nandabalan K, Upmanyu S. The synergy between BXCL701, a DPP inhibitor, and immune checkpoint inhibitors discovered using AI and Big Data analytics. *Cancer Research. Conference: American Association for Cancer Research Annual Meeting*. 2017;77(13 Supplement 1).

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

806. Ratta R ZR, Raggi D, Grassi P, Verzoni E, Necchi A, Di Nicola M, et al. Immunotherapy advances in uro-genital malignancies. *Critical Reviews in Oncology/Hematology*. 2016;105:52-64.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

807. Rautela J BN, Jayatilleke K, Hertzog P, Parker B. Exploiting the type-1 interferon pathway as a biomarker and therapeutic target for metastatic cancer. *Cytokine*. 2014;70(1):25.

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

808. Ravelli A RJ, M, Lanza F, Anfossi S, Cappelletti M, R, Zanotti L, Gobbi A, et al.

Immune-related strategies driving immunotherapy in breast cancer treatment: A real clinical opportunity. *Expert Review of Anticancer Therapy*. 2015;15(6):689-702.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

809. Ravi K NF, McClain C, Arey A, Narla G, Crawford J, Yeshi T. Novel immunodeficient rat models offer a unique platform for drug efficacy studies in human tumor xenografts. *Molecular Cancer Therapeutics*. Conference: AACR NCI EORTC International Conference: Molecular Targets and Cancer Therapeutics. 2017;17(1 Supplement 1).

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

810. Ravindranath M H, Yesowitch P, Sumobay C, Morton D, L. Glycoimmunomics of human cancer: Current concepts and future perspectives. *Future Oncology*. 2007;3(2):201-14.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

811. Ray M HD, R, Loeb C, R, Simko J, Craik C, S. Inhibition of Granzyme B by PI-9 protects prostate cancer cells from apoptosis. *Prostate*. 2012;72(8):846-55.

배제사유 : 동물실험 또는 전임상시험연구

812. Reddel R R. Senescence: An antiviral defense that is tumor suppressive? *Carcinogenesis*. 2010;31(1):19-26.

배제사유 : 동물실험 또는 전임상시험연구

813. Redmond J BP. Role of ion channels in natural killer cell function towards cancer. *Discovery Medicine*. 2017;23 (129) (4).

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

814. Reid L M, Minato N, Gresser I, Holland J, Kadish A, Bloom B, R. Influence of anti-mouse interferon serum on the growth and metastasis of tumor cells persistently infected with virus and of human prostatic tumors in athymic nude mice. *Proceedings of the National Academy of Sciences of the United States of America*. 1981;78(2):1171-5.

배제사유 : 동물실험 또는 전임상시험연구

815. Reinertsen T HJ, Viset T, Flatberg A, Haugsmoen L, L, Skogseth H. Gene expressional changes in prostate fibroblasts from cancerous tissue. *Apmis*. 2012;120(7):558-71.

배제사유 : 동물실험 또는 전임상시험연구

816. Reiter M A, Pfitzenmaier J, Hohenfellner M, Haferkamp A. Immunomodulatory treatment approaches for prostate cancer. [German]. *Urologe - Ausgabe A*. 2009;48(7):755-63.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

817. Ren C KS, Chanda D, Kallman L, Chen J, Mountz J, D, Ponnazhagan S. Cancer gene therapy using mesenchymal stem cells expressing interferon-beta in a mouse prostate cancer lung metastasis model. *Gene Therapy*. 2008;15(21):1446-53.

배제사유 : 동물실험 또는 전임상시험연구

818. Rescigno M AF, Curigliano G. Challenges and prospects of immunotherapy as cancer treatment. *Biochimica et Biophysica Acta - Reviews on Cancer*. 2007;1776(1):108-23.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

819. Restifo N P, Dudley M, E, Rosenberg S, A. Adoptive immunotherapy for cancer:

- Harnessing the T cell response. *Nature Reviews Immunology*. 2012;12(4):269-81.
 배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
820. Ribatti D NB, Crivellato E, Vacca A. Macrophages and tumor angiogenesis. *Leukemia*. 2007;21(10):2085-9.
 배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
821. Ribatti D. The concept of immune surveillance against tumors. The first theories. *Oncotarget*. 2017;8(4):7175-80.
 배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
822. Richardson P G, Jagannath S, Moreau P, Jakubowiak A, S, Raab M Facon T, Vij R, et al. A phase 2 study of elotuzumab (elo) in combination with lenalidomide and low-dose dexamethasone (ld) in patients (pts) with relapsed/refractory multiple myeloma (r/r mm): updated results. *Blood*. 2012;120(21).
 배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
823. Richter J VS, Svoboda J, Cimburek Z, Rosina J, Fiserova A. Advanced flow cytometry for detection of stress proteininduced expression of NKG2D and CD161 in the course of local radiotherapy in prostate cancer patients. *Urology*. 2009;74 (4 SUPPL S):S200.
 배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
824. Riether C SC, Ochsenbeina A, F. From 'magic bullets' to specific cancer immunotherapy. *Swiss Medical Weekly*. 2013;143 (w13734).
 배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
825. Rigamonti N BM. Prostate cancer, tumorimmunity and a renewed sense of optimism in immunotherapy. *Cancer Immunology, Immunotherapy*. 2012;61(4):453-68.
 배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
826. Ringden O. Immunotherapy by Allogeneic Stem Cell Transplantation. *Advances in Cancer Research*. 2007;97:25-60.
 배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
827. Rittenhouse-Olson K. JAA-F11: Extending the life of mice with breast cancer. *Expert Opinion on Biological Therapy*. 2007;7(7):923-8.
 배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
828. Rivera A FX, Tao L, Zhang X. Expression of mouse CD47 on human cancer cells profoundly increases tumor metastasis in murine models. *BMC Cancer*. 2015;15:964.
 배제사유 : 동물실험 또는 전임상시험연구
829. Rivera G P, Inostroza S, J, Treulen F. Intraprostatic BCG vaccine in patients with prostatic cancer, expression of interferon gamma and interleukin 4. [Spanish]. *Actas Urologicas Espanolas*. 2002;26(5):351-5.
 배제사유 : 한국어 또는 영어로 출판되지 않은 연구
830. Roato I VM. The Uncovered Role of Immune Cells and NK Cells in the Regulation of Bone Metastasis. *Frontiers in Endocrinology*. 2019;10:145.
 배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

831. Robert Siemens D HT, Barsoum I, Li X, Miles E, Graham C. A mechanism of hypoxia-induced immune escape in prostate cancer cells. *Journal of Urology*. 2011;1):e509-e10.
 배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
832. Roberts L K. Cancer vaccines: Asymptotically approaching product approval. *BioPharm International*. 2007;20(8 SUPPL.):69-77.
 배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
833. Roigas J WE, S, Loening S, A, Moseley P, L. Heat shock protein (HSP72) surface expression enhances the lysis of a human renal cell carcinoma by IL-2 stimulated NK cells. *Advances in Experimental Medicine & Biology*. 1998;451:225-9.
 배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구
834. Rola Pleszczynski M LH. Human natural cytotoxic lymphocytes: Definition by a monoclonal antibody of a subset which kills an anchorage-dependent target cell line but not the K-562 cell line. *Cellular Immunology*. 1983;82(2):326-33.
 배제사유 : 동물실험 또는 전임상시험연구
835. Romero I GF, Garcia-Lora A, M. A novel preclinical murine model of immune-mediated metastatic dormancy. *OncoImmunology*. 2014;3 (6) (e29258).
 배제사유 : 동물실험 또는 전임상시험연구
836. Roop J PA, Campisi A, Gabrilovich D, Kumar A, Dominguez G. Using artificial intelligence to distinguish subjects with prostate cancer (PCa) from benign prostate hyperplasia (BPH) through immunophenotyping of MDSCs and lymphocyte cell populations. *Journal for ImmunoTherapy of Cancer*. Conference: 33rd Annual Meeting and Pre Conference Programs of the Society for Immunotherapy of Cancer, SITC. 2018;6(Supplement 1).
 배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
837. Rosental B HU, Brusilovsky M, Campbell K, S, Porgador A. A novel mechanism for cancer cells to evade immune attack by NK cells: The interaction between NKp44 and proliferating cell nuclear antigen. *OncoImmunology*. 2012;1(4):572-4.
 배제사유 : 동물실험 또는 전임상시험연구
838. Rosewell Shaw A SM. Recent advances in oncolytic adenovirus therapies for cancer. *Current Opinion in Virology*. 2016;21:9-15.
 배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
839. Rossi E FF. CTCs 2020: Great expectations or unreasonable dreams. *Cells*. 2019;8 (9) (989).
 배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
840. Roth M D, Harui A. Human tumor infiltrating lymphocytes cooperatively regulate prostate tumor growth in a humanized mouse model. *Journal for ImmunoTherapy of Cancer*. 2015;3 (1) (12).
 배제사유 : 동물실험 또는 전임상시험연구

841. Rothschild S I, Zippelius A. Cancer immunotherapy - Novel perspectives. *Therapeutische Umschau*. 2012;69(10):559-63.
 배제사유 : NK 세포 활성도를 다루지 않는 연구
842. Roufas C CD, Makris A, Efstathiades C, Dimopoulos C, Zaravinos A. The Expression and Prognostic Impact of Immune Cytolytic Activity-Related Markers in Human Malignancies: A Comprehensive Meta-analysis. *Frontiers in Oncology*. 2018;8:27.
 배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구
843. Rubenstein M SM, W, Ablin R, J. Further evaluation and characterization of the mononuclear cell population of patients with prostate cancer. *IRCS Medical Science*. 1984;12(8):761-2.
 배제사유 : NK 세포 활성도를 다루지 않는 연구
844. Rubenstein M SM, W, Ray V, Dubin A, McKiel C, F, Guinan P. Application of immunohistologic staining to develop a malignant index to aid in distinguishing benign from malignant prostatic tissue. *Prostate*. 1989;14(4):383-8.
 배제사유 : 동물실험 또는 전임상시험연구
845. Rui X SS, Wang L, Leng J. Identification of recurrence marker associated with immune infiltration in prostate cancer with radical resection and build prognostic nomogram. *BMC Cancer*. 2019;19 (1) (1179).
 배제사유 : 동물실험 또는 전임상시험연구
846. Rusmevichientong A CS, A. Biology and pathophysiology of the new human retrovirus XMRV and its association with human disease. *Immunologic Research*. 2010;48(1-3):27-39.
 배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
847. Russo M SC, Tedesco I, Bilotto S, Russo G, L. The flavonoid quercetin in disease prevention and therapy: Facts and fancies. *Biochemical Pharmacology*. 2012;83(1):6-15.
 배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
848. Rusthoven J J, Robinson J, B, Kolin A, Pinkerton P, H. The natural-killer-cell-associated HNK-1 (Leu-7) antibody reacts with hypertrophic and malignant prostatic epithelium. *Cancer*. 1985;56(2):289-93.
 배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
849. Ryan-Harshman M AW. The relevance of selenium to immunity, cancer, and infectious/inflammatory diseases. *Canadian Journal of Dietetic Practice and Research*. 2005;66(2):98-102.
 배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
850. Saga K KY. NANOG expression induces NK cell resistance in human prostate cancer. *Cancer Science. Conference: 76th Annual Meeting of the Japanese Cancer Association, JCA*. 2017;109(Supplement 1).
 배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
851. Saga K PJ, Nimura K, Kawamura N, Ishibashi A, Nonomura N, Kaneda Y. NANOG helps

cancer cells escape NK cell attack by downregulating ICAM1 during tumorigenesis. *Journal of Experimental & Clinical Cancer Research*. 2019;38(1):416.

배제사유 : 동물실험 또는 전임상시험연구

852. Sage E K, Schmid T, E, Geinitz H, Gehrmann M, Sedelmayr M, Duma M, N, et al. Effects of definitive and salvage radiotherapy on the distribution of lymphocyte subpopulations in prostate cancer patients. *Strahlentherapie und Onkologie*. 2017;193(8):648-55.

배제사유 : NK 세포 활성도를 다루지 않는 연구

853. Sage E K, Schmied T, E, Geinitz H, Gehrmann M, Sedelmayr M, Duma M, N, et al. Effects of local radiotherapy on the composition of lymphocyte subpopulations in prostate and breast cancer patients. *Strahlentherapie und Onkologie*. 2017;193 (1 Supplement 1):S180-S1.

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

854. Saijo H HY, Torigoe T, Kochin V, Takahashi H, Sato N. Cytotoxic T lymphocytes: The future of cancer stem cell eradication? *Immunotherapy*. 2013;5(6):549-51.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

855. Saika T ST, Kusaka N, Ebara S, Mouraviev V, B, Timme T, L, Thompson T, C. Route of administration influences the antitumor effects of bone marrow-derived dendritic cells engineered to produce interleukin-12 in a metastatic mouse prostate cancer model. *Cancer Gene Therapy*. 2004;11(5):317-24.

배제사유 : 동물실험 또는 전임상시험연구

856. Sakaguchi M KK, Abarzua F, Tanimoto R, Watanabe M, Murata H, Than S, S, et al. Overexpression of REIC/Dkk-3 in normal fibroblasts suppresses tumor growth via induction of interleukin-7. *Journal of Biological Chemistry*. 2009;284(21):14236-44.

배제사유 : NK 세포 활성도를 다루지 않는 연구

857. Sakellariou C A, Elhage O, Smith R, A, Dasgupta P, Galustian C. IL-15 increases NK functions in the PCa-lymphocyte microenvironment by a profound increase in shedding of MICA from PCa cells-a novel paradigm. *Cancer Research*. Conference: 106th Annual Meeting of the American Association for Cancer Research, AACR. 2015;75(15 SUPPL. 1).

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

858. Sakellariou C A, Elhage O, Ukimura O, Gill I, Smith R, A, Dasgupta P, et al. Interleukin-15 activates NK and CD8 T cells within the Prostate cancer microenvironment by expanding activatory NK cell receptors and attenuating inhibitory HLA ligands on tumor cells. *Cancer Research*. Conference: 105th Annual Meeting of the American Association for Cancer Research, AACR. 2014;74(19 SUPPL. 1).

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

859. Sakellariou C A, Elhage O, Ukimura O, Gill I, Smith R, Galustian C, et al. IL-15 increases NK functions in the PCA-lymphocyte microenvironment by a profound increase in shedding of mica from PCA cells-a novel paradigm. *Journal of Urology*. 2015;1):e748.

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

860. Sakellariou C EO, Papaevangelou E, Giustarini G, Esteves A, M, Smolarek D, Smith R, A, et al. Prostate cancer cells enhance interleukin-15-mediated expansion of NK cells. *BJU International*. 2020;125(1):89-102.
 배제사유 : 동물실험 또는 전임상시험연구
861. Sakellariou C SD, Elhage O, Ukimura O, Gill I, Smith R, Galustian C, et al. A tale of tails: A novel approach to cytokine immunotherapy. *Urology*. 2014;1):S43.
 배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
862. Sakic K. Refresher course: spinal anesthesia and the stress/immune response. *Regional anesthesia and pain medicine*. 2015;40(5):e65?e7.
 배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
863. Sakiyama M J, Espinoza I, Kumar D, Reddy A, Bhanat E, Syrigos K, et al. MHC class I polypeptide related sequence A as contributing factor to chemotherapy-induced resistance. *Cancer Research. Conference*. 2018;78(13 Supplement 1).
 배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
864. Sakiyama M J, Espinoza I, Reddy A, de Carlo F, Kumar A, Levenson A, S, et al. Race-associated expression of MHC class I polypeptide-related sequence A (MICA) in prostate cancer. *Experimental & Molecular Pathology*. 2019;108:173-82.
 배제사유 : 동물실험 또는 전임상시험연구
865. Sakiyama M J, Espinoza I, Reddy A, Lewin J, R, Zhou X, Zhang X, et al. MHC class I polypeptide related sequence A (MICA) in context of aggressive prostate cancer. *Cancer Research. Conference: American Association for Cancer Research Annual Meeting*. 2017;77(13 Supplement 1).
 배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
866. Sakiyama M J, Garcia A, Espinoza I, Lewin J, Zhang X, Tarsi E, et al. MHC class I polypeptide-related sequence A (MICA) as a factor of aggressive prostate cancer. *Cancer Research. Conference: 107th Annual Meeting of the American Association for Cancer Research, AACR*. 2016;76(14 Supplement).
 배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
867. Salama A K, S, Postow M, A, Salama J, K. Irradiation and immunotherapy: From concept to the clinic. *Cancer*. 2016;122(11):1659-71.
 배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
868. Samudio I HE, Cho B, Li M, Bolduc K, Bu L, Liu G, et al. UV Light-inactivated HSV-1 Stimulates Natural Killer Cell-induced Killing of Prostate Cancer Cells. *Journal of Immunotherapy*. 2019;42(5):162-74.
 배제사유 : 동물실험 또는 전임상시험연구
869. Sanford M A, Yan Y, Canfield S, E, Hassan W, Selleck W, A, Atkinson G, et al. Independent contributions of GR-1+ leukocytes and Fas/FasL interactions to induce apoptosis following interleukin-12 gene therapy in a metastatic model of prostate cancer. *Human Gene Therapy*. 2001;12(12):1485-98.
 배제사유 : 동물실험 또는 전임상시험연구

870. Santegoets S J, Van Mens L, J, J, Belien J, A, M, Stam A, G, M, Lougheed S, M, Scheper R, J, et al. Inflammatory responses with infiltrating DC and functional cytotoxic T lymphocytes in the dermal vaccination sites of GVAX/ipilimumab treated prostate cancer patients. *Cancer Research. Conference: 104th Annual Meeting of the American Association for Cancer Research, AACR. 2013;73(8 SUPPL. 1).*
배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
871. Santos M F, Mannam V, K, Craft B, S, Punecky L, V, Sheehan N, T, Lewis R, E, et al. Comparative analysis of innate immune system function in metastatic breast, colorectal, and prostate cancer patients with circulating tumor cells. *Experimental & Molecular Pathology. 2014;96(3):367-74.*
배제사유 : NK 세포 활성도를 다루지 않는 연구
872. Sarkar D K, Boyadjieva N, I, Chen C, P, Ortiguela M, Reuhl K, Clement E, M, et al. Cyclic adenosine monophosphate differentiated beta-endorphin neurons promote immune function and prevent prostate cancer growth. *Proceedings of the National Academy of Sciences of the United States of America. 2008;105(26):9105-10.*
배제사유 : 동물실험 또는 전임상시험연구
873. Sarkar D K, Jabbar S, Gangisetty O, Murugan S, Zhang C. Fetal alcohol programming of the neuroendocrine-immune axis increases the susceptibility to carcinogenesis. *Alcoholism: Clinical and Experimental Research. 2015;1):301A.*
배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
874. Sarkar D K, Murugan S, Zhang C, Boyadjieva N. Regulation of cancer progression by beta-endorphin neuron. *Cancer Research. 2012;72(4):836-40.*
배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
875. Sarkar D K, Zhang C, Murugan S, Boyadjieva N, Ortiguela M. Beta-endorphin neuron transplants suppress mammary tumor growth and progression: Role of immune cells. *Cancer Research. Conference: 104th Annual Meeting of the American Association for Cancer Research, AACR. 2013;73(8 SUPPL. 1).*
배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
876. Sarkar D K, Zhang C, Murugan S, Boyadjieva N. Prenatal alcohol exposure increases susceptibility to mammary and prostate carcinogenesis and alters tumor phenotypes in adults. *Alcoholism: Clinical and Experimental Research. 2013;2):291A.*
배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
877. Sarkar D K. Fetal alcohol exposure increases susceptibility to carcinogenesis and promotes tumor progression in prostate gland. *Advances in Experimental Medicine and Biology. 2015;815:389-402.*
배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
878. Sarkar D K. Increased susceptibility to prostate cancers in fetal alcohol exposed offspring: Role of the neuroendocrine-immune axis. *Alcoholism: Clinical and Experimental Research. 2010;3):48A.*
배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

879. Satge D SM, G. The pattern of malignancies in down syndrome and its potential context with the immune system. *Frontiers in Immunology*. 2018;9 (3058).
 배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
880. Sato K AR, Moriyama M, Kato T, Tsuchida S. [Immune parameters of peripheral blood in chemoembolization with microencapsulated anticancer drugs]. *Gan to Kagaku Ryoho [Japanese Journal of Cancer & Chemotherapy]*. 1989;16(1):73-7.
 배제사유 : 한국어 또는 영어로 출판되지 않은 연구
881. Satoh T ST, Ebara S, Kusaka N, Timme T, L, Yang G, Wang J, et al. Macrophages transduced with an adenoviral vector expressing interleukin 12 suppress tumor growth and metastasis in a preclinical metastatic prostate cancer model. *Cancer Research*. 2003;63(22):7853-60.
 배제사유 : 동물실험 또는 전임상시험연구
882. Satoh T TT, L, Saika T, Ebara S, Yang G, Wang J, Ren C, et al. Adenoviral vector-mediated mRTVP-1 gene therapy for prostate cancer. *Human Gene Therapy*. 2003;14(2):91-101.
 배제사유 : 동물실험 또는 전임상시험연구
883. Saxena M BS, Roudko V, Bhardwaj N. Towards superior dendritic-cell vaccines for cancer therapy. *Nature Biomedical Engineering*. 2018;2(6):341-4.
 배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구
884. Saxena S AU, Agarwal A, Murthy N, S, Mohanty N, K. Adjuvant intravesical therapy based on an in vitro cytotoxicity assay in the management of superficial transitional cell cancer of the urinary bladder. *BJU international*. 2006;98(5):1012??7.
 배제사유 : 동물실험 또는 전임상시험연구
885. Sayitoglu E C, Georgoudaki A, M, Chrobok M, Ozkazanc D, Josey B, J, Arif M, et al. Boosting Natural Killer Cell-Mediated Targeting of Sarcoma Through DNAM-1 and NKG2D. *Frontiers in Immunology*. 2020;11 (40).
 배제사유 : 동물실험 또는 전임상시험연구
886. Schenk A ET, Wallberg H, Bloch W, Herden J, Heidenreich A, Zimmer P. Influence of acute endurance exercise on epigenetic modification, effector function and tumor infiltration of natural killer cells - A study protocol. *Oncology Research and Treatment*. 2018;41 (Supplement 1):163.
 배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
887. Schilling D CS, E, Multhoff G. Increased MICA serum levels do not affect the NKG2D expression of NK cells in lung cancer patients. *Strahlentherapie und Onkologie*. 2017;193 (1 Supplement 1):S107.
 배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
888. Schlom J HJ, W. Introduction: Therapeutic cancer vaccines. *Seminars in Oncology*. 2012;39(3):243-4.
 배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

889. Schlom J. Multimodal approach to cancer immunotherapy. *Journal of Acquired Immune Deficiency Syndromes*. 2019;81 (Supplement 1):37.
 배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
890. Schudde M BA, Pende D, Sonnemann J, Klier U, Beck J, F, Moretta L, et al. Histone deacetylase inhibitors sensitize tumour cells for cytotoxic effects of natural killer cells. *Cancer Letters*. 2008;272(1):110-21.
 배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구
891. Schoenhals J E, Skrepnik T, Selek U, Cortez M, A, Li A, Welsh J, W. Optimizing radiotherapy with immunotherapeutic approaches. *Advances in Experimental Medicine and Biology*. 2017;995:53-71.
 배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구
892. Schrotten C SR, Boon L, de Ridder C, M, Bangma C, H, Kraaij R. Tumor protection by IL-7 secreting whole cell vaccine is merely mediated by NK1.1-positive cells. *Journal of Immunotherapy*. 2012;35(2):125-30.
 배제사유 : 동물실험 또는 전임상시험연구
893. Schultze J L, Fiore F, von Bergwelt-Baildon M. DCs in lymphoma - Biology and therapeutic aspects. *Cytotherapy*. 2004;6(2):138-47.
 배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
894. Schultze J L, Grabbe S, Von Bergwelt-Baildon M, S. DCs and CD40-activated B cells: Current and future avenues to cellular cancer immunotherapy. *Trends in Immunology*. 2004;25(12):659-64.
 배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
895. Schumacher O GD, A, Taaffe D, R, Chee R, Spry N, Newton R, U. Exercise modulation of tumour perfusion and hypoxia to improve radiotherapy response in prostate cancer. *Prostate Cancer & Prostatic Diseases*. 2020;06:06.
 배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
896. Schwartz J E, Scuderi P, Wiggins C, Rudolph A, Hersh E, M. A phase I trial of recombinant tumor necrosis factor (rTNF) administered by continuous intravenous infusion in patients with disseminated malignancy. *Biotherapy*. 1989;1(3):207-14.
 배제사유 : NK 세포 활성도를 다루었으나 인터페론 감마를 보고하지 않은 연구
897. Schwemmer B LA, Hofmann R, Braun J. Natural killer cell activity in patients with prostatic carcinoma and its in vivo boosting with bacillus Calmette-Guerin. *Urologia Internationalis*. 1984;39(6):321-6.
 배제사유 : 동물실험 또는 전임상시험연구
898. Schwemmer B. Natural killer T cells in patients with prostatic carcinoma. *Urologia Internationalis*. 2003;71(2):146-9.
 배제사유 : NK 세포 활성도를 다루지 않는 연구
899. Scioli M G, Storti G, D'Amico F, Gentile P, Kim B, S, Cervelli V, et al. Adipose-derived stem cells in cancer progression: New perspectives and opportunities. *International*

Journal of Molecular Sciences. 2019;20 (13) (3296).

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

900. See D MS, Roshan R. Increased Tumor Necrosis Factor alpha (TNF-alpha) and Natural Killer Cell (NK) function using an integrative approach in late stage cancers. Immunological Investigations. 2002;31(2):137-53.

배제사유 : NK 세포 활성도를 다루었으나 인터페론 감마를 보고하지 않은 연구

901. Segler A TA, M. Lenalidomide in solid tumors. Cancer Chemotherapy and Pharmacology. 2012;69(6):1393-406.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

902. Segui E PL, Adamo B, Pineda E, Marin-Aguilera M, Reig O, Corbacho J, G, et al. Immune gene expression, survival outcome and response to PD-1/PD-L1 blockade: A TCGA pan-cancer analysis. Journal of Clinical Oncology. Conference. 2016;34(Supplement 15).

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

903. Sek K MC, Stewart G, D, Kats L, Darcy P, K, Beavis P, A. Targeting adenosine receptor signaling in cancer immunotherapy. International Journal of Molecular Sciences. 2018;19 (12) (3837).

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

904. Sellami M GM, Denham J, Hayes L, D, Stratton D, Padulo J, Bragazzi N. Effects of acute and chronic exercise on immunological parameters in the elderly aged: Can physical activity counteract the effects of aging? Frontiers in Immunology. 2018;9 (OCT) (2187).

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

905. Semeraro M VE, Eggermont A, Galon J, Zitvogel L, Kroemer G, Galluzzi L. Trial Watch: Lenalidomide-based immunochemotherapy. OncoImmunology. 2013;2 (11) (e26494).

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

906. Senovilla L VE, Galon J, Adjemian S, Eggermont A, Fridman W, H, Sautes-Fridman C, et al. Trial watch prognostic and predictive value of the immune infiltrate in cancer. OncoImmunology. 2012;1(8):1323-43.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

907. Sephton S SD. Circadian disruption in cancer: A neuroendocrine-immune pathway from stress to disease? Brain, Behavior, and Immunity. 2003;17(5):321-8.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

908. Sessler D I. Regional anesthesia and prostate cancer recurrence. [French, English]. Canadian Journal of Anesthesia. 2010;57(2):99-102.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

909. Sethi G SB, Aggarwal B, B. Therapeutic potential of VEG1/TL1A in autoimmunity and cancer. Therapeutic Targets of the TNF Superfamily. 2009;Advances in Experimental Medicine and Biology. 647:207-15.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

910. Seyedin S N, Schoenhals J, E, Lee D, A, Cortez M, A, Wang X, Niknam S, et al. Strategies for combining immunotherapy with radiation for anticancer therapy. *Immunotherapy*. 2015;7(9):967-80.
 배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
911. Sfikakis P P, Gourgoulis G, M, Mouloupoulos L, A, Kouvatseas G, Theofilopoulos A, N, Dimopoulos M, A. Age-related thymic activity in adults following chemotherapy-induced lymphopenia. *European Journal of Clinical Investigation*. 2005;35(6):380-7.
 배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구
912. Shahid A BM. The connection between the Th17 cell related cytokines and cancer stem cells in cancer: Novel therapeutic targets. *Immunology Letters*. 2019;213:9-20.
 배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
913. Sharma A SS, K, Blando J, Scutti J, Vence L, Wargo J, Allison J, P, et al. Anti-CTLA-4 immunotherapy does not deplete Foxp3+ regulatory T cells (Tregs) in human cancers. *Clinical Cancer Research*. 2019;25(4):1233-8.
 배제사유 : 동물실험 또는 전임상시험연구
914. Sharpe R W, Rector J, T, Rushin J, M, Garvin D, F, Cotelingam J, D. Splenic metastasis in hairy cell leukemia. *Cancer*. 1993;71(7):2222-6.
 배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구
915. Shaw M W, Ablin R, J, Rubenstein M. Characterization of mononuclear cells in peripheral blood and primary tumour infiltrates of patients with stage D prostate cancer. *Tumor Diagnostik und Therapie*. 1985;6(6):223-5.
 배제사유 : 동물실험 또는 전임상시험연구
916. Sheen Y Y, Kim M, J, Park S, A, Park S, Y, Nam J, S. Targeting the transforming growth factor-beta signaling in cancer therapy. *Biomolecules and Therapeutics*. 2013;21(5):323-31.
 배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
917. Sheikhi A SK, Salmani R, Yahaghi N, Sheikhi A, Siemens D, R. In vitro modulation of natural killer activity of human peripheral blood mononuclear cells against prostate tumor cell line. *Immunopharmacology & Immunotoxicology*. 2011;33(4):700-8.
 배제사유 : 동물실험 또는 전임상시험연구
918. Shen L CM, Miles K, M, Ellis L, Fenstermaker R, Pili R. Targeting myeloid derived suppressor cells as novel strategy to enhance immunotherapy in murine prostate cancer models. *Cancer Research. Conference: 103rd Annual Meeting of the American Association for Cancer Research, AACR*. 2012;72(8 SUPPL. 1).
 배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
919. Shen L MK, M, Ciesielski M, Ellis L, Fenstermaker R, Pili R. Tasquinimod targets immuno-suppressive myeloid cell populations and enhances immunotherapy in murine prostate cancer models. *Cancer Research. Conference: AACR Special Conference on Tumor Immunology: Multidisciplinary Science Driving Basic and Clinical Advances*. 2012;73(1 SUPPL. 1).

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

920. Shen Y C, Kochel C, Francica B, J, Alme A, Nirschl C, Nirschl T, et al. Combining androgen deprivation with immune checkpoint blockade delays the development of castration resistance in a murine model of prostate cancer. *Cancer Research*. Conference: 106th Annual Meeting of the American Association for Cancer Research, AACR. 2015;75(15 SUPPL. 1).

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

921. Shi C ZY, Su Y, Chung L, W, K, Cheng T. beta2-Microglobulin: emerging as a promising cancer therapeutic target. *Drug Discovery Today*. 2009;14(1-2):25-30.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

922. Shi J JD, Yang S, Zhang X, Wang J, Liu Y, Sun Y, et al. LPAR1, Correlated With Immune Infiltrates, Is a Potential Prognostic Biomarker in Prostate Cancer. *Frontiers in Oncology*. 2020;10:846.

배제사유 : 동물실험 또는 전임상시험연구

923. Shiao S L, Chu G, C, Y, Chung L, W, K. Regulation of prostate cancer progression by the tumor microenvironment. *Cancer Letters*. 2016;380(1):340-8.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

924. Shin W J, Zabel B, A, Pachynski R, K. Mechanisms and functions of chemerin in cancer: Potential roles in therapeutic intervention. *Frontiers in Immunology*. 2018;9 (NOV) (02772).

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

925. Shinohara T NN, Hanibuchi M, Nokihara H, Miki T, Hamada H, Sone S. Transduction of KAI1/CD82 cDNA promotes hematogenous spread of human lung-cancer cells in natural killer cell-depleted SCID mice. *International Journal of Cancer*. 2001;94(1):16-23.

배제사유 : 동물실험 또는 전임상시험연구

926. Siegers G M, Ribot E, J, Keating A, Foster P, J. Extensive expansion of primary human gamma delta T cells generates cytotoxic effector memory cells that can be labeled with Feraheme for cellular MRI. *Cancer Immunology, Immunotherapy*. 2013;62(3):571-83.

배제사유 : 동물실험 또는 전임상시험연구

927. Siemens D R, Hu N, Sheikhi A, K, Chung E, Frederiksen L, J, Pross H, et al. Hypoxia increases tumor cell shedding of MHC class I chain-related molecule: role of nitric oxide. *Cancer Research*. 2008;68(12):4746-53.

배제사유 : 동물실험 또는 전임상시험연구

928. Silva A MA, Krstevska K, Pejovski D, Hardy M, P, Owczarek C, Scotney P, et al. The combination of ISCOMATRIX adjuvant and TLR agonists induces regression of established solid tumors in vivo. *Journal of Immunology*. 2015;194(5):2199-207.

배제사유 : 동물실험 또는 전임상시험연구

929. Silvestri I CS, Giantulli S, Nazzari C, Collalti G, Sciarra A. A perspective of immunotherapy for prostate cancer. *Cancers*. 2016;8 (7) (64).

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

930. Simonson W T, N, Allison K, H. Tumour-infiltrating lymphocytes in cancer: Implications for the diagnostic pathologist. *Diagnostic Histopathology*. 2011;17(2):80-90.
 배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
931. Singh K RP. Anti-tumour activity and store operated calcium entry: New roles in immunology. *EMBO Molecular Medicine*. 2013;5(9):1297-9.
 배제사유 : NK 세포 활성화 측정 시 인터페론 감마를 평가대상 검사기술로 측정하지 않은 연구
932. Singh S K, Laske K, Gouttefangeas C, Britten C, M, Welters M, J, P. CIMT 2010: Report on the eighth annual meeting of the association for cancer immunotherapy, May 26-28, 2010, Mainz, Germany. *Cancer Immunology, Immunotherapy*. 2011;60(3):443-50.
 배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
933. Singh S V, Powolny A, A, Stan S, D, Xiao D, Arlotti J, A, Warin R, et al. Garlic constituent diallyl trisulfide prevents development of poorly differentiated prostate cancer and pulmonary metastasis multiplicity in TRAMP mice. *Cancer Research*. 2008;68(22):9503-11.
 배제사유 : 동물실험 또는 전임상시험연구
934. Singh S V, Warin R, Xiao D, Powolny A, A, Stan S, D, Arlotti J, A, et al. Sulforaphane inhibits prostate carcinogenesis and pulmonary metastasis in TRAMP mice in association with increased cytotoxicity of natural killer cells. *Cancer Research*. 2009;69(5):2117-25.
 배제사유 : 동물실험 또는 전임상시험연구
935. Sinkovics J G. Molecular biology of oncogenic inflammatory processes. I. Non-oncogenic and oncogenic pathogens, intrinsic inflammatory reactions without pathogens, and microRNA/DNA interactions (Review). *International Journal of Oncology*. 2012;40(2):305-49.
 배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
936. Sioud M WP, Olsen J, K, E, Mobergslien A. Generation of new peptide-Fc fusion proteins that mediate antibody-dependent cellular cytotoxicity against different types of cancer cells. *Molecular Therapy - Methods and Clinical Development*. 2015;2:15043.
 배제사유 : 동물실험 또는 전임상시험연구
937. Sitkovsky M V. Lessons from the A2A adenosine receptor antagonist- enabled tumor regression and survival in patients with treatment-refractory renal cell cancer. *Cancer Discovery*. 2020;10(1):16-9.
 배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구
938. Siu L L, Burris H, Le D, T, Hollebecque A, Steeghs N, Delord J, P, et al. Preliminary phase 1 profile of BMS- 986179, an anti-CD73 antibody, in combination with nivolumab in patients with advanced solid tumors. *Cancer Research. Conference*. 2018;78(13 Supplement 1).
 배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
939. Slaton J VM, Lu H, Wenner C. East meets west: The mushroom extract PSK enhances docetaxel therapy for castrate resistant prostate cancer. *Journal of Urology*. 2011;1):e295.
 배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

940. Slota M LJ, B, Dang Y, Disis M, L. ELISpot for measuring human immune responses to vaccines. *Expert Review of Vaccines*. 2011;10(3):299-306.
 배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
941. Smith R A, Dzugan S, A, Rafique S, Fumagalli L, Lissoni P. Peripheral blood natural killer cell increase as a predictor of survival in metastatic cancer patients treated by neuroimmunotherapy with subcutaneous low-dose interleukin-2 plus melatonin. *International Journal of Immunotherapy*. 1999;15(3-4):131-5.
 배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구
942. Smolarek D A, Sakellariou C, A, Elhage O, Ukimura O, Gill I, Dagleish A, G, et al. Cytotoxic IL-15 as a novel therapeutic for prostate cancer. *Cancer Research. Conference: 105th Annual Meeting of the American Association for Cancer Research, AACR*. 2014;74(19 SUPPL. 1).
 배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
943. Smolarek D SC, A, Dasgupta P, Smith R, A, G, Galustian C. Cytotopically modified antibodies to checkpoint proteins can actively reconstitute immune checkpoint blockade and inhibit tumor growth in a prostate cancer mouse model. *Cancer Research. Conference: 106th Annual Meeting of the American Association for Cancer Research, AACR*. 2015;75(15 SUPPL. 1).
 배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
944. Smyth M J, Kelly J, M, Baxter A, G, Korner H, Sedgwick J, D. An essential role for tumor necrosis factor in natural killer cell-mediated tumor rejection in the peritoneum. *Journal of Experimental Medicine*. 1998;188(9):1611-9.
 배제사유 : 동물실험 또는 전임상시험연구
945. Smyth M J, Taniguchi M, Street S, E. The anti-tumor activity of IL-12: mechanisms of innate immunity that are model and dose dependent. *Journal of Immunology*. 2000;165(5):2665-70.
 배제사유 : 동물실험 또는 전임상시험연구
946. Smyth M J, Thia K, Y, Cretney E, Kelly J, M, Snook M, B, Forbes C, A, et al. Perforin is a major contributor to NK cell control of tumor metastasis. *Journal of Immunology*. 1999;162(11):6658-62.
 배제사유 : 동물실험 또는 전임상시험연구
947. Sobol R E, Scanlon K, J. Improved cancer vaccines through gene transfer. *Cancer Gene Therapy*. 2005;12(6):515.
 배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
948. Soling A RN, G. Bioluminescence imaging in vivo - Application to cancer research. *Expert Opinion on Biological Therapy*. 2003;3(7):1163-72.
 배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
949. Sotosek S STV, Mrakovcic-Sutic I, Tomas M, I, Dominovic M, Tulic V, Sutic I, et al. Comparative study of frequency of different lymphocytes subpopulation in peripheral blood of patients with prostate cancer and benign prostatic hyperplasia. *Wiener*

Klinische Wochenschrift. 2011;123(23-24):718-25.

배제사유 : NK 세포 활성도를 다루지 않는 연구

950. Spear T T, Nagato K, Nishimura M, I. Strategies to genetically engineer T cells for cancer immunotherapy. *Cancer Immunology, Immunotherapy*. 2016;65(6):631-49.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

951. Spinu D MD, Surcel M, Huica R, Munteanu A, Pirvu I, Ciotaru D, et al. Immunological investigations in prostatic pathology--a prospective study. *Romanian Archives of Microbiology & Immunology*. 2014;73(1-2):51-5.

배제사유 : NK 세포 활성도를 다루지 않는 연구

952. Srinivasan V SD, W, Pandi-Perumal S, R, Trakht I, Cardinali D, P. Therapeutic actions of melatonin in cancer: Possible mechanisms. *Integrative Cancer Therapies*. 2008;7(3):189-203.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

953. Srivastava R M, Khar A. Dendritic cells and their receptors in antitumor immune response. *Current Molecular Medicine*. 2009;9(6):708-24.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

954. Stagg J BP, A, Divisekera U, Liu M, C, P, Moller A, Darcy P, K, Smyth M, J. CD73-Deficient mice are resistant to carcinogenesis. *Cancer Research*. 2012;72(9):2190-6.

배제사유 : 동물실험 또는 전임상시험연구

955. Stawarz B ZH, Szmigielski S, Rappaport E, Debicki P, Petrovich Z. Transrectal hyperthermia as palliative treatment for advanced adenocarcinoma of prostate and studies of cell-mediated immunity. *Urology*. 1993;41(6):548-53.

배제사유 : NK 세포 활성도를 다루지 않는 연구

956. Steel J C, Ramlogan C, A, Yu P, Waldmann T, A, Morris J, C. IL15-VAX: A prostate cancer cellular vaccine expressing IL-15 and IL-15alpha. *Molecular Therapy*. 2011;1):S32.

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

957. Stein M N, Chan N, Silk A, W, Malhotra J, Aisner J, Aiken R, et al. Anticancer and immunostimulatory activity of the imipridone ONC201, a selective DRD2 antagonist, in advanced cancer patients. *Journal of Clinical Oncology*. Conference. 2017;35(15 Supplement 1).

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

958. Stein M N, Malhotra J, Malhotra U, Silk A, W, Chan N, Rodriguez-Rodriguez L, et al. Safety and pharmacodynamics of the DRD2 antagonist ONC201 in advanced solid tumor patients with weekly oral administration. *Journal of Clinical Oncology*. Conference. 2018;36(15 Supplement 1).

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

959. Stein M N, Malhotra J, Tarapore R, S, Malhotra U, Silk A, W, Chan N, et al. Safety and enhanced immunostimulatory activity of the DRD2 antagonist ONC201 in advanced solid tumor patients with weekly oral administration. *Journal for ImmunoTherapy of Cancer*.

2019;7 (1) (136).

배제사유 : NK 세포 활성도를 다루지 않는 연구

960. Stevanovic S. Identification of tumour-associated T-cell epitopes for vaccine development. *Nature Reviews Cancer*. 2002;2(7):514-20.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

961. Stoeckle C GA, K. Immunotherapy: From basic research to clinical applications. *Cancer Immunology, Immunotherapy*. 2009;58(7):1129-36.

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

962. Stone L. Putting a SOCS in prostate cancer. *Nature Reviews Urology*. 2019;16(3):147.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

963. Street S E, Cretney E, Smyth M, J. Perforin and interferon-gamma activities independently control tumor initiation, growth, and metastasis. *Blood*. 2001;97(1):192-7.

배제사유 : 동물실험 또는 전임상시험연구

964. Stroncek D F, Marincola F, M. Dendritic cells: An immunotherapy coming of age. *Immunotherapy*. 2012;4(10):973-4.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

965. Strykowska-Gora A K-BB, Gora T, Krawczak K. Statins and cancers. *Wspolczesna Onkologia*. 2015;19(3):167-75.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

966. Suckow M A. Cancer vaccines: Harnessing the potential of anti-tumor immunity. *Veterinary Journal*. 2013;198(1):28-33.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

967. Sugimoto Y HM, Yoshikawa K, Sumitomo M, Ueda R, Niwa R, Suzawa T, et al. The therapeutic potential of a novel PSMA antibody and its IL-2 conjugate in prostate cancer. *Anticancer Research*. 2014;34(1):89-97.

배제사유 : 동물실험 또는 전임상시험연구

968. Sullivan R. Understanding the practice and politics of cancer immunotherapy. *Scip Clinical Research*. 2009;16(5):9-12.

배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구

969. Sun T PA, Ward S, Rubin J, B. An integrative view on sex differences in brain tumors. *Cellular and Molecular Life Sciences*. 2015;72(17):3323-42.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

970. Sun Y JY, Fu Q. Synergistic effect of IL-15 and IL-27 on the cytotoxicity of NK-92 cells. *European Journal of Immunology*. 2019;49 (Supplement 3):472.

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

971. Sun Y JY, Yu H, Wang Y, Fu Q. IL-27 promotes anti-tumor effect of NK92 cells by up-regulating expression of activated receptors and stats phosphorylation. [Chinese]. *Chinese Journal of Cancer Biotherapy*. 2019;26(5):500-5.

배제사유 : 한국어 또는 영어로 출판되지 않은 연구

972. Sun Y. Translational horizons in the tumor microenvironment: Harnessing breakthroughs and targeting cures. *Medicinal Research Reviews*. 2015;35(2):408-36.
배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
973. Sundin T PD, M, Hentosh P. Disruption of an hTERT-mTOR-RAPTOR protein complex by a phytochemical perillyl alcohol and rapamycin. *Molecular & Cellular Biochemistry*. 2013;375(1-2):97-104.
배제사유 : 동물실험 또는 전임상시험연구
974. Suresh K SE, Klotz L, Venkateswaran V, Gaudie J, Foley R. Induction of specific human cytotoxic T cells using dendritic cells transduced with an adenovector encoding rat epidermal growth factor receptor 2. *International Journal of Oncology*. 2011;39(4):907-13.
배제사유 : 동물실험 또는 전임상시험연구
975. Suzawa K SK, Huang P, Sakaguchi M, Watanabe M, Hashida S, Soh J, et al. Distant bystander effect of REIC/DKK-3 gene therapy through immune system stimulation in a murine model of thoracic malignancies. *Journal of Thoracic Oncology*. 2015;2):S599.
배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
976. Suzuki K NH, Matsui H, Hasumi M, Shibata Y, Ito K, Fukabori Y, et al. NK cell-mediated anti-tumor immune response to human prostate cancer cell, PC-3: immunogene therapy using a highly secretable form of interleukin-15 gene transfer. *Journal of Leukocyte Biology*. 2001;69(4):531-7.
배제사유 : 동물실험 또는 전임상시험연구
977. Swann J CN, Y, Hayakawa Y, Godfrey D, I, Smyth M, J. Regulation of antitumour immunity by CD1d-restricted NKT cells. *Immunology and Cell Biology*. 2004;82(3):323-31.
배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
978. Swanson G P, Jhavar S, G, Hammonds K. The effect of pelvic radiation alone on lymphocyte subgroups. *Clinical and Translational Radiation Oncology*. 2020;23:100-2.
배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구
979. Swart M VI, Beltman J, B. Combination approaches with immune-checkpoint blockade in cancer therapy. *Frontiers in Oncology*. 2016;6 (NOV) (233).
배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
980. Szmigielski S SJ, Sokolska G, Stawarz B, Zielinski H, Petrovich Z. Effects of local prostatic hyperthermia on human NK and T cell function. *International Journal of Hyperthermia*. 1991;7(6):869-80.
배제사유 : NK 세포 활성도를 다루지 않는 연구
981. Sznol M CL. Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer. *Clinical Cancer Research*. 2013;19(5):1021-34.
배제사유 : 동물실험 또는 전임상시험연구
982. Tabata K KS, Watanabe M, Edamura K, Satoh T, Yang G, Abdelfattah E, et al. Tumor

growth and metastasis suppression by Glipr1 gene-modified macrophages in a metastatic prostate cancer model. *Gene Therapy*. 2011;18(10):969-78.

배제사유 : 동물실험 또는 전임상시험연구

983. Tabata K WM, Naruishi K, Edamura K, Satoh T, Yang G, Abdel Fattah E, et al. Therapeutic effects of gelatin matrix-embedded IL-12 gene-modified macrophages in a mouse model of residual prostate cancer. *Prostate Cancer & Prostatic Diseases*. 2009;12(3):301-9.

배제사유 : 동물실험 또는 전임상시험연구

984. Taghizadeh H MM, Tomasich E, Udovica S, Merchant A, Krainer M. Immune checkpoint inhibitors in mCRPC - rationales, challenges and perspectives. *OncoImmunology*. 2019;8(11) (e1644109).

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

985. Tahir S M, Cheng O, Shaulov A, Koezuka Y, Bublely G, J, Wilson S, B, et al. Loss of IFN-gamma production by invariant NK T cells in advanced cancer. *Journal of Immunology*. 2001;167(7):4046-50.

배제사유 : NK 세포 활성도를 다루지 않는 연구

986. Takaki R HY, Nelson A, Sivakumar P, V, Hughes S, Smyth M, J, Lanier L, L. IL-21 enhances tumor rejection through a NKG2D-dependent mechanism. *Journal of Immunology*. 2005;175(4):2167-73.

배제사유 : 동물실험 또는 전임상시험연구

987. Tallerico R CL, Lanzardo S, Sottile R, Garofalo C, Wagner A, K, Johansson M, H, et al. NK cells control breast cancer and related cancer stem cell hematological spread. *OncoImmunology*. 2017;6(3) (e1284718).

배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구

988. Tang M GS, Zhang L, Liu B, Li J, Wang Z, Zhang W. Docetaxel suppresses immunotherapy efficacy of natural killer cells toward castration-resistant prostate cancer cells via altering androgen receptor-lectin-like transcript 1 signals. *Prostate*. 2020;80(10):742-52.

배제사유 : 동물실험 또는 전임상시험연구

989. Tarapore R S, Jhavar S, Stein M, Zloza A, Mueller S, Zhang J, et al. Combination of ONC201 with radiation exhibits synergistic efficacy in high grade gliomas and other advanced cancers. *Cancer Research*. Conference: American Association for Cancer Research Annual Meeting. 2019;79(13 Supplement).

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

990. Tarapore R S, Stein M, N, Zloza A, Rodriguez L, Newman J, Cheeson C, et al. Clinical immunostimulatory activity of imipridone ONC201, a selective DRD2 antagonist, in advanced solid tumor patients. *Cancer Research*. Conference. 2018;78(13 Supplement 1).

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

991. Tarle M KI, Kastelan M. Comparison between NK cell activity and prostate cancer stage and grade in untreated patients: correlation with tumor markers and hormonal serotest data. *Urological Research*. 1993;21(1):17-21.

배제사유 : NK 세포 활성도를 다루지 않는 연구

992. Tarle M KK, Kastelan M. Correlation of cell proliferation marker (TPS), natural killer (NK) activity and tumor load serotest (PSA) in untreated and treated prostatic tumors. *Anticancer Research*. 1993;13(1):215-8.

배제사유 : NK 세포 활성도를 다루지 않는 연구

993. Tarle M. Serial measurements of tissue polypeptide specific antigen (TPS), PSA, PAP and CEA serotest values in treated patients with primary and metastatic prostate cancer. *Anticancer Research*. 1993;13(3):769-77.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

994. Taverna G GG, Seveso M, Hurle R, Colombo P, Stifter S, Grizzi F. Mast cells as a potential prognostic marker in prostate cancer. *Disease Markers*. 2013;35(6):711-20.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

995. Tavri S JP, Meier R, Henning T, D, Muller T, Hostetter D, Knopp C, et al. Optical imaging of cellular immunotherapy against prostate cancer. *Molecular Imaging*. 2009;8(1):15-26.

배제사유 : 동물실험 또는 전임상시험연구

996. Tazume S PM. The relationship between natural killer cells and drugs that modify metastasis of PA-III cells. *Cancer Letters*. 1985;29(3):323-9.

배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구

997. Tekewe A. Vaccines and antibodies for cancer immunotherapy a review. *Pharmacophore*. 2012;3(1):1-17.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

998. Terada T. Mycosis fungoides in plaque stage with pronounced eosinophilic infiltration, folliculotropism, and concomitant invasive squamous cell carcinoma. *International Journal of Clinical & Experimental Pathology*. 2013;6(4):749-56.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

999. Terunuma H DX, Nishino N, Watanabe K. NK cell-based autologous immune enhancement therapy (AIET) for cancer. *Journal of Stem Cells and Regenerative Medicine*. 2013;9(1):9-13.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

1000. Tesniere A KG, Tursz T, Zitvogel L. Personalized immunotherapy: A siren myth? *Personalized Medicine*. 2009;6(5):469-73.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

1001. Thakur A LL, G. "nextGen" Biologics: Bispecific Antibodies and Emerging Clinical Results. *Expert Opinion on Biological Therapy*. 2016;16(5):675-88.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

1002. Thurnher M NO, Gruenbacher G. Novel aspects of mevalonate pathway inhibitors as antitumor agents. *Clinical Cancer Research*. 2012;18(13):3524-31.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

1003. Thyphronitis G KM. Boosting the immune response: An alternative combination therapy for cancer patients. *Anticancer Research*. 2004;24(4):2443-53.
 배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
1004. Tjota A ZY, Q, Piedmonte M, R, Lee C, L. Adoptive immunotherapy using lymphokine-activated killer cells and recombinant interleukin-2 in preventing and treating spontaneous pulmonary metastases of syngeneic Dunning rat prostate tumor. *Journal of Urology*. 1991;146(1):177-83.
 배제사유 : 동물실험 또는 전임상시험연구
1005. Tokmadzic V S, Tomas M, I, Sotosek S, Laskarin G, Dominovic M, Tulic V, et al. Different perforin expression in peripheral blood and prostate tissue in patients with benign prostatic hyperplasia and prostate cancer. *Scandinavian Journal of Immunology*. 2011;74(4):368-76.
 배제사유 : NK 세포 활성도를 다루지 않는 연구
1006. Topalian S L, Weiner G, J, Pardoll D, M. Cancer immunotherapy comes of age. *Journal of Clinical Oncology*. 2011;29(36):4828-36.
 배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
1007. Toriello H V. Policy statement on folic acid and neural tube defects. *Genetics in Medicine*. 2011;13(6):593-6.
 배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구
1008. Torres L OLJ, T, Thuler L, C, S, Mello M, J, G, Jatay K. Loss of the CD28 costimulatory molecules on the immune subsets of TCD4+ cells in prostate cancer elderly patients. *Journal of Clinical Oncology*. Conference. 2016;34(Supplement 15).
 배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
1009. Toso A RA, DiMitri D, Guccini I, Proietti M, Sarti M, Pinton S, et al. Enhancing chemotherapy efficacy in pten-deficient prostate tumors by activating the senescence-associated antitumor immunity. *Cell Reports*. 2014;9(1):75-89.
 배제사유 : 동물실험 또는 전임상시험연구
1010. Tourkova I L, Yamabe K, Chatta G, Shurin G, V, Shurin M, R. NK cells mediate Flt3 ligand-induced protection of dendritic cell precursors in vivo from the inhibition by prostate carcinoma in the murine bone marrow metastasis model. *Journal of Immunotherapy*. 2003;26(6):468-72.
 배제사유 : 동물실험 또는 전임상시험연구
1011. Tsang K FM, Hodge J, W, Fujii R, Fernando I, Jochems C, Heery C, et al. haNK, a cytotoxic human high affinity natural killer cell line, exerts enhanced ADCC mediated by avelumab (an anti-PD-L1 antibody) against multiple human tumor cell lines. *Journal for Immunotherapy of Cancer*. Conference: 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer, SITC. 2016;4(Supplement 1).
 배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
1012. Tschuch C KK, Lenhard D, Rentsch C, Wetterauer C, Bubendorf L, Vlajndic T, et al. Influence of different components of the tumor microenvironment on human

patient-derived lymphoma cell engraftment in immunodeficient mice. *Blood*. 2015;126(23):1459.

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

1013. Tse B W, Russell P, J, Lochner M, Forster I, Power C, A. IL-18 inhibits growth of murine orthotopic prostate carcinomas via both adaptive and innate immune mechanisms. *PLoS ONE [Electronic Resource]*. 2011;6(9):e24241.

배제사유 : 동물실험 또는 전임상시험연구

1014. Tsimberidou A M, Fountzilias E, Nikanjam M, Kurzrock R. Review of precision cancer medicine: Evolution of the treatment paradigm. *Cancer Treatment Reviews*. 2020;86(102019).

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

1015. Ueno M MK, Muraki J, Baba S, Murai M, Tazaki H, Yamamoto Y. Effects of diethylstilbestrol diphosphatase (DES-P) and alpha-interferon on natural killer cell activity in vitro. [Japanese]. *Japanese Journal of Urology*. 1987;78(10):1707-16.

배제사유 : 한국어 또는 영어로 출판되지 않은 연구

1016. Ullrich E BJ, Aigner M, Voelkl S, Kroeger I, Hoffmann P, Kreutz M, et al. Advances in cellular therapy: 6th International Symposium on the clinical use of cellular products, March 24 and 25, 2011, Erlangen, Germany. *Cancer Immunology, Immunotherapy*. 2012;61(3):433-43.

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

1017. Ullrich E BJ, Aigner M, Volkl S, Dudziak D, Spriewald B, Schuler G, et al. Advances in cellular therapy:5th International Symposium on the clinical use of cellular products, 19 and 20 March 2009, Nurnberg, Germany. *Cancer Immunology, Immunotherapy*. 2010;59(11):1745-56.

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

1018. Umansky V GB, A. ESCII-PIVAC meeting "Recent advances in cancer immunotherapy with an emphasis on cancer vaccines" held in Athens, 9-11 October 2008. *Cancer Immunology, Immunotherapy*. 2010;59(4):635-40.

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

1019. Umin J. Phase 1 dose-escalation, safety / tolerability and preliminary efficacy study of intratumoral and subcutaneous administration of GEN0101 in patients with recurrence of castration resistant prostate cancer. <http://www.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000017092>. 2015.

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

1020. Uyangaa E, Choi JY, Ryu HW, Oh SR, Eo SK. Anti-herpes Activity of Vinegar-processed *Daphne genkwa* Flos Via Enhancement of Natural Killer Cell Activity. *Immune Netw*. 2015;15(2):91-9.

배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구

1021. Vacchelli E AF, Obrist F, Eggermont A, Galon J, Cremer I, Zitvogel L, et al. Trial watch: Immunostimulatory cytokines in cancer therapy. *OncoImmunology*. 2014;3 (6)(e29030).

배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구

1022. Vaishampayan U VV, McDermott D, Fishman M, Hoimes C, Cho D, Sun L, et al. Safety, pharmacokinetics and pharmacodynamic effects of ALKS 4230 in patients with advanced solid tumors from the ongoing dose escalation portion of a first in human (FIH) study. *Journal for ImmunoTherapy of Cancer*. Conference: 33rd Annual Meeting and Pre Conference Programs of the Society for Immunotherapy of Cancer, SITC. 2018;6(Supplement 1).

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

1023. Valkenburg K C, Williams B, O. Mouse models of prostate cancer. *Prostate Cancer*. 2011;(895238).

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

1024. Vallera D A, Zhang B, Gleason M, K, Oh S, Weiner L, M, Kaufman D, S, et al. Heterodimeric bispecific single-chain variable-fragment antibodies against EpCAM and CD16 induce effective antibody-dependent cellular cytotoxicity against human carcinoma cells. *Cancer Biotherapy & Radiopharmaceuticals*. 2013;28(4):274-82.

배제사유 : NK 세포 활성도를 다루지 않는 연구

1025. van Egmond M. Neutrophils in antibody-based immunotherapy of cancer. *Expert Opinion on Biological Therapy*. 2008;8(1):83-94.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

1026. Vanmeerbeek I SJ, De Ruyscher D, Tejpar S, Vandenberghe P, Fucikova J, Spisek R, et al. Trial watch: chemotherapy-induced immunogenic cell death in immuno-oncology. *OncoImmunology*. 2020;9 (1) (1703449).

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

1027. Veldwijk M BA, Helmbold I, Gurth N, Kirchner A, Behrens S, Seibold P, et al. Association of T lymphocyte apoptosis after in vitro irradiation with normal tissue late toxicity after radiation therapy in 252 breast cancer patients with 10-year clinical follow-up. *International Journal of Radiation Oncology*. 2016;96 (2 Supplement 1):S64-S5.

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

1028. Vendramini-Costa D B, Carvalho J, E. Molecular link mechanisms between inflammation and cancer. *Current Pharmaceutical Design*. 2012;18(26):3831-52.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

1029. Vetvicka V VJ. beta 1, 3-glucan in cancer treatment. *American Journal of Immunology*. 2012;8(2):38-43.

배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구

1030. Veuillen C GG, Marcy M, Walz J, Bladou F, Salem N, Brunelle S, et al. Alterations of natural killer cells in metastatic prostate cancer. *Journal of Clinical Oncology*. 2009;1:e16131.

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

1031. Vickram A S, Samad H, A, Latheef S, K, Chakraborty S, Dhama K, Sridharan T, B, et

al. Human prostasomes an extracellular vesicle - Biomarkers for male infertility and prostate cancer: The journey from identification to current knowledge. *International Journal of Biological Macromolecules*. 2020;146:946-58.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

1032. Vidal-Vanaclocha F ML, Telleria N, Salado C, Valcarcel M, Gallot N, Carrascal T, et al. Clinical and experimental approaches to the pathophysiology of interleukin-18 in cancer progression. *Cancer and Metastasis Reviews*. 2006;25(3):417-34.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

1033. Vilhelmsson-Timmermand O SE, Thorek D, L, Evans-Axelsson S, Bjartell A, Lilja H, Larson S, M, et al. Radiolabeled antibodies in prostate cancer: a case study showing the effect of host immunity on antibody bio-distribution. *Nuclear Medicine & Biology*. 2015;42(4):375-80.

배제사유 : 동물실험 또는 전임상시험연구

1034. Vinay D S, Ryan E, P, Pawelec G, Talib W, H, Stagg J, Elkord E, et al. Immune evasion in cancer: Mechanistic basis and therapeutic strategies. *Seminars in Cancer Biology*. 2015;35(Supplement):S185-S98.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

1035. Visser O vLF, E. Cancer risk in first generation migrants in North-Holland/Flevoland, The Netherlands, 1995-2004. *European Journal of Cancer*. 2007;43(5):901-8.

배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구

1036. Vivier E US, Blaise D, Chabannon C, Brossay L. Targeting natural killer cells and natural killer T cells in cancer. *Nature Reviews Immunology*. 2012;12(4):239-52.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

1037. Vlaeminck-Guillem V. Extracellular vesicles in prostate cancer carcinogenesis, diagnosis, and management. *Frontiers in Oncology*. 2018;8 (JUN) (222).

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

1038. Vlasveld L T, Hekman A, Vyth-Dreese F, A, Rankin E, M, Scharenberg J, G, Voordouw A, C, et al. A phase I study of prolonged continuous infusion of low dose recombinant interleukin-2 in melanoma and renal cell cancer. Part II: immunological aspects. *British journal of cancer*. 1993;68(3):559-67.

배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구

1039. Voswinkel J FS, Simon J, M, Benderitter M, Gorin N, C, Mohty M, Fouillard L, et al. Use of mesenchymal stem cells (MSC) in chronic inflammatory fistulizing and fibrotic diseases: A comprehensive review. *Clinical Reviews in Allergy and Immunology*. 2013;45(2):180-92.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

1040. Voswinkel J GN, Simon J, Lataillade J, J, Benderitter M, Gourmelon P, Fouillard L, et al. Mesenchymal stromal cells for irradiation-induced gastro-intestinal lesions: First experiences in four over-irradiated patients. *Bone Marrow Transplantation*. 2012;1):S54-S5.

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

1041. Vranova J VS, Richter J, Starec M, Fiserova A, Rosina J. The evolution of rectal and urinary toxicity and immune response in prostate cancer patients treated with two three-dimensional conformal radiotherapy techniques. *Radiation Oncology*. 2011;6:87.
 배제사유 : NK 세포 활성도를 다루지 않는 연구
1042. Vucenik I SJ. Cancer preventive and therapeutic properties of IP6: Efficacy and mechanisms. *Periodicum Biologorum*. 2010;112(4):451-8.
 배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구
1043. Vukanovic J IJ, T. Linomide inhibits angiogenesis, growth, metastasis, and macrophage infiltration within rat prostatic cancers. *Cancer Research*. 1995;55(7):1499-504.
 배제사유 : 동물실험 또는 전임상시험연구
1044. Vyas M KU, Hallek M, Strandmann E, P, V. Natural ligands and antibody-based fusion proteins: Harnessing the immune system against cancer. *Trends in Molecular Medicine*. 2014;20(2):72-82.
 배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
1045. Wade A C, Schmidt M, A, Pollard M. The relationship of natural killer cells to metastasis of a transplantable prostate adenocarcinoma. *Prostate*. 1985;7(1):53-61.
 배제사유 : 동물실험 또는 전임상시험연구
1046. Wagle M YK, Kadel E, E, Holcomb T, Srinivasan S, Castillo J, Halligan D, et al. Association of tumor fusion burden with immune presence and androgen sensitivity in prostate cancer. *Cancer Research*. Conference: American Association for Cancer Research Annual Meeting. 2019;79(13 Supplement).
 배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
1047. Wahab Z A, Wright G, L, Jr. Monoclonal antibody (anti-Leu 7) directed against natural killer cells reacts with normal, benign and malignant prostate tissues. *International Journal of Cancer*. 1985;36(6):677-83.
 배제사유 : 동물실험 또는 전임상시험연구
1048. Wahid B AA, Rafique S, Waqar M, Wasim M, Wahid K, Idrees M. An overview of cancer immunotherapeutic strategies. *Immunotherapy*. 2018;10(11):999-1010.
 배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
1049. Wajchman H J, Pierce C, W, Varma V, A, Issa M, M, Petros J, Dombrowski K, E. Ex vivo expansion of CD8+CD56+ and CD8+CD56- natural killer T cells specific for MUC1 mucin. *Cancer Research*. 2004;64(3):1171-80.
 배제사유 : 동물실험 또는 전임상시험연구
1050. Wald N CJ, Mercier M, Nyawouame F, Brouwer M, Houthuys E, Driessens G, et al. Phenotyping of TIGIT pathway members may be used for cancer selection in the clinical application of anti-TIGIT antibody EOS884448. *Journal for ImmunoTherapy of Cancer*. Conference: 34th Annual Meeting and Pre Conference Programs of the Society for Immunotherapy of Cancer Part. 2019;7(Supplement 1).
 배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

1051. Wald N MM, Cuende J, Nyawouame F, Prasad S, Brouwer M, Houthuys E, et al. TIGIT pathway phenotyping sheds light on promising strategies to restore anti-tumor immunity. *Cancer Research. Conference: American Association for Cancer Research Annual Meeting*. 2019;79(13 Supplement).
 배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
1052. Wang H YD, Xu W, Wang Y, Ruan Z, Zhao T, Han J, et al. Tumor-derived soluble MICs impair CD3(+)/CD56(+) NKT-like cell cytotoxicity in cancer patients. *Immunology Letters*. 2008;120(1-2):65-71.
 배제사유 : 동물실험 또는 전임상시험연구
1053. Wang H YG, Timme T, L, Fujita T, Naruishi K, Frolov A, Brenner M, K, et al. IL-12 gene-modified bone marrow cell therapy suppresses the development of experimental metastatic prostate cancer. *Cancer Gene Therapy*. 2007;14(10):819-27.
 배제사유 : 동물실험 또는 전임상시험연구
1054. Wang J MT, R, Britton H, C, Schwarz J, K, Loberiza F, R, Meza J, L, Talmadge J, E. Lenalidomide and cyclophosphamide immunoregulation in patients with metastatic, castration-resistant prostate cancer. *Clinical and Experimental Metastasis*. 2015;32(2):111-24.
 배제사유 : NK 세포 활성도를 다루지 않는 연구
1055. Wang T GY, Xiao M, Lopez-Coral A, Li L, Roesch A, Huang C, et al. SECTM1 produced by tumor cells attracts human monocytes via CD7-mediated activation of the PI3K pathway. *Journal of Investigative Dermatology*. 2014;134(4):1108-18.
 배제사유 : 동물실험 또는 전임상시험연구
1056. Wang W XJ, Shen S, Wang S, Chen M, Hu Y. Emerging effect of anesthesia on post-operative tumor recurrence and metastasis. *Journal of International Medical Research*. 2019;47(8):3550-8.
 배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
1057. Wang X Y, Yu X. Dual action of the cytosolic viral sensor MDA-5 in tumor killing and immune modulation triggers type I interferon-dependent antitumor immunity. *European Journal of Immunology*. 2016;46 (Supplement 1):429.
 배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
1058. Wang Z HH. Platelet factor-4 (CXCL4/PF-4): An angiostatic chemokine for cancer therapy. *Cancer Letters*. 2013;331(2):147-53.
 배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
1059. Wang Z WY, Peng M, Yi L. UBASH3B Is a Novel Prognostic Biomarker and Correlated With Immune Infiltrates in Prostate Cancer. *Frontiers in Oncology*. 2019;9:1517.
 배제사유 : 동물실험 또는 전임상시험연구
1060. Wangerin H KG, Schlomm T, Stephan C, Gunia S, Zimpfer A, Weichert W, et al. CD57 expression in incidental, clinically manifest, and metastatic carcinoma of the prostate. *BioMed Research International*. 2014;2014:356427.
 배제사유 : 동물실험 또는 전임상시험연구

1061. Wani A L, Parveen N, Ansari M, O, Ahmad M, F, Jameel S, Shadab G, G, H, A. Zinc: An element of extensive medical importance. *Current Medicine Research and Practice*. 2017;7(3):90-8.
 배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
1062. Ware W R. Raising concerns about unmetabolized folic acid. *Journal of Orthomolecular Medicine*. 2008;23(1):43-51.
 배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구
1063. Warren H S. Cd57. *Journal of Biological Regulators and Homeostatic Agents*. 2000;14(4):322-3.
 배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구
1064. Watt J KH, M. The desmoplastic stroma of pancreatic cancer is a barrier to immune cell infiltration. *OncoImmunology*. 2013;2 (12) (e26788).
 배제사유 : 동물실험 또는 전임상시험연구
1065. Wei X X, Chan S, Lewis J, Kwek S, Dao V, Fong L. Recruitment of effector T cells into the tumor rim and center with neoadjuvant systemic GM-CSF in patients with localized prostate cancer. *Cancer Research. Conference: 106th Annual Meeting of the American Association for Cancer Research, AACR*. 2015;75(15 SUPPL. 1).
 배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
1066. Weidle U H, Rohwedder I, Birzele F, Weiss E, H, Schiller C. LST1: A multifunctional gene encoded in the MHC class III region. *Immunobiology*. 2018;223(11):699-708.
 배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
1067. Weintraub K. Drug development: Releasing the brakes. *Nature*. 2013;504(7480):S6-S8.
 배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
1068. Wels W BM, Muller T, Dalken B, Giesubel U, Tonn T, Uherek C. Recombinant immunotoxins and retargeted killer cells: Employing engineered antibody fragments for tumor-specific targeting of cytotoxic effectors. *Cancer Immunology, Immunotherapy*. 2004;53(3):217-26.
 배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
1069. Welters M J, P, Piersma S, J, van der Burg S, H. T-regulatory cells in tumour-specific vaccination strategies. *Expert Opinion on Biological Therapy*. 2008;8(9):1365-79.
 배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
1070. Weng H MK. Differential responses to mutagens among human lymphocyte subpopulations. *Mutation Research - Genetic Toxicology and Environmental Mutagenesis*. 2009;672(1):1-9.
 배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
1071. Wenner C A, Martzen M, R, Lu H, Verneris M, R, Wang H, Slaton J, W. Polysaccharide-K augments docetaxel-induced tumor suppression and antitumor immune response in an immunocompetent murine model of human prostate cancer. *International Journal of Oncology*. 2012;40(4):905-13.

배제사유 : 동물실험 또는 전임상시험연구

1072. Whyard T C, Ablin R, J. Immunoregulatory prostatic macromolecules: effect on single-cell cytotoxicity. *Medical Science Research*. 1990;18(8):291-2.

배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구

1073. Widen K MF, Choudhury A, Mellstedt H. Overcoming immunosuppressive mechanisms. *Annals of Oncology*. 2008;19(SUPPL. 7):vii241-vii7.

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

1074. Willer A. Reduction of the individual cancer risk by physical exercise. *Onkologie*. 2003;26(3):283-9.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

1075. Williams B J, Bhatia S, Adams L, K, Boling S, Carroll J, L, Li X, L, et al. Dendritic cell based PSMA immunotherapy for prostate cancer using a CD40-targeted adenovirus vector. *PLoS ONE [Electronic Resource]*. 2012;7(10):e46981.

배제사유 : 동물실험 또는 전임상시험연구

1076. Williams S V, Wildt S, J, Brooks A, I, Cooper D, M. The SHrNTM scid hairless NOD mouse model: Development and characterization. *Cancer Research*. Conference: 101st Annual Meeting of the American Association for Cancer Research, AACR. 2010;70(8 SUPPL. 1).

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

1077. Wirth M S-DB, J, Ackermann R. Functional properties of natural killer cells in carcinoma of the prostate. *Journal of Urology*. 1985;133(6):973-8.

배제사유 : 동물실험 또는 전임상시험연구

1078. Wise D AJ, Chen Y, Nelson P, Schultz N, Sawyers C, L, Scher H, I. The immunomodulatory protein Dickkopf-1 (DKK1) defines a non-neuroendocrine subtype of metastatic castration-resistant prostate cancer (mCRPC) with low AR and low PSA expression. *Journal of Clinical Oncology*. Conference. 2017;35(15 Supplement 1).

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

1079. Wong Y N, S, Joshi K, Pule M, Peggs K, S, Swanton C, Quezada S, A, et al. Evolving adoptive cellular therapies in urological malignancies. *The Lancet Oncology*. 2017;18(6):e341-e53.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

1080. Wu J D, Atteridge C, L, Wang X, Seya T, Plymate S, R. Obstructing shedding of the immunostimulatory MHC class i chain - Related gene B prevents tumor formation. *Clinical Cancer Research*. 2009;15(2):632-40.

배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구

1081. Wu J D, Basher F, Rubinstein M. Antibody targeting soluble NKG2D ligand sMIC induces regression of primary tumors and eliminates metastasis in multiple pre-clinical cancer models. *Cancer Research*. Conference: 106th Annual Meeting of the American Association for Cancer Research, AACR. 2015;75(15 SUPPL. 1).

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

1082. Wu J D, Higgins L, M, Steinle A, Cosman D, Haugk K, Plymate S, R. Prevalent expression of the immunostimulatory MHC class I chain-related molecule is counteracted by shedding in prostate cancer. *Journal of Clinical Investigation*. 2004;114(4):560-8.
 배제사유 : 동물실험 또는 전임상시험연구
1083. Wu J D, Higgins L, M, Steinle A. Counteracting MIC/NKG2D immunity by shedding MIC in prostate cancer. *Enhancer - Biotherapy of Cancer*. 2005;3(2):18-20.
 배제사유 : 동물실험 또는 전임상시험연구
1084. Wu J D, Lin D, W, Page S, T, Lundgren A, D, True L, D, Plymate S, R. Oxidative DNA damage in the prostate may predispose men to a higher risk of prostate cancer. *Translational Oncology*. 2009;2(1):39-45.
 배제사유 : NK 세포 활성도를 다루지 않는 연구
1085. Wu J D, Liu G, Wang X, Plymate S, Greenberg N, M. Impact of MIC expression and shedding on prostate tumor development and progression in double transgenic TRAMP-MIC mouse models. *Cancer Research. Conference: 101st Annual Meeting of the American Association for Cancer Research, AACR*. 2010;70(8 SUPPL. 1).
 배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
1086. Wu J D, Zhang J, Larrocha P, Dhar P. Antibody targeting soluble NKG2D ligand sMIC sensitizes metastatic prostate tumor and other MIC tumors to PD1/PD-L1 blockade therapy in pre-clinical models. *Cancer Research. Conference: American Association for Cancer Research Annual Meeting*. 2019;79(13 Supplement).
 배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
1087. Wu J. Antibody targeting soluble NKG2D ligand sMIC refuels and invigorates the endogenous immune system to fight cancer. *OncoImmunology*. 2016;5(3).
 배제사유 : 동물실험 또는 전임상시험연구
1088. Wu L SX, Bao J, Guo X, Kote-Jarai Z, Haiman C, A, Eeles R, A, et al. Analysis of over 140,000 European descendants identifies genetically predicted blood protein biomarkers associated with prostate cancer risk. *Cancer Research*. 2019;79(18):4592-8.
 배제사유 : NK 세포 활성도를 다루지 않는 연구
1089. Wu R Y, Wang G, M. Application of high intensity focused ultrasound in treating prostate cancer. [Chinese]. *Fudan University Journal of Medical Sciences*. 2002;29(2):150-3.
 배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
1090. Wu S Y, Guo P, Peng T, Xu J, Hou Q, Q, Sun X, et al. HSF1: A potential target for therapeutic intervention in cancer. *International Journal of Clinical and Experimental Medicine*. 2017;10(3):5637-48.
 배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
1091. Wu T G, Perdigo J, R, Umhoefer T, K, Cao J, Ansari D, A, Albrecht T, B, et al. Heterogeneous interleukin-15 inducibilities in murine B16 melanoma and RM-1 prostate carcinoma by interferon-alpha treatment. *Journal of Interferon & Cytokine Research*.

2009;29(11):719-28.

배제사유 : 동물실험 또는 전임상시험연구

1092. Wu Y G, Ma Q, L, Liu G, F. [Influence of 89Sr on the cell immune function in patients with multiple bone metastases]. Bulletin of Hunan Medical University. 2002;27(3):277-8.

배제사유 : 한국어 또는 영어로 출판되지 않은 연구

1093. Wu Z XY. IL-15R alpha-IgG1-Fc enhances IL-2 and IL-15 anti-tumor action through NK and CD8+ T cells proliferation and activation. Journal Of Molecular Cell Biology. 2010;2(4):217-22.

배제사유 : 동물실험 또는 전임상시험연구

1094. Wurfel F M, Winterhalter C, Trenkwalder P, Wirtz R, M, Wurfel W. European patent in immunoncology: From immunological principles of implantation to cancer treatment. International Journal of Molecular Sciences. 2019;20 (8) (1830).

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

1095. Xia H LX, Yin W. Inhibition of prostate cancer growth by immunization with a GM-CSF-modified mouse prostate cancer RM-1 cell vaccine in a novel murine model. Oncology Letters. 2018;15(1):538-44.

배제사유 : 동물실험 또는 전임상시험연구

1096. Xu D LY, Gao Y, Cui X, Xing J, Yin L, Yao Y, et al. Induction of protective antitumor activity of tumor lysate-pulsed dendritic cells vaccine in RM-1 prostate cancer mode. Journal of Medical Colleges of PLA. 2009;24(1):18-24.

배제사유 : 동물실험 또는 전임상시험연구

1097. Xu L CX, Shen M, Yang D, R, Fang L, Weng G, Tsai Y, et al. Inhibition of IL-6-JAK/Stat3 signaling in castration-resistant prostate cancer cells enhances the NK cell-mediated cytotoxicity via alteration of PD-L1/NKG2D ligand levels. Molecular Oncology. 2018;12(3):269-86.

배제사유 : 동물실험 또는 전임상시험연구

1098. Xu L J, Ma Q, Zhu J, Li J, Xue B, X, Gao J, et al. Combined inhibition of JAK1,2/Stat3-PD-L1 signaling pathway suppresses the immune escape of castration-resistant prostate cancer to NK cells in hypoxia. Molecular Medicine Reports. 2018;17(6):8111-20.

배제사유 : 동물실험 또는 전임상시험연구

1099. Xu L SM, Chen X, Yang D, R, Tsai Y, Keng P, C, Lee S, O, et al. Corrigendum to "In vitro-induced M2 type macrophages induces the resistance of prostate cancer cells to cytotoxic action of NK cells"[Exp Cell Res 364 (2018) 113-123]. Experimental Cell Research. 2020;391(1):112006.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

1100. Xu L SM, Chen X, Yang D, R, Tsai Y, Keng P, C, Lee S, O, et al. In vitro-induced M2 type macrophages induces the resistance of prostate cancer cells to cytotoxic action of NK cells. Experimental Cell Research. 2018;364(1):113-23.

배제사유 : 동물실험 또는 전임상시험연구

1101. Xu L SM, Chen X, Zhu R, Yang D, R, Tsai Y, Keng P, C, et al. Adipocytes affect castration-resistant prostate cancer cells to develop the resistance to cytotoxic action of NK cells with alterations of PD-L1/NKG2D ligand levels in tumor cells. *Prostate*. 2018;78(5):353-64.
 배제사유 : 동물실험 또는 전임상시험연구
1102. Xu L SM, Chen X, Zhu R, Yang D, R, Tsai Y, Keng P, et al. Adipocytes affect castration-resistant prostate cancer cells in resistance to cytotoxic action of NK cells through alterations of pd-l1/nkg2d ligand levels. *Cancer Research. Conference*. 2018;78(13 Supplement 1).
 배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
1103. Xu X LJ, Zou J, Feng X, Zhang C, Zheng R, Duanmu W, et al. Association of Germline Variants in Natural Killer Cells with Tumor Immune Microenvironment Subtypes, Tumor-Infiltrating Lymphocytes, Immunotherapy Response, Clinical Outcomes, and Cancer Risk. *JAMA Network Open*. 2019;2 (9) (e199292).
 배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
1104. Yager N. American Association for Cancer Research - 97th Annual Meeting. Drug research developments - Part 2. 1-5 April 2006, Washington, DC, USA. *IDrugs*. 2006;9(5):341-2.
 배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
1105. Yagi H S-GA, Parekkadan B, Kitagawa Y, Tompkins R, G, Kobayashi N, Yarmush M, L. Mesenchymal stem cells: Mechanisms of immunomodulation and homing. *Cell Transplantation*. 2010;19(6-7):667-79.
 배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
1106. Yakkala C CC, L, L, Kandalaf L, Denys A, Duran R. Cryoablation and immunotherapy: An enthralling synergy to confront the tumors. *Frontiers in Immunology*. 2019;10 (SEP) (2283).
 배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
1107. Yaktapour N SM, Braun A, Friebe E, Sonnemann J, Beck J, F, Broker B, M. Histone deacetylase inhibitors but not proteasome inhibitors sensitize tumor cells for the cytolytic immune effector functions. *European Journal of Immunology*. 2009;1):S527.
 배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
1108. Yamauchi T KT. Prevention of hormonally refractory relapse by a combination with immunochemotherapy on Stage D2 prostate cancer patients: evaluation of immunologic anti-tumor effectors on the basis of peripheral blood lymphocyte subsets. [Japanese]. *Biotherapy*. 1995;9(3):309-10.
 배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
1109. Yamazaki H YY, Inoue T, Tanaka E, Nishikubo M, Sato T, Ishida T, et al. Changes in natural killer cell activity by external radiotherapy and/or brachytherapy. *Oncology Reports*. 2002;9(2):359-63.
 배제사유 : NK 세포 활성도를 다루지 않는 연구

1110. Yan J X, Wang K, R, Chen R, Song J, J, Zhang B, Z, Dang W, et al. Membrane active antitumor activity of NK-18, a mammalian NK-lysin-derived cationic antimicrobial peptide. *Biochimie*. 2012;94(1):184-91.
 배제사유 : 동물실험 또는 전임상시험연구
1111. Yan L SL, S, Zhang L, Xu Y. Role of OGR1 in myeloid-derived cells in prostate cancer. *Oncogene*. 2014;33(2):157-64.
 배제사유 : 동물실험 또는 전임상시험연구
1112. Yang F JH, Wang J, Sun Q, Yan C, Wei F, Ren X. Adoptive cellular therapy (ACT) for cancer treatment. *Advances in Experimental Medicine and Biology*. 2016;909:169-239.
 배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구
1113. Yang L YH, Dong S, Zhong Y, Hu S. Recognizing and managing on toxicities in cancer immunotherapy. *Tumor Biology*. 2017;39(3).
 배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
1114. Yang N XH, Wang W, Li S, Yan H, Wang Y. Effects of doctors' empathy abilities on the cellular immunity of patients with advanced prostate cancer treated by orchiectomy: the mediating role of patients' stigma, self-efficacy, and anxiety. *Patient preference & adherence*. 2018;12:1305-14.
 배제사유 : NK 세포 활성도를 다루지 않는 연구
1115. Yang X GY, Guo Z, Si T, Xing W, Yu W, Wang Y. Cryoablation inhibition of distant untreated tumors (abscopal effect) is immune mediated. *Oncotarget*. 2019;10(41):4180-91.
 배제사유 : 동물실험 또는 전임상시험연구
1116. Yang Z R, Zhao N, Meng J, Shi Z, L, Li B, X, Wu X, W, et al. Peripheral lymphocyte subset variation predicts prostate cancer carbon ion radiotherapy outcomes. *Oncotarget*. 2016;7(18):26422-35.
 배제사유 : NK 세포 활성도를 다루지 않는 연구
1117. Yao H GJ, Li L, Wu X, Yu J. Application of three dimensional conformal radiation therapy combined with high-intensity focused ultrasound for prostate cancer. *Chinese-German Journal of Clinical Oncology*. 2012;11(3):164-7.
 배제사유 : NK 세포 활성도를 다루지 않는 연구
1118. Yermal S J, Witek-Janusek L, Peterson J, Mathews H, L. Perioperative pain, psychological distress, and immune function in men undergoing prostatectomy for cancer of the prostate. *Biological Research for Nursing*. 2010;11(4):351-62.
 배제사유 : 동물실험 또는 전임상시험연구
1119. Yin Y HX, Barbero G, Ye D, Thorpe P, E. Cure of castration-resistant prostate cancer in TRAMP mice by reactivating tumor immunity with a phosphatidylserine-targeting antibody. *Cancer Research*. Conference: 103rd Annual Meeting of the American Association for Cancer Research, AACR. 2012;72(8 SUPPL. 1).
 배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

1120. Yoneda T KN, Kitagawa K, Fukui Y, Saito H, Narikiyo K, Ishiko M, et al. Overexpression of SOCS3 mediated by adenovirus vector in mouse and human castration-resistant prostate cancer cells increases the sensitivity to NK cells in vitro and in vivo. *Cancer Gene Therapy*. 2019;26(11-12):388-99.
배제사유 : 동물실험 또는 전임상시험연구
1121. Yonezawa A DS, Chester C, Kim J, Kohrt H, E. Boosting cancer immunotherapy with anti-CD137 antibody therapy. *Clinical Cancer Research*. 2015;21(14):3113-20.
배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
1122. Yoon M S, Pham C, T, Phan M, T, T, Shin D, J, Jang Y, Y, Park M, H, et al. Irradiation of breast cancer cells enhances CXCL16 ligand expression and induces the migration of natural killer cells expressing the CXCR6 receptor. *Cytotherapy*. 2016;18(12):1532-42.
배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구
1123. Yoshida Y NJ, Wada H, Kakimi K. gammadelta T-cell immunotherapy for lung cancer. *Surgery Today*. 2011;41(5):606-11.
배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
1124. Youlin K JK, Siming L, Li Z, Weiyang H, Chaodong L, Xin G. Potent anti-prostate cancer immune response induced by dendritic cells transduced with recombinant adenoviruses encoding 4-1BBL combined with cytokine-induced killer cells. *Immunotherapy*. 2015;7(1):13-20.
배제사유 : 동물실험 또는 전임상시험연구
1125. Yu L WL, Chen S. Dual character of Toll-like receptor signaling: Pro-tumorigenic effects and anti-tumor functions. *Biochimica et Biophysica Acta - Reviews on Cancer*. 2013;1835(2):144-54.
배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
1126. Yu P SJ, C, Zhang M, Morris J, C, Waitz R, Fasso M, Allison J, P, et al. Simultaneous inhibition of two regulatory T-cell subsets enhanced Interleukin-15 efficacy in a prostate tumor model. *Proceedings of the National Academy of Sciences of the United States of America*. 2012;109(16):6187-92.
배제사유 : 동물실험 또는 전임상시험연구
1127. Yu X FP, Wang X, Y. Inhibition of tumor growth by targeting the MDA5-IPS-1 pathway requires coordinated induction of cancer cell death and immune activation. *Journal of Immunology*. Conference: 101st Annual Meeting of the American Association of Immunologist, IMMUNOLOGY. 2014;192(1 SUPPL. 1).
배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
1128. Yu X GC, Yi H, Qian J, Fisher P, B, Subjeck J, R, Wang X, Y. A multifunctional chimeric chaperone serves as a novel immune modulator inducing therapeutic antitumor immunity. *Cancer Research*. 2013;73(7):2093-103.
배제사유 : 동물실험 또는 전임상시험연구
1129. Yu X WH, Li X, Guo C, Yuan F, Fisher P, B, Wang X, Y. Activation of the

MDA-5-IPS-1 Viral Sensing Pathway Induces Cancer Cell Death and Type I IFN-Dependent Antitumor Immunity. *Cancer Research*. 2016;76(8):2166-76.

배제사유 : 동물실험 또는 전임상시험연구

1130. Yu X WX, Y. Engineering Grp170-based immune modulators for cancer immunotherapy. *OncoImmunology*. 2013;2 (6) (e24385).

배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구

1131. Yu Y ZQ, Meng Q, Zong C, Liang L, Yang X, Lin R, et al. Mesenchymal stem cells overexpressing Sirt1 inhibit prostate cancer growth by recruiting natural killer cells and macrophages. *Oncotarget*. 2016;7(44):71112-22.

배제사유 : 동물실험 또는 전임상시험연구

1132. Yuan H HY, H, Zhang Y, Wang J, Yin C, Shen R, Su Y. Destructive impact of T-lymphocytes, NK and Mast cells on basal cell layers: implications for tumor invasion. *BMC Cancer*. 2013;13:258.

배제사유 : 동물실험 또는 전임상시험연구

1133. Yun H M, Oh J, H, Shim J, H, Ban J, O, Park K, R, Kim J, H, et al. Antitumor activity of IL-32beta through the activation of lymphocytes, and the inactivation of NF-kappaB and STAT3 signals. *Cell Death & Disease*. 2013;4:e640.

배제사유 : 동물실험 또는 전임상시험연구

1134. Zaravinos A RK, Chasiotis D, Makris A, Efstathiades C, Dimopoulos C. Prognostic impact of immune cytolytic activity and its association with checkpoint molecules and TIL/TAN load in human malignancies. *FEBS Open Bio*. 2018;8 (Supplement 1):301.

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

1135. Zaslavsky A AM, Wissmueller S, Campbell D, Klingemann H, Walsh B, Palapattu G, S. Glypican-1 as a novel immunotherapeutic target in prostate cancer. *Journal of Clinical Oncology. Conference*. 2018;36(6 Supplement 1).

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

1136. Zaslavsky A AM, Wissmueller S, Campbell D, Klingemann H, Walsh B, Palapattu G. Glypican-1 as a novel immunotherapeutic target in prostate cancer. *European Urology, Supplements*. 2018;17 (2):e507.

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

1137. Zaugg M LE. Impact of anaesthesia regimen on middle and long-term cancer surgery outcome. *Regional Anesthesia and Pain Medicine*. 2014;1):e22-e3.

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

1138. Zhang J LD, Li G, Staveley-O'Carroll K, F, Graff J, N, Li Z, Wu J, D. Antibody-mediated neutralization of soluble MIC significantly enhances CTLA4 blockade therapy. *Science Advances*. 2017;3(5):e1602133.

배제사유 : 동물실험 또는 전임상시험연구

1139. Zhang M JW, Yao Z, Yu P, Wei B, R, Simpson R, M, Waitz R, et al. Augmented IL-15Ralpha expression by CD40 activation is critical in synergistic CD8 T cell-mediated antitumor activity of anti-CD40 antibody with IL-15 in TRAMP-C2 tumors

in mice. *Journal of Immunology*. 2012;188(12):6156-64.

배제사유 : 동물실험 또는 전임상시험연구

1140. Zhang Q JT, L, Yang X, Park I, Meyer R, E, Kundu S, Pins M, et al. Infiltration of tumor-reactive transforming growth factor-beta insensitive CD8+ T cells into the tumor parenchyma is associated with apoptosis and rejection of tumor cells. *Prostate*. 2006;66(3):235-47.

배제사유 : 동물실험 또는 전임상시험연구

1141. Zhang X YY, Fan D, Xiong D. The development of bispecific antibodies and their applications in tumor immune escape. *Experimental Hematology and Oncology*. 2017;6(1) (12).

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

1142. Zhao P CD, Cheng H. Prognostic significance of soluble major histocompatibility complex class I-related chain A (sMICA) in gastric cancer. *British Journal of Biomedical Science*. 2018;75(4):203-5.

배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구

1143. Zhao S G, Lehrer J, Chang S, L, Das R, Erho N, Liu Y, et al. The Immune Landscape of Prostate Cancer and Nomination of PD-L2 as a Potential Therapeutic Target. *Journal of the National Cancer Institute*. 2019;111(3):301-10.

배제사유 : NK 세포 활성도를 다루지 않는 연구

1144. Zhao S G, Lehrer J, Chang S, W, L, Erho N, G, Sjostrom M, Den R, B, et al. Novel associations between the immune landscape of prostate cancer and postoperative radiation response. *International Journal of Radiation Oncology Biology Physics*. 2017;99 (2 Supplement 1):S2-S3.

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

1145. Zhao Y CW, Zhu W, Meng H, Chen J, Zhang J. Overexpression of Interferon Regulatory Factor 7 (IRF7) Reduces Bone Metastasis of Prostate Cancer Cells in Mice. *Oncology Research*. 2017;25(4):511-22.

배제사유 : 동물실험 또는 전임상시험연구

1146. Zhu D CL, G, Fleming Y, W, Stein B. Immunomodulatory drugs Revlimid (lenalidomide) and CC-4047 induce apoptosis of both hematological and solid tumor cells through NK cell activation. *Cancer Immunology, Immunotherapy*. 2008;57(12):1849-59.

배제사유 : NK 세포 활성도를 다루었으나 인터페론 감마를 보고하지 않은 연구

1147. Zitvogel L AE, Tursz T. Dendritic cell-based immunotherapy of cancer. *Annals of Oncology*. 2000;11(SUPPL. 3):199-205.

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

1148. Zitvogel L CN, Pequignot M, O, Chaput N, Albert M, L, Kroemer G. Immune response against dying tumor cells. *Advances in Immunology*. 2004;84:131-79.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)